

# CITATION REPORT

List of articles citing

**Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial**

**DOI: 10.1016/s0140-6736(01)06102-5**  
**Lancet, The, 2001, 358, 958-65.**

**Source:** <https://exaly.com/paper-pdf/32478474/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2270	Treatment of acute hepatitis C with interferon alfa-2b. <b>2001</b> , 345, 1452-7		634
2269	Is it time for mass screening for hepatitis C?. <b>2001</b> , 111, 667-8		4
2268	[New perspectives in the treatment of chronic hepatitis C]. <i>Gastroenterologia Y Hepatologia</i> , <b>2001</b> , 24, 352-6	0.9	
2267	Is pegylated interferon- $\alpha$ plus ribavirin set to become the standard therapy for patients with hepatitis C?. <b>2001</b> , 17, 5-8		
2266	Prevention of hepatocellular carcinoma in chronic liver disease: molecular markers and clinical implications. <b>2001</b> , 19, 338-44		3
2265	Diagnostic Workup of Hepatitis C and the Patient on Maintenance Dialysis. <b>2001</b> , 24, 843-852		1
2264	Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis C and B virus infections in healthy company employees. <b>2001</b> , 17, 721-8		18
2263	Mechanisms of action of ribavirin in antiviral therapies. <b>2001</b> , 12, 261-72		95
2262	Therapy for acute hepatitis C. <b>2001</b> , 345, 1495-7		37
2261	Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy. <b>2001</b> , 10, 2201-13		23
2260	Hepatitis C information on the world wide web. <b>2002</b> , 35, 754-9		2
2259	Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. <b>2002</b> , 76, 11079-90		57
2258	Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. <b>2002</b> , 76, 11148-54		74
2257	Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. <b>2002</b> , 137, 961-4		110
2256	Investigational pharmacologic treatment for liver disease. <b>2002</b> , 11, 1281-93		
2255	Evaluation and treatment of the HIV/HCV coinfecting patient: a case history and discussion. <b>2002</b> , 16, 319-26		2
2254	Spectrum of disease in U.S. veteran patients with hepatitis C. <b>2002</b> , 97, 1813-20		63

2253	Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question?. <b>2002</b> , 97, 1093-6	11
2252	Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. <b>2002</b> , 185 Suppl 2, S128-37	29
2251	New insights into hepatitis C. <b>2002</b> , 2, 554-9	3
2250	Fully automated detection of hepatitis C virus RNA in serum and whole-blood samples. <b>2002</b> , 9, 1385-8	7
2249	Laboratory assays for diagnosis and management of hepatitis C virus infection. <b>2002</b> , 40, 4407-12	71
2248	Frontiers in Gastroenterology. <b>2002</b> , 15, 241-249	
2247	Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. <b>2002</b> , 76, 8189-99	105
2246	Needlestick transmission of hepatitis C. <b>2002</b> , 287, 2406-13	75
2245	Does hepatitis C virus infection increase the risk of HIV disease progression?. <b>2002</b> , 288, 241-3	19
2244	The Irish paradigm on the natural progression of hepatitis C virus infection: An investigation in a homogeneous patient population infected with HCV 1b (review). <b>2002</b> , 9, 179	
2243	Genetically modified interferon: is there a consensus yet?. <b>2002</b> , 14, 471-3	3
2242	Success in treating mild chronic hepatitis C: different outcomes -- new guidelines?. <b>2002</b> , 14, 595-7	3
2241	Diagnostik und Therapie der akuten und chronischen Hepatitis C bei Drogenabhängigen. <b>2002</b> , 3, S54-S61	
2240	Neuro-psychiatrische Nebenwirkungen von Interferon-alpha bei Drogenabhängigen: Ursachen, Häufigkeit und Therapie. <b>2002</b> , 3, S72-S77	1
2239	DGS Guidelines für Basic Diagnostics, Monitoring and Treatment for Hepatitis C in I.V. Drug Users. <b>2002</b> , 3, 98-103	
2238	Hepatitis C and progression of HIV disease. <b>2002</b> , 288, 199-206	323
2237	[Treatment of chronic hepatitis C with pegylated alpha-interferons]. <b>2002</b> , 127, 563-6	0
2236	Gründe für die ausbleibende Hepatitis-C-Behandlung bei Drogenabhängigen in Opiatsubstitution. <b>2002</b> , 3, S27-S30	1

- 2235 [Chronic hepatitis C virus infection: always treat!--Pro]. **2002**, 127, 1840
- 2234 [Indications for liver transplantation in chronic liver diseases]. **2002**, 40, 891-902 4
- 2233 Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. **2002**, 34, 831-7 615
- 2232 Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfecting with HCV and human immunodeficiency virus. **2002**, 35, 482-7 23
- 2231 Efficacy of induction therapy with high-dose interferon for patients with hemophilia and human immunodeficiency virus-hepatitis C virus coinfection. **2002**, 35, 1527-33 8
- 2230 Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. **2002**, 76, 13001-14 984
- 2229 Sexually acquired hepatitis. **2002**, 78, 235-40 33
- 2228 Empirically calibrated model of hepatitis C virus infection in the United States. **2002**, 156, 761-73 97
- 2227 Assessment and management of chronic hepatitis C infection. **2002**, 2, 302-6 2
- 2226 Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. **2002**, 30, 65-8 46
- 2225 Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. **2002**, 20, 284-8 39
- 2224 Comment to the editorial: Liver biopsy in HIV-infected patients with chronic hepatitis C: pros and cons, by Vincent Soriano and Javier Garc3a-Samaniego. **2002**, 3, 419-20 2
- 2223 Liver biopsy in HIV-infected patients with chronic hepatitis C: pros and cons. **2002**, 3, 351-3 6
- 2222 Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. **2002**, 16, 813-28 176
- 2221 Impact of hepatitis B and hepatitis C on solid organ transplantation. **2002**, 7, 325-331
- 2220 Viral hepatitis. **2002**, 18, 330-3
- 2219 A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. **2002**, 34, 268-71 97
- 2218 Hepatitis C: A Clinician's View at the Turn of the Millennium. **2002**, 11, 205-210

2217	Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection. <b>2002</b> , 14, 1377-82	11
2216	Remission of hepatitis C virus-associated cryoglobulinemic glomerulonephritis with interferon alfa-2b and ribavirin combination therapy after liver transplantation. <b>2002</b> , 74, 1767-8	8
2215	Treatment of chronic hepatitis C infection with cryoglobulinemia. <b>2002</b> , 14, 231-7	10
2214	Chronic hepatitis C: latest treatment options. <b>2002</b> , 27, 32-3, 37-8, 40 passim; quiz 50-1	2
2213	Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. October 2000. <b>2002</b> , 3, 99-114	16
2212	Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV. <b>2002</b> , 3, 324-32	12
2211	Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. <b>2002</b> , 162, 2545-56	34
2210	Molecular targets for prevention of hepatocellular carcinoma. <b>2002</b> , 20, 81-90	25
2209	Mutation Master: profiles of substitutions in hepatitis C virus RNA of the core, alternate reading frame, and NS2 coding regions. <b>2002</b> , 8, 557-71	37
2208	Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. <b>2002</b> , 113, 506-15	170
2207	Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. <b>2002</b> , 76, 12735-46	41
2206	Management of hepatitis C in human immunodeficiency virus-infected patients. <b>2002</b> , 34, 452-9	2
2205	Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. <b>2002</b> , 122, 1303-13	897
2204	Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. <b>2002</b> , 122, 1525-8	185
2203	Molecular diagnosis of viral hepatitis. <b>2002</b> , 122, 1554-68	169
2202	Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. <b>2002</b> , 123, 141-51	111
2201	Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. <b>2002</b> , 123, 1061-9	803
2200	Application of structural biology tools in the study of viral hepatitis and the design of antiviral therapy. <b>2002</b> , 123, 1350-63	5

2199	Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. <b>2002</b> , 123, 1070-83		164
2198	Interferon alpha plus ribavirin produces more sustained virological response in chronic hepatitis C than interferon alpha alone. <b>2002</b> , 6, 134-135		
2197	Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. <b>2002</b> , 62, 507-56		56
2196	Randomised Trial of Two Different Daily Doses of Interferon- $\alpha$ Versus Classical Therapy in Treatment-Naïve Patients with Chronic Hepatitis C. <b>2002</b> , 22, 623-631		2
2195	Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. <b>2002</b> , 347, 975-82		5551
2194	Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin. <b>2002</b> , 37, 1228-34		10
2193	Peginterferon-alpha-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open-label study. <b>2002</b> , 16, 105-9		5
2192	Developments in the treatment of chronic hepatitis C. <b>2002</b> , 11, 515-28		33
2191	Culturally-based health promotion programmes. <i>Lancet, The</i> , <b>2002</b> , 359, 262-263	40	1
2190	Peginterferon alfa-2b plus ribavirin for chronic hepatitis. <i>Lancet, The</i> , <b>2002</b> , 359, 263; author reply 264	40	
2189	Peginterferon alfa-2b plus ribavirin for chronic hepatitis. <i>Lancet, The</i> , <b>2002</b> , 359, 263; author reply 264	40	
2188	Peginterferon alfa-2b plus ribavirin for chronic hepatitis. <i>Lancet, The</i> , <b>2002</b> , 359, 263-4	40	2
2187	Primary interferon resistance and treatment response in chronic hepatitis C infection. <i>Lancet, The</i> , <b>2002</b> , 359, 1064-1065	40	0
2186	Opportunistic infections in HIV-infected individuals: hepatitis C virus. <i>Lancet, The</i> , <b>2002</b> , 360, 584-6	40	9
2185	Monoethylglycinexylide kinetics and galactose elimination capacity during treatment with interferon-alfa for hepatitis C virus infection: Possible predictors of response?. <b>2002</b> , 63, 772-785		1
2184	Introduction to therapy of hepatitis C. <b>2002</b> , 36, S114-20		37
2183	Understudied populations with hepatitis C. <b>2002</b> , 36, S226-36		26
2182	Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone. <b>2002</b> , 36, 819-26		17

2181	High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. <b>2002</b> , 37, 109-16	19
2180	Favourable and disappointing lessons from viral kinetics. <b>2002</b> , 37, 151-3	4
2179	Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). <b>2002</b> , 37, 500-6	337
2178	Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. <b>2002</b> , 37, 831-6	54
2177	Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. <b>2002</b> , 37, 848-54	84
2176	The challenge of developing a vaccine against hepatitis C virus. <b>2002</b> , 37, 684-95	58
2175	What's new in Liver disorders: part 2. <b>2002</b> , 30, 1-3	
2174	HCV RNA-dependent RNA polymerase as a target for antiviral development. <b>2002</b> , 2, 534-40	43
2173	Hepatitis C: molecular virology and antiviral targets. <b>2002</b> , 8, 476-82	43
2172	Prevalence of hepatitis C infection in a large urban hospital-based sample of individuals with spinal cord injury. <b>2002</b> , 83, 1620-3	2
2171	Guidelines for laboratory monitoring of treatment of persistent virus infections. <b>2002</b> , 25, 73-92	7
2170	Antiviral prophylaxis and treatment (excluding HIV therapy). <b>2002</b> , 25, 241-66	9
2169	Hepatitis C viral dynamics: basic concept and clinical significance. <b>2002</b> , 25 Suppl 3, S31-9	10
2168	Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance. <b>2002</b> , 25 Suppl 3, S23-9	87
2167	Pegylated interferons for the treatment of chronic hepatitis C infection. <b>2002</b> , 24, 1363-83	105
2166	[Hepatitis C and pregnancy]. <b>2002</b> , 23, 283-91	2
2165	[Role of interferons in the treatment of hepatitis B and hepatitis C virus infections]. <b>2002</b> , 23 Suppl 4, 459s-474s	2
2164	Treating hepatitis C in methadone maintenance patients: an interim analysis. <b>2002</b> , 67, 117-23	168

2163	[Recommendations of the Spanish AIDS Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral treatment in adult patients with human immunodeficiency virus infection in 2002]. <b>2002</b> , 20, 244-303		20
2162	[Chronic hepatitis C: initial treatment in patients without previous treatment]. <i>Gastroenterología Y Hepatología</i> , <b>2002</b> , 25, 347-55	0.9	
2161	Role of antiviral therapy in the prevention of hepatocellular carcinoma. <b>2002</b> , 13, S191-6		8
2160	[Treatment of chronic hepatitis C in cirrhosis of the liver]. <i>Gastroenterología Y Hepatología</i> , <b>2002</b> , 25, 356-9	0.9	
2159	[Induction therapy with interferon alfa-2a in compensated hepatitis C virus-related cirrhosis. Randomized, multicenter study]. <b>2002</b> , 118, 641-4		7
2158	A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. <b>2002</b> , 36, 959-966		
2157	[Antiviral treatment of chronic hepatitis C in interferon nonresponders]. <i>Gastroenterología Y Hepatología</i> , <b>2002</b> , 25, 342-6	0.9	
2156	Presente y futuro del tratamiento de la hepatitis c. <b>2002</b> , 9, 553-554		
2155	Tratamiento de la recidiva de la hepatitis C postrasplante hepático. Influencia del tratamiento inmunodepresor en los resultados. <i>Gastroenterología Y Hepatología</i> , <b>2002</b> , 25, 280-288	0.9	
2154	[Chronic hepatitis C in patients coinfecting by human immunodeficiency virus]. <i>Gastroenterología Y Hepatología</i> , <b>2002</b> , 25, 423-31	0.9	0
2153	Hepatitis C in adults and adolescents with hemophilia: A randomized, controlled trial of interferon alfa-2b and ribavirin. <b>2002</b> , 36, 967-972		
2152	Hépatite chronique C ¶transaminases normales de fañ r¶¶¶. <b>2002</b> , 18, 357-361		
2151	Recent advances in the management of hepatitis C in the dialysis population. <b>2002</b> , 25, 503-11		7
2150	2.8 Literatur (Auswahl). <b>2002</b> ,		
2149	[Therapy of hepatitis C]. <b>2002</b> , 91, 977-82		
2148	Traitement de hépatite C. <b>2002</b> , 18, 343-352		0
2147	Pharmacogenomics and infectious diseases: impact on drug response and applications to disease management. <b>2002</b> , 59, 1626-31		10
2146	Hepatitis C: who should you treat and how?. <b>2002</b> , 20, 124-36		2



2145	Clinical impact of hepatitis C virus infection in the renal transplant recipient. <b>2002</b> , 91, 541-6	7
2144	Genetic variability of hepatitis C virus in dialysis: the implications. <b>2002</b> , 25, 1034-48	1
2143	[Molecular virology of hepatitis C]. <b>2002</b> , 91, 2247-53	
2142	Dynamics of hepatitis C virus infection. <b>2002</b> , 1, 56-63	19
2141	Hepatitis C. <b>2002</b> , 30, 37-40	
2140	Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. <b>2002</b> , 55, 381-96	43
2139	Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. <b>2002</b> , 80, 259-71	113
2138	Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. <b>2002</b> , 54, 547-70	349
2137	Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. <b>2002</b> , 54, 571-86	192
2136	Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. <b>2002</b> , 46, 3317-26	151
2135	National institutes of health consensus development conference: Management of hepatitis C: 2002. <b>2002</b> , 36, S1-S2	115
2134	Course and outcome of hepatitis C. <b>2002</b> , 36, S21-S29	526
2133	Use and interpretation of virological tests for hepatitis C. <b>2002</b> , 36, S65-S73	147
2132	Introduction to therapy of hepatitis C. <b>2002</b> , 36, S114-S120	53
2131	Optimal therapy of hepatitis C. <b>2002</b> , 36, S121-S127	123
2130	Retreatment of patients with chronic hepatitis C. <b>2002</b> , 36, S128-S134	30
2129	Treatment of chronic hepatitis C: A systematic review. <b>2002</b> , 36, S135-S144	62
2128	Monitoring of viral levels during therapy of hepatitis C. <b>2002</b> , 36, S145-S151	87

2127	The role of liver biopsy in chronic hepatitis C. <b>2002</b> , 36, S152-S160	155
2126	Role of liver biopsy in management of chronic hepatitis C: A systematic review. <b>2002</b> , 36, S161-S172	120
2125	Treatment of patients with hepatitis C and normal serum aminotransferase levels. <b>2002</b> , 36, S179-S184	71
2124	Treatment of patients with hepatitis C and cirrhosis. <b>2002</b> , 36, S185-S194	56
2123	Hepatitis C and human immunodeficiency virus infection. <b>2002</b> , 36, S201-S209	78
2122	Understudied populations with hepatitis C. <b>2002</b> , 36, S226-S236	52
2121	Side effects of therapy of hepatitis C and their management. <b>2002</b> , 36, S237-S244	428
2120	The nonstructural NS5A protein of hepatitis C virus: an expanding, multifunctional role in enhancing hepatitis C virus pathogenesis. <b>2002</b> , 9, 187-97	64
2119	The HCV and HIV coinfecting patient: what have we learned about pathophysiology?. <b>2002</b> , 4, 15-22	4
2118	Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. <b>2002</b> , 4, 23-30	77
2117	Challenges in the HIV patient coinfecting with hepatitis C. <b>2002</b> , 1, 9-15	1
2116	Hepatitis C virus infection in HIV-infected patients. <b>2002</b> , 1, 16-22	1
2115	HIV and hepatitis virus infection. <b>2002</b> , 1, 30-37	
2114	[Virus associated glomerulonephritis]. <b>2003</b> , 44, 1098-106	2
2113	[Hepatitis-C-virus-associated cryoglobulinemia. Pathogenesis, diagnosis and treatment]. <b>2002</b> , 97, 601-8	1
2112	P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease. <b>2002</b> , 12, 3199-202	55
2111	The natural history and antiviral treatment of hepatitis C in haemophilia. <b>2002</b> , 8, 322-9	33
2110	Management of chronic hepatitis C--time for a change?. <b>2002</b> , 9, 82-3	1

2109	Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction. <b>2002</b> , 9, 354-9	12
2108	First-phase parameters in hepatitis C viral kinetics. <b>2002</b> , 9, 332-3	4
2107	A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C. <b>2002</b> , 9, 346-53	25
2106	Treatment of acute hepatitis C virus infection with interferon-alpha 2b and ribavirin: case report and review of the literature. <b>2002</b> , 1, 3	1
2105	A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. <b>2002</b> , 1, 3	86
2104	The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. <b>2002</b> , 97, 1289-94	125
2103	Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. <b>2002</b> , 16, 1091-9	128
2102	Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon. <b>2002</b> , 16, 1611-21	11
2101	Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. <b>2002</b> , 16, 1633-9	65
2100	Polyethylene glycol-interferon: current status in hepatitis C virus therapy. <b>2002</b> , 17 Suppl 3, S344-50	12
2099	High sustained response to daily dosing of interferon with ribavirin in chronic hepatitis C patients naïve to therapy. <b>2002</b> , 17, 577-81	4
2098	Management issues in chronic viral hepatitis: hepatitis C. <b>2002</b> , 17, 415-22	17
2097	Hepatitis C advances in antiviral therapy: what is accepted treatment now?. <b>2002</b> , 17, 431-41	24
2096	Hepatitis C therapeutics: current status and emerging strategies. <b>2002</b> , 1, 867-81	165
2095	Advances in model systems for hepatitis C virus research. <b>2002</b> , 293, 1-9	51
2094	Efficacy of daily induction dosing vs standard thrice weekly dosing of interferon-alpha2B for initial treatment of chronic hepatitis C. <b>2002</b> , 47, 784-92	6
2093	Expected developments in hepatology. <b>2002</b> , 16, 957-70	5
2092	Sample size in trials of hepatitis C. <b>2002</b> , 35, 500	

2091	New therapeutic strategies for hepatitis C. <b>2002</b> , 35, 224-31	118
2090	Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. <b>2002</b> , 35, 447-54	32
2089	Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. <b>2002</b> , 35, 930-6	91
2088	Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. <b>2002</b> , 36, 211-8	157
2087	A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. <b>2002</b> , 36, 959-66	22
2086	Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. <b>2002</b> , 36, 967-72	53
2085	A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. <b>2002</b> , 36, 1253-8	76
2084	Course and outcome of hepatitis C. <b>2002</b> , 36, S21-9	479
2083	Optimal therapy of hepatitis C. <b>2002</b> , 36, S121-7	128
2082	Hepatitis C and human immunodeficiency virus infection. <b>2002</b> , 36, S201-9	61
2081	The role of liver biopsy in chronic hepatitis C. <b>2002</b> , 36, S152-60	115
2080	Treatment of patients with hepatitis C and normal serum aminotransferase levels. <b>2002</b> , 36, S179-84	51
2079	Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. <b>2002</b> , 36, 1280-4	87
2078	Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. <b>2002</b> , 36, 1273-9	153
2077	Monitoring of viral levels during therapy of hepatitis C. <b>2002</b> , 36, S145-51	63
2076	Side effects of therapy of hepatitis C and their management. <b>2002</b> , 36, S237-44	337
2075	Treatment of patients with hepatitis C and cirrhosis. <b>2002</b> , 36, S185-94	38
2074	Use and interpretation of virological tests for hepatitis C. <b>2002</b> , 36, S65-73	118

2073	Retreatment of patients with chronic hepatitis C. <b>2002</b> , 36, S128-34	21
2072	Role of liver biopsy in management of chronic hepatitis C: a systematic review. <b>2002</b> , 36, S161-72	101
2071	National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. <b>2002</b> , 36, S1-2	132
2070	Treatment of chronic hepatitis C: a systematic review. <b>2002</b> , 36, S135-44	48
2069	Treatment of recurrent hepatitis C. <b>2002</b> , 8, S28-37	39
2068	Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. <b>2002</b> , 72, 349-61	42
2067	Combination treatment of IFNalpha2b and ribavirin in patients with chronic hepatitis C and persistently normal ALTs. <b>2003</b> , 48, 921-5	6
2066	Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. <b>2003</b> , 37, 52-9	40
2065	Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. <b>2003</b> , 37, 60-4	138
2064	Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. <b>2003</b> , 37, 568-76	94
2063	Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. <b>2003</b> , 37, 610-21	89
2062	Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. <b>2003</b> , 37, 600-9	223
2061	Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. <b>2003</b> , 37, 1226-7	48
2060	Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. <b>2003</b> , 37, 1351-8	203
2059	Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. <b>2003</b> , 37, 1359-67	54
2058	Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests?. <b>2003</b> , 37, 972-4	96
2057	A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. <b>2003</b> , 37, 1368-74	31
2056	Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. <b>2003</b> , 38, 66-74	73

2055	Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. <b>2003</b> , 38, 75-85	448
2054	Can serum HBV-DNA be used as a primary end point to assess efficacy of new treatments for chronic hepatitis B?. <b>2003</b> , 38, 18-20	9
2053	Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. <b>2003</b> , 38, 481-92	188
2052	Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?. <b>2003</b> , 38, 21-4	4
2051	Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. <b>2003</b> , 38, 493-502	68
2050	Can interferon prolong life?. <b>2003</b> , 38, 292-4	2
2049	Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. <b>2003</b> , 38, 645-52	621
2048	A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. <b>2003</b> , 38, 1289-96	101
2047	E1 therapeutic vaccination for chronic hepatitis C: all that glitters is not gold. <b>2003</b> , 38, 1092-4	1
2046	Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. <b>2003</b> , 9, 57-61	47
2045	Projecting future complications of chronic hepatitis C in the United States. <b>2003</b> , 9, 331-8	450
2044	Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. <b>2003</b> , 9, 1159-65	61
2043	Treatment of patients with hepatitis C virus on the waiting list. <b>2003</b> , 9, S90-4	55
2042	Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation. <b>2003</b> , 9, S14-20	23
2041	How can we identify better those with recurrent hepatitis C who will respond to therapy? What are the optimal treatment regimen and treatment duration?. <b>2003</b> , 9, S109-13	6
2040	Controversies in the management of hepatitis C virus infection after liver transplantation. <b>2003</b> , 9, 1129-44	24
2039	Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin. <b>2003</b> , 48, 594-7	17
2038	Nonresponse to interferon monotherapy in HCV-related chronic hepatitis: results of retreatment and prognostic factors. <b>2003</b> , 48, 809-14	

2037 Buikpijn na een reisbuikpijn na een reis. **2003**, 19, 33-38

2036 Antiviral Therapy for Hepatitis C. **2003**, 6, 445-453

5

2035 Update on chronic hepatitis C. **2003**, 29, 224-32

2034 Treatment for chronic hepatitis C. **2003**, 5, 1-2

2033 Treatment of chronic hepatitis C in nonresponders to previous therapy. **2003**, 5, 78-85

6

2032 Hepatitis C antiviral treatment in special populations. **2003**, 2, 101-107

2031 Hepatitis C in veterans. **2003**, 2, 108-115

9

2030 Alcohol and hepatitis C: Implications for disease progression and treatment. **2003**, 2, 125-131

2029 Treatment of hepatitis C. **2003**, 2, 3-8

0

2028 Pegylated interferons: What role will they play in the treatment of chronic hepatitis C?. **2003**, 2, 17-23

2

2027 Pegylated interferons in combination with ribavirin for the treatment of chronic hepatitis C. **2003**, 2, 24-31

1

2026 Treatment of chronic hepatitis C in patients who have failed to respond to IFN or IFN and ribavirin combination therapy. **2003**, 2, 32-39

1

2025 Treatment of chronic hepatitis C: Improved combination therapy. **2003**, 2, 40-46

2

2024 Bekanntmachung des Arbeitskreises Blut des Bundesministeriums für Gesundheit und soziale Sicherung Hepatitis-C-Virus (HCV). **2003**, 46, 712-722

4

2023 Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. **2003**, 55, 362-9

139

2022 When should decision-analytic modeling be used in the economic evaluation of health care?. **2003**, 4, 143-150

110

2021 CpG immuno-stimulatory motifs enhance humoral immune responses against hepatitis C virus core protein after DNA-based immunization. **2003**, 148, 435-48

24

2020 The treatment of viral hepatitis, present and future. **2003**, 10, 163-7

2019	Combination therapy with interferon-alpha and ribavirin as immunomodulators in patients with chronic hepatitis C. <b>2003</b> , 38, 302-4	3
2018	Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. <b>2003</b> , 42, 184-92	70
2017	Hepatitis C and renal disease: an update. <b>2003</b> , 42, 631-57	269
2016	Combined antiviral options for the treatment of chronic hepatitis C. <b>2003</b> , 60, 135-43	16
2015	Modulation of interferon expression by hepatitis C virus NS5A protein and human homeodomain protein PTX1. <b>2003</b> , 306, 51-9	17
2014	An oligonucleotide complementary to the SL-B1 domain in the 3'-end of the minus-strand RNA of the hepatitis C virus inhibits in vitro initiation of RNA synthesis by the viral polymerase. <b>2003</b> , 314, 206-20	5
2013	A novel high throughput screening assay for HCV NS3 serine protease inhibitors. <b>2003</b> , 107, 245-55	34
2012	Determining hepatitis C genotype by analyzing the sequence of the NS5b region. <b>2003</b> , 109, 187-93	135
2011	A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. <b>2003</b> , 110, 201-9	152
2010	Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. <b>2003</b> , 59, 1-11	119
2009	Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: possible explanation for therapeutic efficacy in patients with chronic HCV infection. <b>2003</b> , 69, 50-8	27
2008	GB virus C genotype determination in GB virus-C/HIV co-infected individuals. <b>2003</b> , 70, 141-9	45
2007	Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection. <b>2003</b> , 70, 219-27	54
2006	Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. <b>2003</b> , 70, 378-86	33
2005	Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. <b>2003</b> , 38, 1437-48	141
2004	Reply. <b>2003</b> , 38, 1593-1594	2
2003	Iron as a co-morbid factor in nonhemochromatotic liver disease. <b>2003</b> , 30, 137-44	80
2002	Quantification génomique : applications aux infections par le virus de l'hépatite C (HCV). <b>2003</b> , 2003, 35-37	



2001	Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors. <b>2003</b> , 13, 785-8	21
2000	Synthesis of 1,2,3-triazolo-carbanucleoside analogues of ribavirin targeting an HCV in replicon. <b>2003</b> , 11, 3633-9	57
1999	Hepatitis C and pregnancy: an update. <b>2003</b> , 43, 290-3	10
1998	Efficacy of a glycyrrhizin suppository for the treatment of chronic hepatitis C: a pilot study. <b>2003</b> , 26, 10-14	23
1997	A randomised, open label, controlled trial on the effect of interferon plus amantadine compared with interferon alone for treatment of chronic hepatitis C. <b>2003</b> , 26, 167-173	9
1996	Consensus interferon versus interferon-alpha 2b plus ribavirin in patients with relapsing HCV infection. <b>2003</b> , 27, 253-259	23
1995	Transition of care between paediatric and adult gastroenterology. Chronic viral hepatitis. <b>2003</b> , 17, 259-75	12
1994	Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus. <b>2003</b> , 81, 67-72	23
1993	Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]. <b>2003</b> , 3, 24	15
1992	Transjugular liver biopsy is safe and diagnostic for patients with congenital bleeding disorders and hepatitis C infection. <b>2003</b> , 9, 613-8	31
1991	The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. <b>2003</b> , 10, 16-22	35
1990	First phase hepatitis c viral kinetics in previous nonresponders patients. <b>2003</b> , 10, 43-9	21
1989	The safety and tolerability of daily infergen plus ribavirin in the treatment of naïve chronic hepatitis C patients. <b>2003</b> , 10, 55-60	20
1988	A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1. <b>2003</b> , 10, 189-96	10
1987	The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C. <b>2003</b> , 10, 103-10	9
1986	High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy. <b>2003</b> , 10, 205-9	11
1985	Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. <b>2003</b> , 10, 111-7	8
1984	Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study. <b>2003</b> , 10, 174-82	17

1983	Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study. <b>2003</b> , 10, 215-23	4
1982	Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial. <b>2003</b> , 10, 197-204	14
1981	Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy. <b>2003</b> , 10, 318-23	40
1980	Slow viral dynamics of hepatitis C virus genotype 4. <b>2003</b> , 10, 351-3	25
1979	A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C. <b>2003</b> , 10, 383-9	7
1978	Intracerebral haemorrhage and hepatitis C treatment. <b>2003</b> , 10, 401-3	8
1977	Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. <b>2003</b> , 10, 271-6	66
1976	Interferon-alpha combined with ketoprofen as treatment of naïve patients with chronic hepatitis C: a randomized controlled trial. <b>2003</b> , 10, 306-9	13
1975	Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy. <b>2003</b> , 10, 467-70	29
1974	Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naïve patients with chronic hepatitis C. <b>2003</b> , 10, 437-45	11
1973	Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naïve chronic hepatitis C patients. A multicentre randomized controlled trial. <b>2003</b> , 10, 460-6	12
1972	Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic. <b>2003</b> , 33, 500-4	12
1971	BHIVA guidelines: coinfection with HIV and chronic hepatitis C virus. <b>2003</b> , 4 Suppl 1, 52-62	10
1970	A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naïve patients with chronic hepatitis C. <b>2003</b> , 17, 687-94	55
1969	Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C. <b>2003</b> , 17, 611-21	24
1968	Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone. <b>2003</b> , 17, 1197-204	3
1967	Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C. <b>2003</b> , 18, 661-70	15
1966	Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. <b>2003</b> , 18, 1071-81	118

1965	Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. <b>2003</b> , 13, 361-71	57
1964	RNA interference: on the road to an alternate therapeutic strategy!. <b>2003</b> , 13, 373-85	65
1963	Efficacy of hepatitis C treatment may be enhanced by a longer interferon administration. <b>2003</b> , 23, 410-2	
1962	Hepatitis C and liver fibrosis. <b>2003</b> , 10 Suppl 1, S59-67	154
1961	Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. <b>2003</b> , 4, 411-9	183
1960	Effect of pegylation on pharmaceuticals. <b>2003</b> , 2, 214-21	2532
1959	New therapies on the horizon for hepatitis C: are we close?. <b>2003</b> , 7, 211-42, xi	30
1958	Pegylated interferons. <b>2003</b> , 7, 139-48	13
1957	[Anterior uveitis in a patient treated with pegylated interferon and ribavirin]. <b>2003</b> , 120, 359	
1956	GI clinical research 2002-2003: the year in review. <b>2003</b> , 1, 415-20	10
1955	[Percutaneous fentanyl in fibromyalgia]. <b>2003</b> , 120, 358-9	2
1954	[Relationship between viral, load and serologic response to hepatitis C virus]. <b>2003</b> , 120, 516	
1953	[Treatment of acute hepatitis C with PEG-interferon and ribavirin]. <i>Gastroenterología Y Hepatología</i> , <b>2003</b> , 26, 275-6	0.9
1952	Factors that influence the severity of recurrent hepatitis C virus following liver transplantation. <b>2003</b> , 7, 603-14	7
1951	Manejo terapéutico de la infección crónica por virus C. <b>2003</b> , 203, 443-444	
1950	Hepatitis C in the HIV-infected patient. <b>2003</b> , 7, 179-94	48
1949	Tratamiento de las hepatitis crónicas víricas en pacientes infectados por el VIH. <b>2003</b> , 203, 193-195	1
1948	Natural history of hepatitis C and outcomes following liver transplantation. <b>2003</b> , 7, 585-602	42

1947	Use and interpretation of hepatitis C virus diagnostic assays. <b>2003</b> , 7, 127-37		34
1946	Treatment strategies for hepatitis C: intervention prior to liver transplant, pre-emptively or after established disease. <b>2003</b> , 7, 631-50, vii		9
1945	Current therapy for hepatitis C: pegylated interferon and ribavirin. <b>2003</b> , 7, 149-61		94
1944	Antiviral and antiretroviral use in pregnancy. <b>2003</b> , 30, 731-49, vii		9
1943	Tratamiento de las hepatitis víricas. <b>2003</b> , 8, 6455-6468		
1942	[Interferon, ribavirin and amantadine in prior nonresponders to interferon and ribavirin therapy with chronic hepatitis C (genotype 1)]. <i>Gastroenterología Y Hepatología</i> , <b>2003</b> , 26, 465-8	0.9	1
1941	Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions. <b>2003</b> , 98, 2344-2347		2
1940	Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. <b>2003</b> , 98, 2491-2499		1
1939	Side effects of therapy for chronic hepatitis C. <b>2003</b> , 124, 1711-9		212
1938	Weight-based ribavirin with pegylated interferon alfa 2b: benefits, risks, and the origin of the evidence. <b>2003</b> , 124, 2003-4; author reply 2004-5		0
1937	Reply. <b>2003</b> , 125, 630-631		2
1936	Developments in hepatitis C therapy during 2000-2002. <b>2003</b> , 8, 9-25		6
1935	Treatment of hepatitis C virus in the coinfecting patient. <b>2003</b> , 14, 525-795		1
1934	Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. <b>2003</b> , 63, 701-30		42
1933	Can we identify liver fibrosis in HCV-infected patients without a liver biopsy?. <b>2003</b> , 2, 145-151		4
1932	Weight-based dosing of pegylated interferon-alpha in chronic hepatitis C: just a marketing 'gag'?. <b>2003</b> , 35, 601-6		6
1931	Progression of fibrosis in chronic hepatitis C. <b>2003</b> , 124, 97-104		319
1930	Serine protease inhibitors cause F-actin redistribution in pancreatic acini?. <b>2003</b> , 124, 583-4		1

1929	PEG-interferon versus conventional interferon and liver fibrosis: do we have evidence of superiority?. <b>2003</b> , 124, 584; author reply 584-5		
1928	Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. <b>2003</b> , 124, 642-50	283	
1927	Optimal IFN therapy for 40-year-old patients with severe HCV-1b infection. <b>2003</b> , 124, 1166-7	0	
1926	Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs. <b>2003</b> , 278, 11979-84	285	
1925	Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. <b>2003</b> , 35, 3042-4	58	
1924	Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. <b>2003</b> , 4, 541-51	11	
1923	Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. <b>2003</b> , 125, 80-8	421	
1922	Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. <b>2003</b> , 38, 1437-1448	225	
1921	A comparison of fibrosis progression in chronic liver diseases. <b>2003</b> , 38, 257-65	338	
1920	Management of hepatitis C. <b>2003</b> , 38 Suppl 1, S104-18	98	
1919	Hepatitis C virus and renal failure. <b>2003</b> , 35, 416-8		
1918	Do we know how to achieve optimal response to Pegylated interferon alpha and Ribavirin?. <b>2003</b> , 39, 136-138	1	
1917	Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. <b>2003</b> , 39, 389-96	248	
1916	A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. <b>2003</b> , 39, 843-9	26	
1915	Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen. <b>2003</b> , 39, 826-33	25	
1914	Sustained virological response after a short course of treatment with interferon and ribavirin in two chronic hepatitis C patients. <b>2003</b> , 39, 655-6	10	
1913	Hepatocellular carcinoma. <i>Lancet, The</i> , <b>2003</b> , 362, 1907-17	40	3580
1912	Viral hepatitis C. <i>Lancet, The</i> , <b>2003</b> , 362, 2095-100	40	683

1911	[Use of erythropoietin in the treatment of anemia induced by ribavirin/interferon in patients with hepatitis C]. <b>2003</b> , 51, 520-4	4
1910	A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. <b>2003</b> , 44, 104-12	198
1909	Hepatitis C virus/HIV coinfection: a new challenge for nurses in AIDS care. <b>2003</b> , 14, 7S-17S	1
1908	Pathophysiology of hepatitis C and HIV coinfection. <b>2003</b> , 14, 27S-48S; quiz 49S-51S	2
1907	[Hepatitis C. Chronic hepatitis. Outcome and treatment]. <b>2003</b> , 58, 489-91	
1906	Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin. <b>2003</b> , 19, 1083-9	20
1905	Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. <b>2003</b> , 98, 2491-9	185
1904	Good safety profile and efficacy of leucocyte interferon-alpha in combination with oral ribavirin in treatment-naive patients with chronic hepatitis C: a multicentre, randomised, controlled study. <b>2003</b> , 17, 433-9	4
1903	Leucocyte interferon-alpha for patients with chronic hepatitis C intolerant to other alpha-interferons. <b>2003</b> , 17, 201-5	8
1902	Recent developments in the discovery of hepatitis C virus serine protease inhibitors--towards a new class of antiviral agents?. <b>2003</b> , 12, 153-63	33
1901	Interferon Biology, pharmacology and therapy for chronic viral hepatitis. <b>2003</b> , 1233-1254	1
1900	Hepatitis C-HIV coinfection: current and future therapy. <b>2003</b> , 1, 433-9	
1899	Current and emerging therapeutic approaches to hepatitis C infection. <b>2003</b> , 1, 441-54	6
1898	[Antiviral treatment in liver cirrhosis due to hepatitis C virus]. <i>Gastroenterología Y Hepatología</i> , <b>2003</b> , 26, 303-6	0.9
1897	Hepatitis B y C en niños. <b>2003</b> , 1, 71-79	
1896	Hepatitis C virus genetic variability: pathogenic and clinical implications. <b>2003</b> , 7, 45-66	165
1895	Development of a hepatitis C virus vaccine. <b>2003</b> , 7, 243-59, xi	27
1894	Hepatitis. <b>2003</b> , 30, 81-107	1

1893	Epidermodysplasia verruciformis with multiple mucosal carcinomas treated with pegylated interferon alfa and acitretin. <b>2003</b> , 14, 184-8	25
1892	Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. <b>2003</b> , 77, 3181-90	289
1891	Selection of DNA aptamers that bind the RNA-dependent RNA polymerase of hepatitis C virus and inhibit viral RNA synthesis in vitro. <b>2003</b> , 13, 455-63	41
1890	Molecular therapies for viral hepatitis. <b>2003</b> , 17, 81-91	8
1889	Stealth nucleosides: mode of action and potential use in the treatment of viral diseases. <b>2003</b> , 17, 169-77	12
1888	Interferon-alpha (IFN alpha) daily dose versus IFN alpha plus ribavirin for treatment-naive chronic hepatitis c patients infected by genotype 1b. <b>2003</b> , 17, 281-6	4
1887	Diagnosis of acute hepatitis C: anti-HCV or HCV-RNA?. <b>2003</b> , 38, 556-8	5
1886	Hepatitis C virus RNA levels during initial induction or standard interferon therapy: influence of continued treatment on sustained response. <b>2003</b> , 35, 180-5	3
1885	Treatment of hepatitis C. The 2002 French consensus. <b>2003</b> , 52, 1784-7	49
1884	Chronic hepatitis C virus infection. <b>2003</b> , 289, 2413-7	75
1883	Ribavirin quantification in combination treatment of chronic hepatitis C. <b>2003</b> , 47, 124-9	85
1882	Managing occupational risks for hepatitis C transmission in the health care setting. <b>2003</b> , 16, 546-68	79
1881	Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. <b>2003</b> , 187, 1264-71	54
1880	Should treatment of hepatitis C in HIV-seropositive and HIV-seronegative patients with hemophilia include induction doses of interferon?. <b>2003</b> , 37, 463-4; author reply 464-5	
1879	Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. <b>2003</b> , 14, 145-52	50
1878	Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. <b>2003</b> , 36, 97-100	137
1877	Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. <b>2003</b> , 188, 1498-507	84
1876	Hematologic disorders associated with hepatitis C virus infection and their management. <b>2003</b> , 37, 533-41	79

1875	Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection. <b>2003</b> , 188, 1528-32	15
1874	Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. <b>2003</b> , 52, 288-92	227
1873	Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. <b>2003</b> , 77, 546-59	107
1872	Hepatitis C virus therapies: current treatments, targets and future perspectives. <b>2003</b> , 14, 1-21	40
1871	Dinucleotide analogues as novel inhibitors of RNA-dependent RNA polymerase of hepatitis C Virus. <b>2003</b> , 47, 2674-81	7
1870	Implications of anemia in human immunodeficiency virus, cancer, and hepatitis C virus. <b>2003</b> , 37 Suppl 4, S293-6	7
1869	Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. <b>2003</b> , 290, 228-37	188
1868	Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfecting with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial. <b>2003</b> , 36, 1295-304	21
1867	Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. <b>2003</b> , 77, 1092-104	194
1866	Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon?. <b>2003</b> , 51, 487-91	16
1865	Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. <b>2003</b> , 52, 425-32	157
1864	Hepatitis C virus. <b>2003</b> , 127-171	
1863	Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions. <b>2003</b> , 98, 2344-7	7
1862	Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT. <b>2003</b> , 98, 1588-93	52
1861	Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patients. <b>2003</b> , 187, 982-7	14
1860	Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfecting patients. <b>2003</b> , 36, 1564-71	12
1859	Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases. <b>2003</b> , 52, 1644-8	34
1858	Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. <b>2003</b> , 100, 6753-8	135



1857	Drugs acting on the immune system. <b>2003</b> , 26, 393-415	
1856	Promising candidates for the treatment of chronic hepatitis C. <b>2003</b> , 12, 1269-80	16
1855	Pharmacokinetics and metabolism of [ <sup>14</sup> C]viramidine in rats and cynomolgus monkeys. <b>2003</b> , 47, 2458-63	22
1854	Anemia in the treatment of hepatitis C virus infection. <b>2003</b> , 37 Suppl 4, S315-22	62
1853	Peptide inhibitors of hepatitis C virus NS3 protease. <b>2003</b> , 14, 225-33	5
1852	Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy. <b>2003</b> , 17, 2279-90	35
1851	Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. <b>2003</b> , 17, 1023-8	143
1850	[Combination therapy for chronic viral hepatitis C]. <b>2003</b> , 128, 370-4	
1849	Clinical trial results of peginterferons in combination with ribavirin. <b>2003</b> , 23 Suppl 1, 35-46	18
1848	Implications of peginterferon use in special populations infected with HCV. <b>2003</b> , 23 Suppl 1, 47-52	4
1847	Hepatitis C virus RNA tests: performance attributes and their impact on clinical utility. <b>2003</b> , 3, 689-702	3
1846	Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice. <b>2003</b> , 98, 1159-66	26
1845	Peginterferon alfa-2a plus ribavirin for chronic hepatitis C. <b>2003</b> , 348, 259-60; author reply 259-60	6
1844	Hepatitis C virus in human immunodeficiency virus-infected individuals: an emerging comorbidity with significant implications. <b>2003</b> , 23, 149-66	22
1843	Minilaparoscopy for early diagnosis of cirrhosis: is the endoscopist's eye better than the histopathologist's?. <b>2003</b> , 35, 74-5	4
1842	Viral kinetics in hepatitis C virus: special patient populations. <b>2003</b> , 23 Suppl 1, 29-33	11
1841	Diagnostic testing in hepatitis C virus infection: viral kinetics and genomics. <b>2003</b> , 23 Suppl 1, 3-11	4
1840	Treatment of chronic hepatitis C virus infection. <b>2003</b> , 17, 751-753	25

1839	Treatment considerations in patients with hepatitis C and cirrhosis. <b>2003</b> , 37, 395-8	15
1838	Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. <b>2003</b> , 9, 93-110	43
1837	Hepatitis B and C virus infections in the immune compromised. <b>2003</b> , 16, 473-9	6
1836	Didanosine+ribavirin combination. <b>2003</b> , 17, 2665-2667	4
1835	A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients. <b>2003</b> , 36, 352-5	14
1834	Intrafamilial transmission of HIV-1. <b>2003</b> , 17, 2673-4	
1833	The nature of interferon-alpha resistance in hepatitis C virus infection. <b>2003</b> , 16, 587-92	63
1832	Hepatitis C virus RNA load in relapsed patients. <b>2003</b> , 15, 1067-1071	4
1831	First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C. <b>2003</b> , 15, 1299-304	4
1830	Chronic hepatitis C: updated Swedish consensus. <b>2003</b> , 35, 445-51	19
1829	A physician with a positive hepatitis C virus RNA test after a needlestick injury. <b>2003</b> , 15, 1367-9	5
1828	Hepatitis C: a review. <b>2003</b> , 112, 597-605	5
1827	Response to Soriano et al., Treatment of chronic hepatitis C virus infection. <b>2003</b> , 17, 2665-2667	1
1826	Antiviral Agents. <b>2003</b> ,	
1825	Hepatitis C in the HIV-Infected Person. <b>2003</b> , 138, 197-207	299
1824	Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. <b>2003</b> , 102, 996-9	247
1823	Responding to blood-borne infections among persons with severe mental illness. <b>2003</b> , 54, 860-5	22
1822	Hepatitis C Virus (HCV). <b>2003</b> , 30, 239-250	2

1821	Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS. <b>2003</b> , 124, 406-10	50
1820	Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients. <b>2003</b> , 114, 48-52, 57-9, 62	5
1819	Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial. <b>2003</b> , 2, 135-139	12
1818	A rational use of laboratory tests in the diagnosis and management of hepatitis C virus infection. <b>2003</b> , 2, 76-83	9
1817	Genetic diversity in the major histocompatibility complex and the immune response to infectious diseases. <b>2003</b> , 77-116	1
1816	Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting. <b>2003</b> , 178, 267-71	16
1815	Early prediction of nonresponders to treatment with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. <b>2003</b> , 17, 483-7	6
1814	New developments in the treatment of hepatitis C. <b>2003</b> , 52, 756-7	4
1813	Aperçū d'une anthropologie du vaccin: regards sur l'Éthique d'une pratique humanitaire. <b>2003</b> , 10, 519-536	3
1812	[Therapy of viral hepatitis]. <b>2003</b> , 60, 651-6	
1811	Treatment of HCV-related liver diseases after renal transplantation: modern views. <b>2003</b> , 26, 373-82	3
1810	[Hepatitis: associated diseases. Risk groups -- prevention -- treatment]. <b>2003</b> , 92, 1351-7	0
1809	Hepatitis C in haemophiliacs. <b>2004</b> , 92, 1259-68	18
1808	[Hepatitis C]. <b>2004</b> , 61, 493-8	2
1807	Prescribing practices for the treatment of hepatitis C in a Veterans Affairs medical center. <b>2004</b> , 61, 1479-82	
1806	Side effects of medical therapy for chronic hepatitis C. <b>2004</b> , 3, 5-10	30
1805	9 Infektionen der Leber. <b>2004</b> ,	
1804	Hepatitis C: An Update for Occupational Health Nurses. <b>2004</b> , 52, 210-217	1

1803	Diagnosis and Treatment of Hepatitis C. <b>2004</b> , 97, 223-225	8
1802	Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy. <b>2004</b> , 5, 41-56	19
1801	Skin reaction in antiviral therapy for chronic hepatitis C: a role for polyethylene glycol interferon?. <b>2004</b> , 84, 120-3	12
1800	An audit of obstetricians' management of women potentially infected with blood-borne viruses. <b>2004</b> , 180, 328-32	14
1799	Hepatitis Viruses. 199-247	1
1798	The management of chronic viral hepatitis: A Canadian consensus conference 2004. <b>2004</b> , 15, 313-26	10
1797	The challenge of recurrent hepatitis C virus in liver transplant recipients. <b>2004</b> , 18 Suppl C, 19C-26C	1
1796	The management of chronic viral hepatitis: a Canadian consensus conference 2004. <b>2004</b> , 18, 715-28	41
1795	Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?. <b>2004</b> , 140, 370-81	184
1794	Recent developments in target identification against hepatitis C virus. <b>2004</b> , 8, 295-307	7
1793	Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection. <b>2004</b> , 47, 355-61	17
1792	Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. <b>2004</b> , 24 Suppl 2, 47-54	61
1791	Liver biopsy sampling in chronic viral hepatitis. <b>2004</b> , 24, 89-97	146
1790	[Treatment of hepatitis B and C -- current standards]. <b>2004</b> , 129 Suppl 2, S57-9	0
1789	Chronic hepatitis C. <b>2004</b> , 24 Suppl 2, 1-2	3
1788	Cost-effectiveness of pegylated IFN-alpha2b and -2a and ribavirin for chronic hepatitis C treatment. <b>2004</b> , 4, 495-504	1
1787	Predictors of response to therapy for chronic hepatitis C. <b>2004</b> , 24 Suppl 2, 25-31	65
1786	Treatment of chronic hepatitis C in blacks and non-Hispanic whites. <b>2004</b> , 351, 831-2; author reply 831-2	

1785	Treatment of advanced head and neck cancer. <b>2004</b> , 351, 829-31; author reply 829-31	2
1784	[Standard treatment of acute and chronic hepatitis C]. <b>2004</b> , 42, 714-9	24
1783	Histological response to interferon alfa-based therapies in hepatitis C. <b>2004</b> , 24 Suppl 2, 55-60	9
1782	Biologic immunomodulatory therapies in the vasculitic diseases. <b>2004</b> , 25, 595-607	3
1781	Is the current standard therapy for hepatitis C of peginterferon and ribavirin an option for patients coinfecting with HIV?. <b>2004</b> , 1, 70-1	
1780	Interferon for hepatitis C patients with psychiatric disorders. <b>2004</b> , 161, 2331-2; author reply 2332-4	10
1779	[Criteria for the definition of acute and chronic hepatitis C]. <b>2004</b> , 42, 707-13	4
1778	Past, present, and future hepatitis C treatments. <b>2004</b> , 24 Suppl 2, 97-104	49
1777	MxA and PKR expression in chronic hepatitis C. <b>2004</b> , 24, 659-63	15
1776	Evaluation of the core antigen assay as a second-line supplemental test for diagnosis of active hepatitis C virus infection. <b>2004</b> , 42, 4054-9	21
1775	Hepatitis C virus quasispecies variability modulates nonstructural protein 5A transcriptional activation, pointing to cellular compartmentalization of virus-host interactions. <b>2004</b> , 78, 4617-27	24
1774	Interaction between HIV-1 and HCV infections: towards a new entity?. <b>2004</b> , 53, 936-46	21
1773	Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. <b>2004</b> , 53, 1345-51	115
1772	Synthesis of beta-enantiomers of N4-hydroxy-3'-deoxypyrimidine nucleosides and their evaluation against bovine viral diarrhoea virus and hepatitis C virus in cell culture. <b>2004</b> , 15, 43-55	14
1771	Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver. <b>2004</b> , 48, 1872-5	24
1770	Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. <b>2004</b> , 53, 425-30	125
1769	Epidemiology, Diagnosis, and Treatment of Chronic Hepatitis C. <b>2004</b> , 17, 229-238	
1768	Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. <b>2004</b> , 38, 128-33	249

1767	HIV Infection, hepatitis C infection, and HAART: hard clinical choices. <b>2004</b> , 292, 243-50	22
1766	Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. <b>2004</b> , 53, 744-9	323
1765	Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. <b>2004</b> , 78, 13779-92	228
1764	Antiretroviral therapy in patients with hepatitis and HIV: weighing risks and benefits. <b>2004</b> , 38 Suppl 2, S109-13	25
1763	Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. <b>2004</b> , 292, 2839-48	626
1762	Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. <b>2004</b> , 42, 421-5	29
1761	Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin. <b>2004</b> , 48, 4006-8	16
1760	Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood. <b>2004</b> , 48, 3813-6	28
1759	Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. <b>2004</b> , 164, 2371-6	45
1758	A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load. <b>2004</b> , 47, 102-7	9
1757	Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. <b>2004</b> , 53, 1504-8	126
1756	Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase. <b>2004</b> , 48, 4813-21	49
1755	Use of the MagNA pure LC automated nucleic acid extraction system followed by real-time reverse transcription-PCR for ultrasensitive quantitation of hepatitis C virus RNA. <b>2004</b> , 42, 4130-6	42
1754	Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. <b>2004</b> , 19, 3054-61	191
1753	Treatment of hepatitis C in HIV-infected patients: significant progress but not the final step. <b>2004</b> , 292, 2909-13	11
1752	Dominant negative effect of wild-type NS5A on NS5A-adapted subgenomic hepatitis C virus RNA replicon. <b>2004</b> , 85, 1867-1875	10
1751	Management of hepatitis C. <b>2004</b> , 70, 51-69	14
1750	Pegylated interferons. <b>2004</b> , 2, 113-127	1

1749	Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. <b>2004</b> , 189, 1397-400	47
1748	Treatment of early diagnosed HCV infection in hemodialyzed patients with interferon-alpha. Treatment of hepatitis C. <b>2004</b> , 22, 344-50	19
1747	Changes in hepatitis C viral response after initiation of highly active antiretroviral therapy and control of HIV viremia in chronically co-infected individuals. <b>2004</b> , 5, 25-32	8
1746	Can epoetin alfa maintain ribavirin doses in patients with hepatitis C virus on combination therapy?. <b>2004</b> , 1, 24-5	1
1745	Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. <b>2004</b> , 18, 59-66	37
1744	Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. <b>2004</b> , 18, 67-73	64
1743	The bisexual bridge revisited: sexual risk behavior among men who have sex with men and women, San Francisco, 1998-2003. <b>2004</b> , 18, 1604-6	40
1742	Screening for HIV-specific T-cell responses using overlapping 15-mer peptide pools or optimized epitopes. <b>2004</b> , 18, 1595-8	34
1741	A single-nucleotide polymorphism in the human beta-defensin 1 gene is associated with HIV-1 infection in Italian children. <b>2004</b> , 18, 1598-600	110
1740	Verification of an assay for quantification of hepatitis C virus RNA by use of an analyte-specific reagent and two different extraction methods. <b>2004</b> , 42, 3581-8	24
1739	Answer. <b>2004</b> , 53, 430-430	2
1738	Complexity and diversity of hepatitis C virus RNA in african americans and whites: analysis of the envelope-coding domain. <b>2004</b> , 190, 511-4	7
1737	Pegylated interferons. <b>2004</b> , 2, 113-127	
1736	Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. <b>2004</b> , 99, 1733-7	95
1735	A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy. <b>2004</b> , 99, 2359-64	20
1734	Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. <b>2004</b> , 63 Suppl 2, ii18-ii24	110
1733	Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response?. <b>2004</b> , 99, 866-72	55
1732	Chronic hepatitis C and normal ALT: considerations for treatment. <b>2004</b> , 99, 1706-7	4

1731	Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. <b>2004</b> , 20, 351-3	36
1730	Sensitivity of hepatitis C virus RNA to the antiviral enzyme ribonuclease L is determined by a subset of efficient cleavage sites. <b>2004</b> , 24, 664-76	44
1729	Atlas of the Liver. <b>2004</b> ,	
1728	Phacomatosis pigmentokeratolica complicated with juvenile onset hypertension. <b>2004</b> , 84, 397-8	3
1727	Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). <b>2004</b> , 42, 563-9	83
1726	Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. <b>2004</b> , 350, 2265-71	485
1725	Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. <b>2004</b> ,	7
1724	HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. <b>2004</b> , 38 Suppl 2, S65-72	87
1723	A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. <b>2004</b> , 189, 964-70	79
1722	Treatment of chronic hepatitis C in children. <b>2004</b> , 8, 639-43	9
1721	Management of chronic hepatitis C virus infection: a new era of disease control. <b>2004</b> , 34, 324-37	20
1720	Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?. <b>2004</b> , 19, 551-7	17
1719	Management of hepatitis C virus genotype 4. <b>2004</b> , 19, 1233-9	18
1718	Treatment of hepatitis C virus infection in patients of northern India. <b>2004</b> , 19, 1058-65	14
1717	Factors contributing to ribavirin-induced anemia. <b>2004</b> , 19, 1312-7	66
1716	Natural history and treatment of hepatitis C infection in children. <b>2004</b> , 19, S379-S381	2
1715	Treatment of chronic HCV infection in compensated and decompensated cirrhosis. <b>2004</b> , 19, S94-S98	
1714	Hepatitis C viral kinetics. <b>2004</b> , 19, S133-S137	2



1713	Interactions between non-alcoholic fatty liver disease and hepatitis C viral infection. <b>2004</b> , 19, S253-S257	3
1712	Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?. <b>2004</b> , 99, 1167-75	90
1711	A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy. <b>2004</b> , 19, 339-47	11
1710	Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy. <b>2004</b> , 19, 551-62	30
1709	Review article: the evolving role of liver biopsy. <b>2004</b> , 20, 249-59	81
1708	Combination therapy for the treatment of hepatitis C in the veteran population: higher than expected rates of therapy discontinuation. <b>2004</b> , 20, 629-36	6
1707	Review article: pegylated interferons: chemical and clinical differences. <b>2004</b> , 20, 825-30	76
1706	The management of side-effects during therapy for hepatitis C. <b>2004</b> , 20, 917-29	42
1705	Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. <b>2004</b> , 20, 931-8	71
1704	Interest of transjugular liver biopsy in adult patients with haemophilia or other congenital bleeding disorders infected with hepatitis C virus. <b>2004</b> , 125, 769-76	18
1703	Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients. <b>2004</b> , 136, 328-33	28
1702	CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection. <b>2004</b> , 137, 408-16	30
1701	Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. <b>2004</b> , 10, 413-21	22
1700	Hepatitis C infection in children with haemophilia: a pilot study. <b>2004</b> , 10, 722-6	8
1699	Same day outpatient transjugular liver biopsies in haemophilia. <b>2004</b> , 10, 727-31	20
1698	Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. <b>2004</b> , 11, 243-50	123
1697	Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C. <b>2004</b> , 11, 206-16	18
1696	Polymorphisms of NS5B protein relates to early clearance of hepatitis C virus by interferon plus ribavirin: a pilot study. <b>2004</b> , 11, 225-35	10

1695	Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C. <b>2004</b> , 11, 191-7	13
1694	Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expression. <b>2004</b> , 11, 310-8	11
1693	Treatment of patients with HCV infection with or without liver biopsy. <b>2004</b> , 11, 536-42	16
1692	A multicentre study of the usefulness of liver biopsy in hepatitis C. <b>2004</b> , 11, 375-82	16
1691	Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options. <b>2004</b> , 11, 287-96	15
1690	Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads. <b>2004</b> , 11, 448-54	10
1689	Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. <b>2004</b> , 11, 479-87	55
1688	A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. <b>2004</b> , 11, 543-51	9
1687	Hepatitis C: How should we manage the patient?. <b>2004</b> , 11 Suppl 1, 19-22	3
1686	Hepatitis C: What is the best treatment?. <b>2004</b> , 11 Suppl 1, 23-7	18
1685	Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients. <b>2004</b> , 44, 790-4	13
1684	A randomized, double-blind, placebo-controlled clinical trial of high-dose interferon-alpha induction treatment combined with ribavirin for chronic hepatitis C in hemophilia. <b>2004</b> , 2, 194-6	10
1683	Lymphocyte T helper-specific reactivity in sustained responders to interferon and ribavirin with negativation (seroreversion) of anti-hepatitis C virus. <b>2004</b> , 24, 413-8	8
1682	Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan. <b>2004</b> , 24, 595-602	14
1681	Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy. <b>2004</b> , 24, 603-10	53
1680	A primer on the molecular virology of hepatitis C. <b>2004</b> , 24, 519-25	19
1679	Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. <b>2004</b> , 24, 568-74	67
1678	Hepatitis C virus infection in San Francisco's HIV-infected urban poor. <b>2004</b> , 19, 357-65	77

1677	Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon. <b>2004</b> , 10, 1067-74	5
1676	Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. <b>2004</b> , 10, 290-3	329
1675	Inducible nitric oxide synthase gene (NOS2A) haplotypes and the outcome of hepatitis C virus infection. <b>2004</b> , 5, 183-7	14
1674	Host genetic determinants in hepatitis C virus infection. <b>2004</b> , 5, 237-45	101
1673	Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. <b>2004</b> , 432, 922-4	307
1672	Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. <b>2004</b> , 4, 1375-8	19
1671	What is disrupting IFN-alpha's antiviral activity?. <b>2004</b> , 22, 395-9	28
1670	Biomedicines to reduce inflammation but not viral load in chronic HCV--what's the sense?. <b>2004</b> , 22, 517-23	34
1669	Performance attributes of the LCx HCV RNA quantitative assay. <b>2004</b> , 115, 207-15	14
1668	[Acute hepatitis C: early, delayed or immediate treatment?]. <b>2004</b> , 28, 126-8	1
1667	[Obesity and alcoholic and viral chronic liver disease]. <b>2004</b> , 28, 268-71	1
1666	[Is combined treatment with interferon alpha and ribavirin for 3 months enough in selected patients with a genotype 2 or 3 hepatitis C virus?]. <b>2004</b> , 28, 304-6	
1665	[Treatment of hepatitis C and drug addiction: is the development of "clinically significant" fibrosis a good decision-making criterion?]. <b>2004</b> , 28, 529-31	
1664	Management of hepatitis C patients: a French population-based study. <b>2004</b> , 28, 1101-5	4
1663	Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. <b>2004</b> , 43, 617-23	140
1662	Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy. <b>2004</b> , 24, 1546-53	24
1661	Hepatitis C prevention and treatment for substance users in the United States: acknowledging the elephant in the living room. <b>2004</b> , 15, 81-91	22
1660	A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors. <b>2004</b> , 63, 25-32	17

1659	A novel therapy for acute hepatitis utilizing dehydroepiandrosterone in the murine model of hepatitis. <b>2004</b> , 68, 2283-9	12
1658	Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. <b>2004</b> , 25, 472-92	151
1657	Elective cesarean delivery to prevent perinatal transmission of hepatitis C virus: a cost-effectiveness analysis. <b>2004</b> , 191, 998-1003	10
1656	What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?. <b>2004</b> , 23, 261-72	19
1655	Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada. <b>2004</b> , 81, 428-47	40
1654	Cell-mediated immunity and the outcome of hepatitis C virus infection. <b>2004</b> , 58, 391-424	168
1653	Natural interferon alpha treatment and interferon alpha receptor 2 levels in acute hepatitis C. <b>2004</b> , 49, 289-94	3
1652	Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. <b>2004</b> , 49, 1000-6	26
1651	Hepatitis C virus infection and the brain. <b>2004</b> , 19, 351-6	9
1650	A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan. <b>2004</b> , 39, 570-4	55
1649	Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. <b>2004</b> , 39, 668-73	290
1648	Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment. <b>2004</b> , 39, 776-82	11
1647	Ribavirin-induced hemolytic anemia in chronic hepatitis C patients. <b>2004</b> , 39, 704-5	4
1646	Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C. <b>2004</b> , 39, 1090-4	5
1645	How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients. <b>2004</b> , 39, 1125-6	
1644	Positive effect of the hepatitis C virus nonstructural 5A protein on viral multiplication. <b>2004</b> , 149, 1353-71	13
1643	Utility of a novel HCV-NS4 antigen detection immunoassay for monitoring treatment of HCV-infected individuals with pegylated interferon $\alpha$ a. <b>2004</b> , 28, 68-72	4
1642	Differences in epidemiology, liver disease and treatment response among HCV genotypes. <b>2004</b> , 29, 129-135	25

1641	Identification of [(naphthalene-1-carbonyl)-amino]-acetic acid derivatives as nonnucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase. <b>2004</b> , 14, 4221-4	9
1640	Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection. <b>2004</b> , 49, 1966-70	19
1639	[Hepatitis (Hep-Net) competence network]. <b>2004</b> , 45, 415-21	3
1638	Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine. <b>2004</b> , 116, 530-5	4
1637	Guidelines for stopping therapy in chronic hepatitis C. <b>2004</b> , 6, 17-21	16
1636	Fat, diabetes, and liver injury in chronic hepatitis C. <b>2004</b> , 6, 22-9	34
1635	New therapies for chronic hepatitis C virus infection. <b>2004</b> , 6, 77-86	15
1634	When to treat patients with chronic hepatitis C. <b>2004</b> , 6, 261-3	
1633	Update on viral kinetics and hcv antiviral therapy. <b>2004</b> , 3, 5-9	
1632	Adherence to antiviral therapy in chronic hepatitis C. <b>2004</b> , 3, 10-15	2
1631	Current status of immunomodulatory therapies in HCV infection. <b>2004</b> , 3, 16-22	2
1630	Maintenance therapies for hepatitis C. <b>2004</b> , 3, 23-29	2
1629	Recent peginterferon and ribavirin combination trials. <b>2004</b> , 3, 30-37	4
1628	Hematopoietic growth factors for acute myelogenous leukemia. <b>2004</b> , 3, 38-9	1
1627	Alcohol and hepatitis C: Implications for disease progression and treatment. <b>2004</b> , 3, 105-111	
1626	Hepatitis C virus among african-american persons. <b>2004</b> , 3, 129-135	1
1625	Acute hepatitis C infection: Can immunology teach us the right way to treat?. <b>2004</b> , 3, 148-156	2
1624	Nonresponders to Previous Chronic Hepatitis C Treatment. <b>2004</b> , 7, 469-475	1

1623	Current Treatment for Chronic Hepatitis C. <b>2004</b> , 7, 491-499	4
1622	Treatment Options for Hepatitis C Infection in Children. <b>2004</b> , 7, 373-379	9
1621	Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. <b>2004</b> , 32, 33-46	79
1620	Combination therapy with ribavirin and interferon in a cohort of children with hepatitis C and haemophilia followed at a pediatric haemophilia treatment center. <b>2004</b> , 10, 87-93	13
1619	Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial. <b>2004</b> , 11, 69-73	18
1618	Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. <b>2004</b> , 11, 84-7	81
1617	Reversible myopathy during successful treatment with pegylated interferon and ribavirin for acute hepatitis C. <b>2004</b> , 11, 183-6	5
1616	Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. <b>2004</b> , 11, 157-65	42
1615	Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. <b>2004</b> , 11, 2-17	46
1614	Response to article by Formann et Al. (2003). <b>2004</b> , 11, 187; author reply 189-90	2
1613	Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. <b>2004</b> , 18, 166-73	90
1612	HIV and HCV coinfection in haemophilia. <b>2004</b> , 10, 1-8	66
1611	Subtype mutations in the envelope 2 region including phosphorylation homology domain of hepatitis C virus do not predict effectiveness of antiviral therapy. <b>2004</b> , 11, 45-54	9
1610	A comparison of hepatitis C treatment and outcomes at academic, private and Veterans' Affairs treatment centres. <b>2004</b> , 19, 69-77	8
1609	Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. <b>2004</b> , 39, 554-67	51
1608	Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin. <b>2004</b> , 39, 989-98	58
1607	Diagnosis, management, and treatment of hepatitis C. <b>2004</b> , 39, 1147-71	1280
1606	Defining the standard of care: randomized controlled trials for the treatment of hepatitis C in the HIV-infected person. <b>2004</b> , 39, 906-8	6

1605	Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. <b>2004</b> , 39, 1213-9	132
1604	Low membrane protein sulfhydryls but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C. <b>2004</b> , 39, 1248-55	26
1603	Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. <b>2004</b> , 39, 1702-8	234
1602	Effects of antiviral therapy on the cellular immune response in acute hepatitis C. <b>2004</b> , 40, 87-97	120
1601	Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. <b>2004</b> , 39, 1721-31	141
1600	A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. <b>2004</b> , 40, 120-4	135
1599	Long-term follow-up after successful interferon therapy of acute hepatitis C. <b>2004</b> , 40, 98-107	62
1598	Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. <b>2004</b> , 40, 1078-87	193
1597	Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. <b>2004</b> , 40, 1260-5	233
1596	Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. <b>2004</b> , 40, 1450-8	119
1595	Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. <b>2004</b> , 40, 1442-9	34
1594	Tinkering and tailoring with HCV therapy: can we get away with less?. <b>2004</b> , 40, 1249-51	5
1593	Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. <b>2004</b> , 10, 199-207	123
1592	Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing. <b>2004</b> , 10, 595-8	23
1591	Predictive value of early HCV RNA quantitation for sustained response in nonresponders receiving daily interferon and ribavirin therapy. <b>2004</b> , 72, 46-51	5
1590	High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. <b>2004</b> , 73, 387-91	89
1589	The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment. <b>2004</b> , 73, 392-6	17
1588	Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. <b>2004</b> , 74, 41-53	30

1587	Laparoscopic splenectomy reverses thrombocytopenia in patients with hepatitis C cirrhosis and portal hypertension. <b>2004</b> , 8, 120-6	65
1586	Cell culture and animal models for human viral hepatitis. <b>2004</b> , 28, 61-67	2
1585	Medical treatment of viral pneumonia including SARS in immunocompetent adult. <b>2004</b> , 49, 262-73	78
1584	Treatment of chronic viral hepatitis. <b>2004</b> , 18 Suppl, 113-20	5
1583	Histological findings, genotype distribution and percentage of patients fulfilling the treatment criteria among patients with chronic hepatitis C virus infection in a single Swedish centre. <b>2004</b> , 39, 164-7	7
1582	Rapporto costo-efficacia della terapia peginterferone $\alpha$ 2a + ribavirina in confronto a interferone $\alpha$ 2b + ribavirina in pazienti affetti da epatite cronica di tipo C precedentemente non trattati. <b>2004</b> , 6, 105-114	3
1581	Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. <b>2004</b> , 18, 239-45	35
1580	Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. <b>2004</b> , 22, 257-65	55
1579	Interleukin-2 plus ribavirin versus interferon-alpha-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-alpha-2b treatment. <b>2004</b> , 18, 407-13	4
1578	Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. <b>2004</b> , 140, 346-55	2231
1577	Future trends in managing hepatitis C. <b>2004</b> , 33, S51-61	17
1576	Nonresponders to hepatitis C virus antiviral therapy: pegylated interferons and beyond. <b>2004</b> , 33, 527-47, viii	6
1575	Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. <b>2004</b> , 2, 425-31	21
1574	Role of epoetin alfa in maintaining ribavirin dose. <b>2004</b> , 33, S25-35	18
1573	Treating hepatitis C: the state of the art. <b>2004</b> , 33, S1-9	9
1572	Treatment of relapsers after combination therapy for chronic hepatitis C. <b>2004</b> , 33, 513-26, viii	4
1571	Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (octubre 2004). <b>2004</b> , 22, 564-642	1
1570	Sarcoidosis tras tratamiento con interferón y ribavirina. Presentación de un caso y revisión de la bibliografía. <b>2004</b> , 40, 45-49	9



1569	Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. <b>2004</b> , 2, 183-97	16
1568	Adherence to combination therapy: influence on sustained virologic response and economic impact. <b>2004</b> , 33, S11-24	22
1567	Treatment of chronic hepatitis B: who to treat, what to use, and for how long?. <b>2004</b> , 2, 839-48	24
1566	[Treatment of hepatitis C in nonresponders to ribavirin and/or interferon]. <i>Gastroenterology</i> & <i>Hepatology</i> , <b>2004</b> , 27, 24-6	0.9
1565	Hepatitis C virus antiviral therapy in patients with cirrhosis. <b>2004</b> , 33, 549-62, ix	6
1564	Antiviral therapy for treatment naïve patients with hepatitis C virus. <b>2004</b> , 33, 497-511, viii	6
1563	[Necrotic lesion in a patient with hepatitis C virus liver disease under treatment with pegylated interferon]. <b>2004</b> , 22, 497-8	1
1562	A general approach to the management of chronic hepatitis C. <b>2004</b> , 33, 463-77, vii	1
1561	Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. <b>2004</b> , 351, 451-9	753
1560	Treatment of the hepatitis C virus in patients coinfecting with HIV. <b>2004</b> , 33, 479-96, vii-viii	2
1559	Sarcoidosis Following Combined Ribavirin and Interferon Therapy: a Case Report and Review of the Literature. <b>2004</b> , 40, 45-49	9
1558	Foreword. <b>2004</b> , 36, S333	1
1557	Pharmacokinetics of pegylated interferons: what is misleading?. <b>2004</b> , 36 Suppl 3, S334-9	39
1556	Early virologic response with pegylated interferons. <b>2004</b> , 36 Suppl 3, S340-3	7
1555	Treatment of cirrhotic patients in the pegylated interferon era. <b>2004</b> , 36 Suppl 3, S344-8	6
1554	Weight-based dosing: which impact on efficacy and safety of therapy?. <b>2004</b> , 36 Suppl 3, S349-53	6
1553	Antiviral action of ribavirin in chronic hepatitis C. <b>2004</b> , 126, 703-14	238
1552	Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. <b>2004</b> , 126, 1015-23; discussion 947	393

1551	Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. <b>2004</b> , 126, 1302-11	471
1550	Chronic hepatitis C with normal aminotransferase levels. <b>2004</b> , 126, 1409-15	33
1549	Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. <b>2004</b> , 127, 1347-55	284
1548	Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. <b>2004</b> , 127, 1724-32	190
1547	Treatment of chronic hepatitis C in naive patients with high-dose interferon-alpha2a induction therapy and two different ribavirin doses. <b>2004</b> , 36, 367-8	
1546	Reported risk factors are useless in detecting HCV-positive subjects in the general population. <b>2004</b> , 36, 547-50	2
1545	Natural history of initially mild chronic hepatitis C. <b>2004</b> , 36, 646-54	38
1544	Care of the Adult Patient with HIV Infection. <b>2004</b> , 305-370	
1543	Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors. <b>2004</b> , 47, 6603-8	89
1542	Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations. <b>2004</b> , 27, 7-24	10
1541	Treatment of hepatitis C in solid organ transplantation. <b>2004</b> , 64, 489-98	8
1540	Challenges in the management of HIV and hepatitis C virus co-infection. <b>2004</b> , 64, 693-700	8
1539	Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection. <b>2004</b> , 64, 2823-43	10
1538	Serum levels of hepatitis C virus core antigen as a marker of infection and response to therapy. <b>2004</b> , 99, 1738-43	19
1537	Hepatitis Prevention and Treatment. <b>2004</b> ,	
1536	Coinfection VIH-VHC : Quelle prise en charge ?. <b>2004</b> , 6, 151-163	
1535	Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. <b>2004</b> , 44, 265-75	44
1534	Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT. <b>2004</b> , 99, 1700-5	34

1533 Chronic viral hepatitis. **2004**, 45-58

1532 Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. **2004**, 351, 438-50 1079

1531 Peginterferon-alpha(2b) and ribavirin. **2004**, 2, 17-25 15

1530 New antiviral therapies for hepatitis C. **2004**, 2, 235-43

1529 Hepatitis C drug discovery: in vitro and in vivo systems and drugs in the pipeline. **2004**, 2, 375-88 2

1528 Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression. **2004**, 33, S35-50 22

1527 Increased sensitivity of the Roche COBAS AMPLICOR HCV test, version 2.0, using modified extraction techniques. **2004**, 6, 225-30 3

1526 A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States. **2004**, 73, 227-36 18

1525 The utility of indirect predictors of hepatitis C viremia. **2004**, 74, 15-9 6

1524 Expression, purification, and characterization of rat interferon-beta, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters. **2004**, 34, 229-42 38

1523 De novo cryptogenic hepatitis after sustained eradication of hepatitis C following liver transplantation. **2004**, 36, 1494-7 7

1522 A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. **2004**, 22, 3080-6 58

1521 A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins. **2004**, 23, 58-68 38

1520 Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus. **2004**, 30, 283-90 25

1519 TaqMan amplification system with an internal positive control for HCV RNA quantitation. **2004**, 31, 227-34 67

1518 Comparing the public health burden of chronic hepatitis C and HIV infection in France. **2004**, 40, 319-26 51

1517 Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. **2004**, 40, 478-83 35

1516 Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin. **2004**, 40, 527-32 22

1515	Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. <b>2004</b> , 40, 669-74	187
1514	Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. <b>2004</b> , 40, 689-95	34
1513	Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis C. <b>2004</b> , 40, 845-52	22
1512	HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. <b>2004</b> , 40, 831-6	38
1511	Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses. <b>2004</b> , 40, 971-8	22
1510	Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. <b>2004</b> , 40, 993-9	346
1509	Inhibition of hepatitis C virus NS3-mediated cell transformation by recombinant intracellular antibodies. <b>2004</b> , 40, 1000-7	14
1508	Optimizing PEG-interferon and ribavirin combination therapy for patients infected with HCV-2 or HCV-3: is the puzzle completed?. <b>2004</b> , 40, 1032-5	11
1507	A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. <b>2004</b> , 41, 312-8	6
1506	Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. <b>2004</b> , 41, 474-81	83
1505	Induction therapy in chronic hepatitis C: dfficu with pegylated interferons?. <b>2004</b> , 41, 488-90	6
1504	Hepatitis C treatment update. <b>2004</b> , 117, 344-52	63
1503	[A pluridisciplinary point of view of hepatitis C virus infections]. <b>2004</b> , 33, 544-9	
1502	HIV and hepatitis C virus co-infection. <b>2004</b> , 4, 437-44	135
1501	Tratamiento de la infecci3n por VHB y VHC. <b>2004</b> , 9, 674-680	
1500	Fortschritte auf dem Gebiet der Lebertransplantation. <b>2004</b> , 20, 28-35	0
1499	?HCV?C????????????????????????????????HCV????v2.0(?????)???. <b>2004</b> , 45, 223-223	2
1498	Evaluation of common liver problems. <b>2004</b> , 94, 149-56	1

1497	Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial. <b>2004</b> , 35, 464-72	20
1496	Dr. Hendin and Colleagues Reply. <b>2004</b> , 161, 2330-2331	1
1495	Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients. <b>2004</b> , 18, 1602-4	2
1494	Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. <b>2004</b> , 77, 190-4	151
1493	Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. <b>2004</b> , 77, 1066-70	52
1492	Diagnosis and treatment of hepatitis C. <b>2004</b> , 97, 223-5	10
1491	Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. <b>2004</b> , 161, 429-35	44
1490	Hepatitis C: an emerging epidemic. <b>2004</b> , 6, 589-605	0
1489	New hopes for HIV and HCV coinfection in 2004. <b>2004</b> , 5, 232-51	7
1488	Successful long-term application of highly purified natural interferon-alpha (multiferon) after preceding interferon approaches in a chronic hepatitis C patient with thrombocytopenia. <b>2004</b> , 36, 395-9	4
1487	Knowledge of chronic hepatitis C among East London primary care physicians following the Department of Health's educational campaign. <b>2004</b> , 97, 331-6	30
1486	Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. <b>2004</b> , 140, 215-7	37
1485	Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. <b>2004</b> , 18, F27-36	277
1484	Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin. <b>2004</b> , 18, 1805-9	19
1483	The prostate as a reservoir for HIV-1. <b>2004</b> , 18, 1600-2	24
1482	Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. <b>2004</b> , 18, F21-5	110
1481	Chronic hepatitis C virus and the Hispanic community: cultural factors impacting care. <b>2004</b> , 27, 230-8	5
1480	Advances in hepatitis B and C. <b>2004</b> , 17, 449-59	7

1479	Viral hepatitis in 2003. <b>2004</b> , 20, 241-7	6
1478	HEPATITIS C AND STEATOSIS: DOES FAT MATTER?. <b>2004</b> , 5, 30-31	
1477	Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C. <b>2004</b> , 38, 595-8	12
1476	Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy. <b>2004</b> , 38, 599-604	20
1475	Care of patients with hepatitis C and HIV co-infection. <b>2004</b> , 18, 1-12	156
1474	Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. <b>2004</b> , 18, 75-9	36
1473	Long-term outcome of hepatitis C infection after bone marrow transplantation. <b>2004</b> , 103, 1618-24	143
1472	Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. <b>2004</b> , 141, 715-7	66
1471	Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. <b>2004</b> , 140, 465-79	76
1470	References. <b>2005</b> , 181-199	
1469	Cell culture models and animal models of viral hepatitis. Part II: hepatitis C. <b>2005</b> , 34, 39-47	21
1468	Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. <b>2005</b> , 45, 275-85	12
1467	The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. <b>2005</b> , 39, S9-13	48
1466	Hepatitis C virus infection and mixed cryoglobulinaemia vasculitis: a review of neurological complications. <b>2005</b> , 19 Suppl 3, S128-34	54
1465	Peginterferon alpha/ribavirin combination therapy for the treatment of hepatitis C infection. <b>2005</b> , 28, 317-28	4
1464	Update on viral hepatitis in 2004. <b>2005</b> , 21, 300-7	4
1463	Diagnosis of liver cirrhosis: a comparison of modified ultrasound and laparoscopy in 100 consecutive patients. <b>2005</b> , 39, 529-32	11
1462	High rates of uninsured among HCV-positive individuals. <b>2005</b> , 39, 826-30	22

1461	Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. <b>2005</b> , 40, 47-52	72
1460	Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. <b>2005</b> , 39, S23-7	40
1459	Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. <b>2005</b> , 39, 401-5	67
1458	Hematologic side effects of interferon and ribavirin therapy. <b>2005</b> , 39, S3-8	80
1457	Role of growth factors in the treatment of patients with HIV/HCV coinfection and patients with recurrent hepatitis C following liver transplantation. <b>2005</b> , 39, S14-22	11
1456	New paradigms in the management of HIV and hepatitis C virus coinfection. <b>2005</b> , 18, 550-60	11
1455	Ribavirin plus interferon versus interferon for chronic hepatitis C. <b>2005</b> , CD005445	14
1454	Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection. <b>2005</b> , 17, 1153-5	30
1453	Validity of original studies in health technology assessment reports: significance of standardized assessment and reporting. <b>2005</b> , 21, 410-3	3
1452	Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization. <b>2005</b> , 17, 1157-64	50
1451	Hepatitis C infection: eligibility for antiviral therapies. <b>2005</b> , 17, 1185-9	17
1450	Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. <b>2005</b> , 21, 47-54	29
1449	Estimating the mortality rate of hepatitis C using multiple data sources. <b>2005</b> , 133, 121-5	15
1448	Management of chronic hepatitis C in French departments of internal medicine and infectious diseases. <b>2005</b> , 133, 305-14	8
1447	Assessment of the patient who failed treatment for chronic hepatitis C. <b>2005</b> , 28, S24-30	3
1446	Biological and clinical basis for molecular studies of interferons. <b>2005</b> , 116, 1-23	15
1445	Efficacy of prolonged treatment following combination with ribavirin and interferon for chronic hepatitis type C: A pilot study. <b>2005</b> , 31, 211-6	2
1444	Contribution of Irf-1 promoter polymorphisms to the Th1-type cell response and interferon-beta monotherapy for chronic hepatitis C. <b>2005</b> , 32, 25-32	6

1443	Emerging drugs for chronic hepatitis C. <b>2005</b> , 32, 146-53	11
1442	Traitements catabolisants. <b>2005</b> , 19, 25-29	3
1441	Synthesis of 5-haloethynyl- and 5-(1,2-dihalo)vinyluracil nucleosides: antiviral activity and cellular toxicity. <b>2005</b> , 13, 6015-24	9
1440	Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-1-heteroalkyl-4-hydroxyquinolon-3-yl-benzothiadiazines. <b>2005</b> , 15, 1577-82	43
1439	Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. <b>2005</b> , 77, 90-100	57
1438	Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. <b>2005</b> , 77, 214-24	32
1437	Virale hepatitis. <b>2005</b> , 21, 323-333	
1436	Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis. <b>2005</b> , 192, 1153-61	52
1435	Molecular methods of hepatitis C genotyping. <b>2005</b> , 5, 507-20	36
1434	Hepatitis C virus infection. <b>2005</b> , 11, 86-94	80
1433	Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London. <b>2005</b> , 6, 206-15	31
1432	BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005). <b>2005</b> , 6 Suppl 2, 96-106	27
1431	Barriers to the treatment of hepatitis C. Patient, provider, and system factors. <b>2005</b> , 20, 754-8	154
1430	Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic hepatitis C. <b>2005</b> , 25, 772-8	18
1429	Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin. <b>2005</b> , 25, 91-5	7
1428	Antiviral therapy in advanced chronic liver disease due to hepatitis C virus infection: pilot study. <b>2005</b> , 20, 527-35	4
1427	Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. <b>2005</b> , 20, 577-82	53
1426	Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. <b>2005</b> , 20, 752-8	77



1425	Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. <b>2005</b> , 20, 1553-9	35
1424	Reasons for non-treatment of hepatitis C in veterans in care. <b>2005</b> , 12, 81-5	71
1423	The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. <b>2005</b> , 12, 86-90	37
1422	Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. <b>2005</b> , 12, 96-100	75
1421	Therapeutic modalities in hepatitis C: challenges and development. <b>2005</b> , 12, 10-9	22
1420	Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. <b>2005</b> , 12, 58-66	18
1419	Enhanced expression of suppressor of cytokine signalling-1 in the liver of chronic hepatitis C: possible involvement in resistance to interferon therapy. <b>2005</b> , 12, 130-8	23
1418	Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. <b>2005</b> , 12, 543-50	26
1417	Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. <b>2005</b> , 12, 283-91	63
1416	A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C. <b>2005</b> , 12, 292-9	41
1415	Treatment of hepatitis C. <b>2005</b> , 12, 223-35	66
1414	Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. <b>2005</b> , 12, 380-5	61
1413	Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. <b>2005</b> , 12, 405-13	117
1412	Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C. <b>2005</b> , 12, 176-85	16
1411	Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. <b>2005</b> , 12, 421-8	25
1410	Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece. <b>2005</b> , 12, 551-7	37
1409	Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy. <b>2005</b> , 12, 465-72	32
1408	Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. <b>2005</b> , 12, 473-80	27

1407	Amantadine in treatment of chronic hepatitis C virus infection?. <b>2005</b> , 12, 445-55	12
1406	Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*. <b>2005</b> , 12, 481-7	16
1405	Silymarin treatment of viral hepatitis: a systematic review. <b>2005</b> , 12, 559-67	122
1404	Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C*. <b>2005</b> , 12, 531-5	30
1403	Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study. <b>2005</b> , 12, 536-42	10
1402	Pathways of care and resource utilization in a national cohort of patients with transfusion-acquired hepatitis C. <b>2005</b> , 12, 618-26	4
1401	Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment. <b>2005</b> , 11, 270-5	22
1400	Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy -- patients' views of early cessation of therapy. <b>2005</b> , 21, 43-7	1
1399	Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C. <b>2005</b> , 21, 49-55	17
1398	Retinal toxicity during pegylated alpha-interferon therapy for chronic hepatitis C: a multifocal electroretinogram investigation. <b>2005</b> , 21, 723-32	23
1397	Dynamic decision analysis to determine optimal treatment duration in chronic hepatitis C. <b>2005</b> , 21, 539-47	3
1396	Is the management of hepatitis C patients appropriate? A population-based study. <b>2005</b> , 21, 1007-15	15
1395	The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. <b>2005</b> , 21, 1163-71	54
1394	Review article: an unexpected virus-host interaction--the hepatitis C virus-diabetes link. <b>2005</b> , 22 Suppl 2, 56-60	30
1393	Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. <b>2005</b> , 130, 644-6	56
1392	Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection. <b>2005</b> , 142, 362-9	35
1391	Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. <b>2005</b> , 36, 709-13	38
1390	Bi-allelic presence of the interleukin-10 receptor 1 G330R allele is associated with cirrhosis in chronic HCV-1 infection. <b>2005</b> , 6, 242-7	20

1389	Mechanism of action of interferon and ribavirin in treatment of hepatitis C. <b>2005</b> , 436, 967-72	795
1388	The road to new antiviral therapies. <b>2005</b> , 5, 65-76	4
1387	Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. <b>2005</b> , 84, 93-8	45
1386	Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. <b>2005</b> , 67, 46-54	24
1385	A cognitive therapy conceptualization of panic disorder exacerbated by interferon treatment. <b>2005</b> , 27, 329-37	7
1384	Disposal of injection material used for the treatment of hepatitis C: comparison with insulin-dependent diabetes and thromboembolism. <b>2005</b> , 29, 64-69	1
1383	Treatment of chronic hepatitis C in patients unresponsive to interferon. Interest of re-treatment combining interferon induction therapy and ribavirin (a multicenter pilot study). <b>2005</b> , 29, 117-21	1
1382	[Psychiatric disorders during treatment of chronic hepatitis C]. <b>2005</b> , 29, 123-33	8
1381	[Acute hepatitis C in 2005]. <b>2005</b> , 29, 1149-56	1
1380	Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. <b>2005</b> , 5, 118-24	170
1379	A strategy for obtaining near full-length HCV cDNA clones (assemblicons) by assembly PCR. <b>2005</b> , 123, 115-24	4
1378	Clinical performance of the LCx HCV RNA quantitative assay. <b>2005</b> , 123, 171-8	5
1377	Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus. <b>2005</b> , 25, 862-75	
1376	Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic. <b>2005</b> , 25, 1230-41	23
1375	Role of La autoantigen and polypyrimidine tract-binding protein in HCV replication. <b>2005</b> , 335, 72-86	75
1374	High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. <b>2005</b> , 41, 275-9	174
1373	Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. <b>2005</b> , 41, 643-51	93
1372	Pushing the treatment envelope for chronic hepatitis C--is more necessarily better?. <b>2005</b> , 41, 234-6	1

1371	Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. <b>2005</b> , 41, 832-5	158
1370	Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. <b>2005</b> , 41, 1013-8	167
1369	T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. <b>2005</b> , 41, 1365-75	46
1368	Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. <b>2005</b> , 42, 255-62	299
1367	Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. <b>2005</b> , 42, 711-23	105
1366	Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. <b>2005</b> , 42, 724-31	200
1365	New kinetic models for the hepatitis C virus. <b>2005</b> , 42, 749-54	120
1364	Remission of natural-killer cell lymphoma of the liver with anti-hepatitis C therapy. <b>2005</b> , 78, 212-5	2
1363	HCV-hepatocellular carcinoma: new findings and hope for effective treatment. <b>2005</b> , 68, 130-48	12
1362	Liver transplantation in HIV-infected recipients. <b>2005</b> , 11, 76-81	38
1361	Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. <b>2005</b> , 75, 27-34	43
1360	Mutations in the nonstructural region 5B of hepatitis C virus genotype 1b: their relation to viral load, response to interferon, and the nonstructural region 5A. <b>2005</b> , 75, 504-12	17
1359	Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. <b>2005</b> , 77, 66-9	45
1358	Chemiluminescence enzyme immunoassay for monitoring hepatitis C virus core protein during interferon-alpha2b and ribavirin therapy in patients with genotype 1 and high viral loads. <b>2005</b> , 77, 77-82	9
1357	Treatment of hepatocellular carcinoma. <b>2005</b> , 19, 129-45	33
1356	Factors influencing early virological response in children with chronic hepatitis C treated with pegylated interferon and ribavirin. <b>2005</b> , 32, 224-6	3
1355	Management of chronic hepatitis C virus in patients with HIV. <b>2005</b> , 8, 433-41	4
1354	Clinical trials report. <b>2005</b> , 7, 9-10	

1353	Children with hepatitis C. <b>2005</b> , 7, 37-44	2
1352	Maintenance therapy for chronic hepatitis C. <b>2005</b> , 7, 50-3	13
1351	Treatment of HCV infection with pegylated interferons. <b>2005</b> , 4, 49-55	3
1350	Management of hematologic side effects: Impact on compliance and efficacy. <b>2005</b> , 4, 56-60	1
1349	Antifibrotic targets and therapy in HCV. <b>2005</b> , 4, 61-67	
1348	Antiviral therapy in the liver transplant candidate and recipient. <b>2005</b> , 4, 75-82	
1347	HCV viral kinetics. <b>2005</b> , 4, 158-161	
1346	Hepatitis C Virus in patients with inherited bleeding disorders. <b>2005</b> , 4, 87-91	
1345	Viral hepatitis in minorities. <b>2005</b> , 4, 92-96	
1344	Management of hepatitis C virus in patients with porphyria cutanea tarda. <b>2005</b> , 4, 104-111	2
1343	Infection-related vasculitis. <b>2005</b> , 7, 281-7	9
1342	Peginterferon alfa-2b treatment for patients affected by acute hepatitis C: presentation of six case reports. <b>2005</b> , 33, 30-2	6
1341	Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. <b>2005</b> , 33, 25-9	22
1340	Immunogenic properties of a chimeric plant virus expressing a hepatitis C virus (HCV)-derived epitope: new prospects for an HCV vaccine. <b>2005</b> , 25, 142-52	34
1339	The Structured Interview for the Treatment of the Hepatitis C Virus (SIT-HCV). <b>2005</b> , 12, 57-69	4
1338	Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. <b>2005</b> , 50, 719-26	33
1337	Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. <b>2005</b> , 50, 727-32	34
1336	Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C. <b>2005</b> , 50, 970-5	12

1335	Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, randomized multicenter trial. <b>2005</b> , 50, 1148-55	5
1334	Dendritic Cell Immunotherapy of Hepatitis C Virus Infection: Toxicology of Lipopeptide-Loaded Dendritic Cells. <b>2005</b> , 11, 223-235	8
1333	High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study. <b>2005</b> , 5, 27	20
1332	Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients. <b>2005</b> , 4, 9	4
1331	Treatment of chronic hepatitis C in Canadian prison inmates. <b>2005</b> , 19, 153-6	21
1330	Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. <b>2005</b> , 141, 865-8	63
1329	Interferon-alpha-induced changes in metallothionein expression in liver biopsies from patients with chronic hepatitis C. <b>2005</b> , 19, 481-6	12
1328	Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy. <b>2005</b> , 19, 359-65	41
1327	Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. <b>2005</b> , 142, 105-14	229
1326	The prevalence of hepatitis C virus infection in Texas: implications for future health care. <b>2005</b> , 18, 3-6	14
1325	Hepatocellular carcinoma: therapy and prevention. <b>2005</b> , 11, 7391-400	186
1324	New approaches and therapeutic modalities for the treatment of patients with chronic hepatitis C. <b>2005</b> , 4, 144-150	2
1323	Current concepts in the management and treatment of hepatitis C in HIV-infected patients. <b>2005</b> , 4, 151-160	5
1322	[Cost comparison of two combination therapies with peginterferon alfa and ribavirin for the treatment of hepatitis C]. <b>2005</b> , 94, 1207-14	0
1321	Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. <b>2005</b> , 11, 687-94	20
1320	[The elder patient with advanced liver disease]. <b>2005</b> , 94, 743-50	1
1319	Feasibility and outcome of HCV treatment in a Canadian federal prison population. <b>2005</b> , 95, 1737-9	39
1318	[Treatment of hepatitis C virus infection]. <b>2005</b> , 94, 721-6	2

1317	Hepatitis C Virus (HCV). <b>2005</b> , 32, 184-195	
1316	Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: outcome after resumption of therapy. <b>2005</b> , 11, 5392-3	20
1315	Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. <b>2005</b> , 40 Suppl 5, S339-45	68
1314	Treatment of hepatitis C in HIV/hepatitis C co-infected patients: what is the evidence?. <b>2005</b> , 16, 1-4	3
1313	Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response. <b>2005</b> , 79, 2788-96	29
1312	Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. <b>2005</b> , 100, 1772-9	156
1311	Treatment for hepatitis C virus infection among current injection drug users in Australia. <b>2005</b> , 40 Suppl 5, S325-9	47
1310	Reply to Coen et al.. <b>2005</b> , 191, 1993-1993	
1309	Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase. <b>2005</b> , 5, 1103-12	22
1308	Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries. <b>2005</b> , 40 Suppl 5, S373-8	28
1307	Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. <b>2005</b> , 40 Suppl 5, S313-20	121
1306	Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. <b>2005</b> , 40 Suppl 5, S286-91	81
1305	New drug targets for HIV and hepatitis C virus coinfection. <b>2005</b> , 41 Suppl 1, S101-4	3
1304	Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients. <b>2005</b> , 17, 471-6	16
1303	Hepatitis C virus infection among prisoners in the California state correctional system. <b>2005</b> , 41, 177-86	86
1302	In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. <b>2005</b> , 280, 36784-91	177
1301	Management of HIV Infection in Persons Co-infected With Hepatitis. <b>2005</b> , 18, 295-309	
1300	Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. <b>2005</b> , 49, 3997-4008	37

- 1299 Treating hepatitis C virus infection in active substance users. **2005**, 40 Suppl 5, S321-4 57
- 1298 Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. **2005**, 40 Suppl 5, S276-85 161
- 1297 Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. **2005**, 54, 1014-20 50
- 1296 Reply to Shenoy et al.. **2005**, 191, 1995-1996
- 1295 Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. **2005**, 54, 858-66 128
- 1294 Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients. **2005**, 55, 824-7 6
- 1293 Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy. **2005**, 56, 991-5 12
- 1292 Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections. **2005**, 43, 2590-7 32
- 1291 Review of the treatment of hepatitis C: where are we now?. **2005**, 6, 32-34
- 1290 Functional analysis of RNA binding by the hepatitis C virus RNA-dependent RNA polymerase. **2005**, 280, 38011-9 35
- 1289 Clinical trials of treatment for hepatitis C virus infection in HIV-infected patients: past, present, and future. **2005**, 41 Suppl 1, S63-8 8
- 1288 Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials. **2005**, 165, 2206-12 26
- 1287 Aktuelle Diagnostik und Therapie der Hepatitis C. **2005**, 1, 55-72
- 1286 Aktuelles und künftige Entwicklungen in der Therapie von Hepatitis B und C. **2005**, 31, 466-471
- 1285 [The diagnosis of liver cirrhosis: a comparative evaluation of standard laparoscopy, mini-laparoscopy and histology]. **2005**, 43, 17-21 13
- 1284 Development of prophylactic and therapeutic vaccines against hepatitis C virus. **2005**, 4, 351-71 11
- 1283 Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfecting with HIV and HCV. **2005**, 41 Suppl 1, S105-9 42
- 1282 Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. **2005**, 17, 695-704 46



1281	A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective. <b>2005</b> , 41 Suppl 1, S73-8	13
1280	Pegylated IFNs for chronic hepatitis C: an update. <b>2005</b> , 2, 219-26	20
1279	Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection. <b>2005</b> , 353, 1182-3; author reply 1182-3	4
1278	Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. <b>2005</b> , 352, 2609-17	534
1277	Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin. <b>2005</b> , 25, 33-51	28
1276	Aktuelles und künftige Entwicklungen in der Therapie von Hepatitis B und C. <b>2005</b> , 31, 466-471	
1275	Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. <b>2005</b> , 25, 18-32	28
1274	Iron in nonhemochromatotic liver disorders. <b>2005</b> , 25, 461-72	100
1273	Therapie der Hepatitis C bei Drogenabhängigen. <b>2005</b> , 6, 137-141	
1272	Current and future concepts in hepatitis C therapy. <b>2005</b> , 25, 72-83	48
1271	Fluoroquinolone antibiotics in a hospital sewage line; occurrence, distribution and impact on bacterial resistance. <b>2004</b> , 36, 752-5	18
1270	Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection. <b>2005</b> , 191, 686-93	9
1269	Treating Opportunistic Infections among HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. <b>2005</b> , 40, S131-S235	49
1268	Chronic hepatitis C treatment patterns in African American patients: an update. <b>2005</b> , 100, 716-22	19
1267	High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. <b>2005</b> , 100, 2717-23	49
1266	The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV. <b>2005</b> , 100, 313-21	10
1265	Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. <b>2005</b> , 100, 1415-9	45
1264	IFN-alpha gene therapy for woodchuck hepatitis with adeno-associated virus: differences in duration of gene expression and antiviral activity using intraportal or intramuscular routes. <b>2005</b> , 12, 68-76	28

1263	Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. <b>2005</b> , 100, 1509-15	188
1262	Liver transplantation for hepatitis C virus related liver disease. <b>2005</b> , 81, 765-71	2
1261	Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. <b>2005</b> , 79, 12828-39	241
1260	An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. <b>2005</b> , 79, 8217-29	238
1259	An in vitro model of hepatitis C virion production. <b>2005</b> , 102, 2579-83	96
1258	Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. <b>2005</b> , 192, 497-503	110
1257	Higher clearance of hepatitis C virus infection in females compared with males. <b>2006</b> , 55, 1183-7	94
1256	Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance. <b>2005</b> , 25, 528-39	43
1255	Cost of Hepatitis C Treatment in the Correctional Setting. <b>2005</b> , 11, 199-212	3
1254	The experience of interferon-based treatments for hepatitis C infection. <b>2005</b> , 15, 635-46	32
1253	Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. <b>2005</b> , 23, 468-73	211
1252	Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. <b>2005</b> , 48, 138-44	46
1251	Replication-competent chimeric hepatitis C virus subgenomic replicons. <b>2005</b> , 48, 183-91	16
1250	Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C. <b>2005</b> , 51, 167-9	25
1249	Liver-directed gamma interferon gene delivery in chronic hepatitis C. <b>2005</b> , 79, 13412-20	22
1248	Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. <b>2005</b> , 79, 12979-88	93
1247	Host cell targets in HCV therapy: novel strategy or proven practice?. <b>2005</b> , 16, 69-90	9
1246	Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. <b>2005</b> , 40 Suppl 1, S1-84	56

1245	Integrating treatment for hepatitis C virus infection into an HIV clinic. <b>2005</b> , 40 Suppl 5, S362-6	24
1244	Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. <b>2005</b> , 40 Suppl 5, S330-5	71
1243	Interferon Methods and Protocols. <b>2005</b> ,	
1242	Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy?. <b>2005</b> , 48, 59-63	7
1241	Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. <b>2005</b> , 48, 372-80	242
1240	Management of chronic hepatitis C. <b>2005</b> , 81, 376-82	21
1239	Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. <b>2005</b> , 191, 93-9	70
1238	Hepatitis C treatment in a Canadian federal correctional population: Preliminary feasibility and outcomes. <b>2005</b> , 1, 13-18	5
1237	Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. <b>2005</b> , 40 Suppl 5, S304-12	92
1236	Clinical significance of in vitro replication-enhancing mutations of the hepatitis C virus (HCV) replicon in patients with chronic HCV infection. <b>2005</b> , 192, 1710-9	18
1235	Chronic hepatitis C virus infection in older adults. <b>2005</b> , 41, 1606-12	21
1234	In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. <b>2005</b> , 192, 2112-6	45
1233	Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. <b>2005</b> , 21, 55-65	30
1232	Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. <b>2005</b> , 40, 501-7	48
1231	Approaching treatment for hepatitis C virus infection in substance users. <b>2005</b> , 41 Suppl 1, S79-82	22
1230	Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. <b>2005</b> , 40, 41-6	116
1229	Treatment of hepatitis C virus in HIV patients: a review. <b>2005</b> , 19 Suppl 3, S166-73	8
1228	Prediction of treatment outcome in chronic hepatitis C patients based on early viral dynamics during high-dose induction interferon and ribavirin therapy. <b>2005</b> , 48, 230-8	7

1227	Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. <b>2005</b> , 43, 2363-9		95
1226	Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients. <b>2005</b> , 192, 1078-87		29
1225	Mass spectrometry for genotyping hepatitis C virus: a promising new approach. <b>2005</b> , 51, 1091-2		
1224	Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: interferon-induced functional androgen deficiency or depression?. <b>2005</b> , 185, 345-52		46
1223	A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. <b>2005</b> , 19 Suppl 3, S179-89		46
1222	Hepatitis C virus treatment decision-making in the context of HIV co-infection: the role of medical, behavioral and mental health factors in assessing treatment readiness. <b>2005</b> , 19 Suppl 3, S190-8		13
1221	Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. <i>Lancet, The</i> , <b>2005</b> , 365, 123-9	40	948
1220	Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection. <b>2005</b> , 192, 1566-76		29
1219	Genetic diversity and evolution of hepatitis C virus in the Latin American region. <b>2005</b> , 34 Suppl 2, S1-7		142
1218	[Willing to undergo hepatitis C treatment in a sample of injection drug users in Toronto, Canada]. <b>2005</b> , 34, 1209-12		11
1217	Should HIV/HCV coinfecting patients with severe hepatitis be treated for hepatitis C. <b>2005</b> , 34, 1585-8		2
1216	Treatment of chronic hepatitis C infection: one step at a time. <b>2005</b> , 5, 524-6		16
1215	Global epidemiology of hepatitis C virus infection. <b>2005</b> , 5, 558-67		2085
1214	P.3.02 The time course of neuropsychiatric symptoms induced by pegylated interferon-alpha-2b and ribavirin treatment for hepatitis C: a follow-up study. <b>2005</b> , 15, S53-S54		
1213	P.3.03 Poststroke depression [diagnosis and treatment]. <b>2005</b> , 15, S54-S55		
1212	Hepatitis C. <b>2005</b> , 12, 74-85		
1211	Update on chronic hepatitis C. <b>2005</b> , 3, 507-20		21
1210	Treatment of hepatitis C in the patient with decompensated cirrhosis. <b>2005</b> , 3, S106-12		14

1209	Use of virologic assays in the diagnosis and management of hepatitis C virus infection. <b>2005</b> , 9, 371-82, v	29
1208	Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. <b>2005</b> , 129, 522-7	119
1207	Treatment of hepatitis C in patients who have decompensated cirrhosis. <b>2005</b> , 9, 473-86, viii	11
1206	Chronic hepatitis C: genotypes 4 to 9. <b>2005</b> , 9, 411-26, vi	40
1205	Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. <b>2005</b> , 3, 604-9	85
1204	Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. <b>2005</b> , 3, S97-S101	154
1203	Use of growth factors with antiviral therapy for chronic hepatitis C. <b>2005</b> , 9, 439-51, vii	23
1202	Management of the hematologic complications of hepatitis C therapy. <b>2005</b> , 9, 601-16, vi	35
1201	Management of hepatitis C virus in special populations: patient and treatment considerations. <b>2005</b> , 3, 311-8	27
1200	Advances in gastrointestinal pharmacotherapy. <b>2005</b> , 3, 1167-79	5
1199	Chronic hepatitis C in African Americans. <b>2005</b> , 9, 427-38, vii	9
1198	Treatment of hepatitis C after liver transplantation. <b>2005</b> , 9, 579-600, vi	31
1197	Ribavirin monotherapy for Hepatitis C virus infection in renal transplant recipient. <b>2005</b> , 1, 12-15	
1196	Percentage of hepatitis C virus-infected hepatocytes is a better predictor of response than serum viremia levels. <b>2005</b> , 7, 535-43	18
1195	Costo efficacia di peginterferone $\alpha$ 2a + ribavirina verso peginterferone $\alpha$ 2b + ribavirina nel trattamento dell'epatite cronica di tipo C in pazienti non pretrattati. <b>2005</b> , 7, 207-218	1
1194	Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. <b>2005</b> , 280, 37481-8	310
1193	Treatment of hepatitis C: critical appraisal of the evidence. <b>2005</b> , 6, 399-408	17
1192	Residential substance user treatment programs as venues for HCV pharmacological treatment: client and staff perspectives. <b>2005</b> , 40, 1811-29	6

1191	Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1. <b>2005</b> , 23, 1043-55	15
1190	Pharmacological agents can ameliorate some of the neuropsychiatric adverse effects of interferon- $\alpha$ treatment. <b>2005</b> , 21, 18-22	
1189	Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. <b>2005</b> , 40, 688-96	22
1188	Patents and development of HBV and HCV clinical treatment: from 2001 to April 2005. <b>2005</b> , 15, 1027-1039	4
1187	Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. <b>2005</b> , 79, 6023-34	229
1186	Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus. <b>2005</b> , 100, 1748-53	31
1185	Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. <b>2005</b> , 49, 2059-69	114
1184	Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses. <b>2005</b> , 25, 632-49	28
1183	Highly sensitive hepatitis C virus RNA detection assays for decision of treatment (dis)continuation in patients with chronic hepatitis C. <b>2005</b> , 42, 605-6	6
1182	Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. <b>2005</b> , 42, 632-8	110
1181	Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. <b>2005</b> , 42, 315-22	222
1180	Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. <b>2005</b> , 42, 266-74	46
1179	Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. <b>2005</b> , 42, 491-8	61
1178	Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC). <b>2005</b> , 42, 499-504	25
1177	Management of cirrhosis due to chronic hepatitis C. <b>2005</b> , 42 Suppl, S65-74	19
1176	Should we treat patients with chronic hepatitis C on the waiting list?. <b>2005</b> , 42, 456-62	27
1175	Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. <b>2005</b> , 42, 793-8	149
1174	Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. <b>2005</b> , 42, 799-805	252

1173	Chronic hepatitis C, depression and interferon. <b>2005</b> , 42, 788-9	9
1172	Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. <b>2005</b> , 43, 243-9	62
1171	GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection. <b>2005</b> , 43, 388-93	24
1170	A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. <b>2005</b> , 43, 599-605	62
1169	Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. <b>2005</b> , 43, 425-33	425
1168	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. <b>2005</b> , 43, 250-7	127
1167	HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin. <b>2005</b> , 43, 783-90	19
1166	Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. <b>2005</b> , 43, 776-82	32
1165	The management of HCV infected pregnant women and their children European paediatric HCV network. <b>2005</b> , 43, 515-25	66
1164	Divining the role of liver biopsy in hepatitis C. <b>2005</b> , 43, 374-6	6
1163	Mutagenic effects of ribavirin in vivo. <b>2005</b> , 43, 553-5	13
1162	Rethinking hepatitis C viral kinetics: Insights into host-virus interactions in 'difficult-to-treat' groups and implications for novel treatment approaches. <b>2005</b> , 43, 748-50	2
1161	HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen. <b>2005</b> , 347, 991-1003	17
1160	Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy. <b>2005</b> , 32, 86-91	44
1159	Genotyping of hepatitis C virus by Taqman real-time PCR. <b>2005</b> , 34, 108-14	50
1158	Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. <b>2005</b> , 19, 23-7	124
1157	Depressive symptoms and viral clearance: In response. <b>2005</b> , 19, 273-274	3
1156	The association between viral clearance and depression in patients with hepatitis C receiving interferon-alpha and ribavirin. <b>2005</b> , 19, 271-2; author reply 273-4	7

1155	SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. <b>2005</b> , 331, 543-8	77
1154	Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients. <b>2005</b> , 114, 183-9	31
1153	Blocking of interleukin-10 receptor--a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus. <b>2005</b> , 117, 57-64	80
1152	Combination therapy with pegylated interferon plus ribavirin in the treatment of hepatitis C virus-related thrombocytopenia. <b>2005</b> , 66, 247-53	1
1151	Therapy for treatment-refractory chronic hepatitis C virus genotype 1b infection: A retrospective analysis. <b>2005</b> , 66, 451-62	
1150	Clinical experience with nonstandard doses of interferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis. <b>2005</b> , 66, 433-50	
1149	[Generalized eczema secondary to combined treatment with peginterferon alfa-2a and ribavirin in a patient with chronic hepatitis from the hepatitis C virus]. <b>2005</b> , 96, 122-3	2
1148	Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation. <b>2005</b> , 37, 4403-5	19
1147	Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients. <b>2005</b> , 37, 3963-4	21
1146	[Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up]. <b>2005</b> , 26, 280-7	4
1145	Treatment of hepatitis C. <b>2005</b> , 118, 808-15	70
1144	[Recommendations of the CEVIHP/SEIP/AEP/PNS on antiretroviral treatment in HIV-infected children and teenagers]. <b>2005</b> , 23, 279-312	4
1143	[Prevalences of hepatitis virus coinfection and indications for chronic hepatitis C virus treatment and liver transplantation in Spanish HIV-infected patients. The GESIDA 29/02 and FIPSE 12185/01 Multicenter Study]. <b>2005</b> , 23, 340-8	32
1142	Viral hepatitis and hepatocellular carcinoma. <b>2005</b> , 3, 27	94
1141	Treatment of hepatitis C in special populations. <b>2005</b> , 9, 567-77, v	2
1140	[Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection]. <b>2005</b> , 23, 32-40	4
1139	Generalised Dermatitis Induced by Pegylated Interferon-alpha-2b in a Patient Infected with Genotype-1 Hepatitis C Virus : Presentation of a Case. <b>2005</b> , 25, 281-4	3
1138	Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. <b>2005</b> , 128, 313-27	83



1137	Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. <b>2005</b> , 128, 1056-66	92
1136	Peginterferon- $\alpha$ (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C. <b>2005</b> , 129, 522-527	349
1135	Interferon-induced depression: prevalence and management. <b>2005</b> , 37, 102-7	27
1134	Interferon treatment in children with chronic hepatitis C: long-lasting remission in responders, and risk for disease progression in non-responders. <b>2005</b> , 37, 336-41	16
1133	Pathophysiology of portal hypertension in HCV-related cirrhosis. Putative role of assessment of portal pressure gradient in Peginterferon-treated patients. <b>2005</b> , 37, 886-93	7
1132	Second thoughts about secondary analyses. <b>2005</b> , 37, 805-7; author reply 808-9	
1131	Response to letter from Professor Peter Ferenci. <b>2005</b> , 37, 808-809	
1130	Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. <b>2005</b> , 37, 882-5	19
1129	Chronic hepatitis C: management of treatment failures. <b>2005</b> , 3, S102-5	13
1128	Treatment of hepatitis C virus/HIV coinfection. <b>2005</b> , 9, 525-33, ix	1
1127	Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response. <b>2005</b> , 9, 453-71, vii-viii	16
1126	Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis. <b>2005</b> , 3, 1034-42	26
1125	Steatosis and chronic hepatitis C infection: mechanisms and significance. <b>2005</b> , 3, S92-6	9
1124	Therapies for HIV and viral hepatitis coinfection. <b>2005</b> , 3, 81-9	1
1123	Hepatitis C virus infection: the new global epidemic. <b>2005</b> , 3, 241-9	34
1122	Therapy of hepatitis C in patients with HIV infection. <b>2005</b> , 3, 375-84	1
1121	Thymalfasin for the treatment of chronic hepatitis C infection. <b>2005</b> , 3, 885-92	9
1120	Clinical role of serum and tissue matrix metalloproteinase-9 expression in chronic HCV patients treated with pegylated IFN-alpha2b and ribavirin. <b>2005</b> , 25, 453-8	7

1119	Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit. <b>2005</b> , 25, 283-5	20
1118	Neuropsychiatric adverse effects of interferon-alpha: recognition and management. <b>2005</b> , 19, 105-23	357
1117	A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. <b>2005</b> , 100, 2453-62	114
1116	Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. <b>2005</b> , 100, 2447-52	71
1115	Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection. <b>2005</b> , 3, 610-5	6
1114	Modifications of T-lymphocyte subsets before and during interferon and ribavirin treatment for chronic hepatitis C infection. <b>2005</b> , 18, 197-204	4
1113	Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a. <b>2005</b> , 100, 862-7	14
1112	Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. <b>2005</b> , 100, 299-307	50
1111	Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. <b>2005</b> , 100, 332-7	31
1110	Design, synthesis, and antiviral activity of adenosine 5'-phosphonate analogues as chain terminators against hepatitis C virus. <b>2005</b> , 48, 2867-75	85
1109	Simple but highly effective three-dimensional chemical-feature-based pharmacophore model for diketo acid derivatives as hepatitis C virus RNA-dependent RNA polymerase inhibitors. <b>2005</b> , 48, 6304-14	37
1108	Control of hepatitis C: a medicinal chemistry perspective. <b>2005</b> , 48, 1-20	132
1107	Involvement of PKR and RNase L in translational control and induction of apoptosis after Hepatitis C polyprotein expression from a vaccinia virus recombinant. <b>2005</b> , 2, 81	10
1106	Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. <b>2005</b> , 2, 80	66
1105	Quasispecies: Concept and Implications for Virology. <b>2006</b> ,	43
1104	The Role of Peginterferon $\alpha$ 2a (40kD) Plus Ribavirin in the Management of Chronic Hepatitis C Mono-Infection. <b>2006</b> , 14, 303-320	
1103	HIV-related liver disease: infections versus drugs. <b>2006</b> , 35, 487-505	4
1102	Antiviral therapy for treatment naïve patients with hepatitis C virus. <b>2006</b> , 20, 99-113, vi-vii	6

1101	An artificial neural network approach to the drug efficacy of interferon treatments. <b>2006</b> , 7, 1017-24	38
1100	Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response. <b>2006</b> , 20, 115-35	4
1099	Hepatitis C virus population dynamics during infection. <b>2006</b> , 299, 261-84	88
1098	Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interferon induces HR independent of sustained virologic response (SVR). <b>2006</b> , 22, 1091-8	5
1097	A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C. <b>2006</b> , 101, 1268-73	11
1096	Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured?. <b>2006</b> , 101, 1811-6	22
1095	Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. <b>2006</b> , 22, 315-20	16
1094	Replication and Pathogenesis of Hepatitis C Virus. <b>2006</b> , 125-147	1
1093	Treatment options for chronic hepatitis B and C infection in children. <b>2006</b> , 4, 583-91	2
1092	Present and future therapy for hepatitis C virus. <b>2006</b> , 4, 781-93	11
1091	Proteases in Gastrointestinal Tissues. <b>2006</b> ,	
1090	Hepatitis C Viral Proteases And Inhibitors. <b>2006</b> , 153-181	1
1089	Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. <b>2006</b> , 24, 661-72	43
1088	Manage psychiatric and/or substance use comorbidities in patients with hepatitis C virus infection to improve antiviral outcomes. <b>2006</b> , 22, 14-17	
1087	Improving anti-hepatitis C virus therapy. <b>2006</b> , 6, 923-33	16
1086	Treatment of interferon-alpha for chronic hepatitis C. <b>2006</b> , 7, 1163-79	9
1085	Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment. <b>2006</b> , 22, 393-400	22
1084	Treating viral hepatitis C: efficacy, side effects, and complications. <b>2006</b> , 55, 1350-9	474

1083	Antiviral activity of transiently expressed IFN-kappa is cell-associated. <b>2006</b> , 26, 40-52	15
1082	Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. <b>2006</b> , 41, 1087-94	30
1081	Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. <b>2006</b> , 55, 1631-8	67
1080	Hepatitis C in Pregnancy and Mother-to-Infant Transmission of HCV. <b>2006</b> , 153-171	
1079	Current therapy of hepatitis C. <b>2006</b> , 65-9	1
1078	Histamine dihydrochloride: actions and efficacy in the treatment of chronic hepatitis C infection. <b>2006</b> , 4, 377-85	2
1077	Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3. <b>2006</b> , 87, 1-10	24
1076	High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives. <b>2006</b> , 42, 945-52	41
1075	Ribavirina y análogos. <i>Gastroenterología Y Hepatología</i> , <b>2006</b> , 29, 129-134	0.9
1074	Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders. <b>2006</b> , 47, 112-21	27
1073	Hepatitis C treatment for people with severe mental illness. <b>2006</b> , 47, 93-107	33
1072	An overview of psychiatric issues in liver disease for the consultation-liaison psychiatrist. <b>2006</b> , 47, 188-205	29
1071	[Recurrent hepatitis C after liver transplantation: Erythropoietin allows maintenance of antiviral treatment]. <b>2006</b> , 35, 233-6	2
1070	Aspectos actuales y perspectivas de futuro del tratamiento de las hepatitis virales. <b>2006</b> , 9, 4443-4449	
1069	[Management of psychological disorders in patients with chronic hepatitis C]. <b>2006</b> , 32, 198-203	2
1068	A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. <b>2006</b> , 44, 671-8	86
1067	New therapies: oral inhibitors and immune modulators. <b>2006</b> , 10, 867-80	3
1066	The economics of hepatitis C virus. <b>2006</b> , 10, 717-34	19

1065	Management of hepatitis C in the setting of liver transplantation. <b>2006</b> , 10, 321-37, ix	3
1064	Role of obesity, insulin resistance, and steatosis in hepatitis C virus infection. <b>2006</b> , 10, 793-819	14
1063	Treatment of hepatitis C infection. <b>2006</b> , 35, 463-86	10
1062	Optimizing treatment regimens in hepatitis C. <b>2006</b> , 10, 835-50	13
1061	Hepatitis B and C in children: current treatment and future strategies. <b>2006</b> , 10, 133-48, vii	28
1060	Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. <b>2006</b> , 80, 6146-54	127
1059	Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. <b>2006</b> , 45, 1353-61	43
1058	Chronic hepatitis C therapy: changing the rules of duration. <b>2006</b> , 4, 963-71	13
1057	Treatment of relapsers after combination therapy for chronic hepatitis C. <b>2006</b> , 20, 137-53	1
1056	Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study. <b>2006</b> , 67, 343-7	21
1055	American Gastroenterological Association technical review on the management of hepatitis C. <b>2006</b> , 130, 231-64; quiz 214-7	312
1054	Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. <b>2006</b> , 130, 632-8	160
1053	Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. <b>2006</b> , 130, 1086-97	417
1052	Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. <b>2006</b> , 130, 1098-106	79
1051	Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. <b>2006</b> , 130, 1607-16	124
1050	Optimizing outcomes in hepatitis C: is treatment beyond 48 weeks ever justified?. <b>2006</b> , 130, 1357-62	7
1049	Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin. <b>2006</b> , 130, 2189-97	26
1048	Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. <b>2006</b> , 131, 451-60	311

1047	Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. <b>2006</b> , 131, 478-84		125
1046	Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. <b>2006</b> , 131, 470-7		405
1045	Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. <b>2006</b> , 131, 997-1002		348
1044	Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. <b>2006</b> , 131, 1040-8		162
1043	Use of ribavirin in patients with chronic HCV genotype 1: when enough is really enough. <b>2006</b> , 131, 1339-41		5
1042	Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. <b>2006</b> , 66, 155-74		66
1041	Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection. <b>2006</b> , 66, 1807-15		22
1040	Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b. <b>2006</b> , 26, 655-62		25
1039	[Thyroid alterations following treatment with pegylated interferon and ribavirin: differences between HIV-coinfected and non-coinfected patients]. <b>2006</b> , 24, 213-4		2
1038	[HIV and HCV coinfection]. <b>2006</b> , 24, 335-45; quiz 346		3
1037	[Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting]. <b>2006</b> , 24, 568-75		1
1036	[Early virologic response value as predictive factor of sustained virologic response to treatment with interferon alpha-2b plus ribavirin in chronic hepatitis C patients with or without HIV coinfection]. <b>2006</b> , 127, 561-6		0
1035	[Applicability of hepatitis C virus kinetics in patients co-infected with HIV]. <b>2006</b> , 127, 574-5		
1034	[Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting]. <i>Gastroenterología Y Hepatología</i> , <b>2006</b> , 29, 551-9	0.9	4
1033	Situación actual. Perspectivas y vacunación. <i>Gastroenterología Y Hepatología</i> , <b>2006</b> , 29, 96-100	0.9	
1032	Pacientes naïve con genotipo 1. <i>Gastroenterología Y Hepatología</i> , <b>2006</b> , 29, 135-138	0.9	
1031	Tratamiento de la hepatitis crónica C por genotipos 2 y 3: revisión sistemática. <i>Gastroenterología Y Hepatología</i> , <b>2006</b> , 29, 139-145	0.9	
1030	Tratamiento de pacientes genotipo 4. <i>Gastroenterología Y Hepatología</i> , <b>2006</b> , 29, 146-149	0.9	1

1029	Manejo de los efectos adversos del tratamiento. <i>Gastroenterología Y Hepatología</i> , <b>2006</b> , 29, 184-189	0.9	4
1028	Coste-efectividad de interferón pegilado alfa en el tratamiento de la hepatitis crónica por virus C. <i>Gastroenterología Y Hepatología</i> , <b>2006</b> , 29, 200-205	0.9	
1027	Enfermedades hepáticas. <i>Gastroenterología Y Hepatología</i> , <b>2006</b> , 29, 99-111	0.9	1
1026	Pegylation of IFN-alpha and antiviral activity. <b>2006</b> , 26, 849-53		13
1025	[Treatment of viral hepatitis (II). Treatment of chronic hepatitis C]. <b>2006</b> , 24, 518-25; quiz 526		1
1024	Propagation of hepatitis C virus infection: Elucidating targets for therapeutic intervention. <b>2006</b> , 3, 471-477		
1023	Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen. <b>2006</b> , 38, 27-32		39
1022	Expert Consensus Conference. The screening for hepatitis C virus infection in adults in Italy, May 5-6, 2005. <b>2006</b> , 38, 445-51		10
1021	Short-term treatment duration for HCV-2 and HCV-3 infected patients. <b>2006</b> , 38, 741-8		22
1020	The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. <b>2006</b> , 281, 3793-9		172
1019	Peginterferon and ribavirin for chronic hepatitis C. <b>2006</b> , 355, 2444-51		379
1018	Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. <b>2006</b> , 38, 497-505		24
1017	Antiviral treatment of hepatitis C. <b>2006</b> , 7, 2025-35		8
1016	Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. <b>2006</b> , 55, 1332-8		80
1015	Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. <b>2006</b> , 343, 879-84		118
1014	Interferonbeta-induced changes in metallothionein expression and subcellular distribution of zinc in HepG2 cells. <b>2006</b> , 34, 312-9		8
1013	Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. <b>2006</b> , 49, 6074-86		214
1012	Genetic predisposition of responsiveness to therapy for chronic hepatitis C. <b>2006</b> , 7, 697-709		30

1011	Synthesis and characterization of a hemoglobin-ribavirin conjugate for targeted drug delivery. <b>2006</b> , 17, 530-7	22
1010	Convert hepatitis C virus into a non-enveloped virus like hepatitis A, by targeting its envelope rather than the RNA. <b>2006</b> , 66, 847-50	
1009	Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. <b>2006</b> , 44, 83-7	43
1008	A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. <b>2006</b> , 44, 88-96	65
1007	Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. <b>2006</b> , 44, 97-103	356
1006	Treating patients with HCV genotype 1 and low viraemia: more than meets the eye. <b>2006</b> , 44, 4-7	6
1005	HCV virological assessment. <b>2006</b> , 44, S35-9	20
1004	Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patients. <b>2006</b> , 44, S60-4	8
1003	Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management. <b>2006</b> , 44, S114-8	14
1002	The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. <b>2006</b> , 44, 411-21	67
1001	Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis. <b>2006</b> , 44, 864-8	32
1000	Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway. <b>2006</b> , 45, 271-9	77
999	Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. <b>2006</b> , 45, 539-46	66
998	The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. <b>2006</b> , 148, 353-8	81
997	Prevalence of mutations in hepatitis C virus core protein associated with alteration of NF-kappaB activation. <b>2006</b> , 121, 51-7	17
996	Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. <b>2006</b> , 24, 4343-53	102
995	Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. <b>2006</b> , 3, 35-40	73
994	Molecular virology of hepatitis C virus (HCV): 2006 update. <b>2006</b> , 3, 29-34	58



993	Antiviral therapy of HCV in the cirrhotic and transplant candidate. <b>2006</b> , 3, 75-8	2
992	Daily interferon induction regimen using different manufactured interferons (alpha-2A or alpha-2B) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study. <b>2006</b> , 43, 275-9	2
991	Weight-based combination therapy with peginterferon alpha-2b and ribavirin for naïve, relapser and non-responder patients with chronic hepatitis C. <b>2006</b> , 10, 311-6	8
990	Antiviral therapy decreases GpIIb/IIIa activation of platelets in patients with chronic hepatitis C. <b>2006</b> , 95, 260-6	6
989	Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence. <b>2006</b> , 12, 4253-5	9
988	[Therapy of chronic hepatitis C]. <b>2006</b> , 95, 1451-7	1
987	Treatment outcomes in a centralized specialty clinic for hepatitis C virus are comparable with those from clinical trials. <b>2006</b> , 20, 87-90	3
986	Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation. <b>2006</b> , 20, 427-31	7
985	Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. <b>2006</b> , 20, 479-85	21
984	Two cases of chronic hepatitis C with sustained virological response in whom serum HCV RNA reappeared two or twelve years after the end of IFN treatment. <b>2006</b> , 47, 550-557	4
983	Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. <b>2006</b> , 20, 589-92	47
982	Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients. <b>2006</b> , 20, 107-11	11
981	Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. <b>2006</b> , 20, 661-3	39
980	Erythropoietin and hepatitis C therapy: useful adjuvant therapy but remember to treat the patient and not just a number. <b>2006</b> , 20, 519-20	1
979	Usefulness of liver biopsies in chronic infection with hepatitis C virus. <b>2006</b> , 5, S19-S21	
978	Predictive factors for response to treatment of chronic hepatitis C. <b>2006</b> , 5, S24-S28	4
977	Treatment of hepatitis C virus infection and hemophilia. <b>2006</b> , 5, S56-S57	
976	Cost efficacy and cost-benefit of treatment of hepatitis C. <b>2006</b> , 5, S69-S73	2

- 975 Treatment of chronic hepatitis C infection in cirrhotic patients. **2006**, 5, S36-S39 1
- 974 Treatment of hepatitis C patients who do not respond to treatment or relapse after treatment. **2006**, 5, S40-S41
- 973 Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C. **2006**, 55, 111-7 5
- 972 References. 145-186
- 971 Liver Diseases. **2006**, 151-201
- 970 Hepatitis C. **2006**,
- 969 Peginterferon  $\alpha$ 2b in the treatment of hepatitis C. **2006**, 1, 279-292 1
- 968 Hepatitis C virus and oxidative stress: a dangerous liaison. **2006**, 1, 223-232 4
- 967 Representations of people with HIV and hepatitis C in editorials of medical journals: discourses and interdiscursive relations. **2006**, 3, 15-25 6
- 966 Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful?. **2006**, 107, 3409-10 3
- 965 Improved outcome in central nervous system aspergillosis. **2006**, 107, 3410-1; author reply 3411-2
- 964 Albumin-interferon- $\alpha$ 2b in the treatment of chronic hepatitis C. **2006**, 1, 269-278 3
- 963 Efficacy and safety of treatment with interferon- $\alpha$ 2b plus ribavirin in children with chronic hepatitis C. **2006**, 3, 316-317 0
- 962 Can therapy of hepatitis C affect the development of hepatocellular carcinoma?. **2006**, 4, 751-7 7
- 961 Standard of Care for HCV/HIV-Coinfected Patients. **2006**, 18, 21-26
- 960 The kinetics of hepatitis C virus. **2006**, 18, 339-42 13
- 959 Pegylated interferons for the treatment of chronic hepatitis B. **2006**, 1, 85-94 4
- 958 Case report of 3 patients with severe mental illness and chronic hepatitis C virus infection treated with interferon-alpha. **2006**, 36, 449-55 6

957	Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity. <b>2006</b> , 20, 2123-5	30
956	Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-alpha2b plus ribavirin treatment in a patient with hepatitis B and C coinfection. <b>2006</b> , 18, 1019-22	13
955	Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. <b>2006</b> , 82, 43-7	74
954	Prise en charge de l'infection par les virus des hépatites B ou C chez l'insuffisant rénal chronique. <b>2006</b> , 1, 1-10	
953	Is time to treat for HCV all the HIV/HCV co-infected hemophiliacs?. <b>2006</b> , 11, 209-13	2
952	Individualization of antiviral treatment regimens for chronic hepatitis C. <b>2006</b> , 18, 321-5	3
951	Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. <b>2006</b> , 18, 159-66	63
950	Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. <b>2006</b> , 41, 31-6	103
949	Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study. <b>2006</b> , 29, 138-43	33
948	Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. <b>2006</b> , 40, 322-35	138
947	Transplantation and viral hepatitis: major progress. <b>2006</b> , 11, 579-582	
946	The role of antiviral agents in the management of viral hepatitis. <b>2006</b> , 6, 29-34	
945	Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. <b>2006</b> , 20, 345-51	12
944	Clinical virology of hepatitis C virus. <b>2006</b> , 1, 649-657	
943	Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. <b>2006</b> , 20, 2361-9	112
942	Update on viral hepatitis: 2005. <b>2006</b> , 22, 241-7	2
941	Antisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cells. <b>2006</b> , 6, 18	12
940	Comparison of characteristics of treated and non-treated patients with Hepatitis C infection. <b>2006</b> , 15, 71-6	13

939	Hepatitis C: who should be treated?. <b>2006</b> , 15, 77-9	0
938	Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. <b>2006</b> , 21, 406-12	41
937	Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: Incidence, associated factors and prognosis. <b>2006</b> , 21, 319-326	3
936	Effect of combination therapy with ribavirin and high-dose interferon-alpha2b for 24 weeks in chronic hepatitis C. <b>2006</b> , 21, 308-12	4
935	Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C. <b>2006</b> , 21, 1177-83	2
934	Alpha-tocopherol [corrected] and ascorbic acid attenuates the ribavirin [corrected] induced decrease of eicosapentaenoic acid in erythrocyte membrane in chronic hepatitis C patients. <b>2006</b> , 21, 1269-75	15
933	Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. <b>2006</b> , 21, 1789-93	16
932	Chronic hepatitis C virus infection in renal transplant: treatment and outcome. <b>2006</b> , 20, 677-83	38
931	A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. <b>2006</b> , 26, 73-81	41
930	Rat liver fibrosis regresses better with pegylated interferon alpha2b and ursodeoxycholic acid treatments than spontaneous recovery. <b>2006</b> , 26, 261-8	25
929	Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. <b>2006</b> , 26, 319-25	25
928	Definition and management of anemia in patients infected with hepatitis C virus. <b>2006</b> , 26, 389-98	65
927	Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma. <b>2006</b> , 26, 536-42	18
926	Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1. <b>2006</b> , 26, 520-8	7
925	Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection. <b>2006</b> , 26, 650-9	20
924	Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C. <b>2006</b> , 26, 1148-54	8
923	Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. <b>2006</b> , 26, 1119-25	42
922	Zinc is a negative regulator of hepatitis C virus RNA replication. <b>2006</b> , 26, 1111-8	41

921	Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. <b>2006</b> , 26, 1079-86	29
920	A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. <b>2006</b> , 26, 1187-95	7
919	Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals. <b>2006</b> , 7, 248-54	22
918	Anti-HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with hemophilia: a possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin. <b>2006</b> , 4, 469-70	11
917	Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. <b>2006</b> , 30, 1520-6	46
916	Treatment of hepatitis C virus infection in intravenous drug users. <b>2006</b> , 18, 183-92	3
915	2',5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. <b>2006</b> , 31, 441-6	11
914	A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers. <b>2006</b> , 13, 182-9	13
913	A rapid real-time PCR assay for determination of hepatitis C virus genotypes 1, 2 and 3a. <b>2006</b> , 13, 222-9	2
912	Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders. <b>2006</b> , 13, 235-41	27
911	Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*. <b>2006</b> , 13, 242-9	37
910	Fibrosis progression in initially mild chronic hepatitis C. <b>2006</b> , 13, 297-302	52
909	Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. <b>2006</b> , 13, 311-5	53
908	Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. <b>2006</b> , 13, 322-8	49
907	Pilot study of interferon-alpha-ribavirin-interleukin-2 for treatment of nonresponder patients with severe liver disease infected by hepatitis C virus genotype 1. <b>2006</b> , 13, 139-44	7
906	Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. <b>2006</b> , 13, 371-6	15
905	Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. <b>2006</b> , 13, 409-14	95
904	Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus. <b>2006</b> , 13, 466-73	15

903	Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. <b>2006</b> , 13, 441-8	37
902	Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection. <b>2006</b> , 13, 544-51	13
901	Viral kinetics in the treatment of chronic hepatitis C. <b>2006</b> , 13, 499-504	22
900	Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation. <b>2006</b> , 13, 538-43	21
899	Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication. <b>2006</b> , 13, 582-90	26
898	Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. <b>2006</b> , 13, 678-82	28
897	Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. <b>2006</b> , 13, 683-9	92
896	Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C. <b>2006</b> , 13, 701-7	10
895	HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. <b>2006</b> , 13, 762-9	58
894	Assessing evidence from clinical trials in chronic hepatitis C. <b>2006</b> , 13 Suppl 1, 1-5	3
893	Evaluating the evidence from clinical trials in chronic hepatitis C. <b>2006</b> , 13 Suppl 1, 15-25	1
892	Issues in designing and interpreting clinical trials of treatments for chronic hepatitis C. <b>2006</b> , 13 Suppl 1, 6-14	
891	Treatment rates in patients with chronic hepatitis C after liver biopsy. <b>2006</b> , 13, 783-6	16
890	Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b. <b>2006</b> , 13, 811-20	34
889	Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C. <b>2006</b> , 97, 1105-10	25
888	Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. <b>2006</b> , 23, 107-14	100
887	Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. <b>2006</b> , 23, 507-11	61
886	Review article: predicting response in hepatitis C virus therapy. <b>2006</b> , 23, 1043-54	53

885	Effect of anti-viral therapy for occult hepatitis C virus infection. <b>2006</b> , 23, 1153-9	28
884	Sustained virological response to peginterferon plus ribavirin in chronic hepatitis C genotype 1 patients is associated with a persistent Th1 immune response. <b>2006</b> , 24, 117-28	16
883	Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. <b>2006</b> , 24, 593-600	28
882	Comparison of simple tests for the non-invasive diagnosis of clinically silent cirrhosis in chronic hepatitis C. <b>2006</b> , 24, 797-804	19
881	Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity. <b>2006</b> , 24, 1133-49	35
880	Cost-effectiveness of growth factors during hepatitis C anti-viral therapy. <b>2006</b> , 24, 1067-77	12
879	Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C. <b>2006</b> , 24, 1483-93	12
878	Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. <b>2006</b> , 24, 1223-30	37
877	Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C. <b>2006</b> , 24, 1563-73	28
876	Treatment of chronic hepatitis C in patients with haemophilia: a review of the literature. <b>2006</b> , 12, 473-8	23
875	Effects of interferon plus ribavirin treatment on NF-kappaB, TGF-beta1, and metalloproteinase activity in chronic hepatitis C. <b>2006</b> , 19, 1047-54	14
874	Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. <b>2006</b> , 25, 5015-25	195
873	Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase. <b>2006</b> , 16, 457-60	41
872	Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: identification of 2-[(4-diarylmethoxy)phenyl]-benzimidazole. <b>2006</b> , 16, 1859-63	113
871	Timing of interferon therapy and sources of infection in patients with acute hepatitis C. <b>2006</b> , 34, 35-40	4
870	Hepatic steatosis is a predictor of poor response to interferon alpha-2b and ribavirin combination therapy in Japanese patients with chronic hepatitis C. <b>2006</b> , 35, 19-25	24
869	Lactoferrin inhibits lipid peroxidation in patients with chronic hepatitis C. <b>2006</b> , 36, 27-32	33
868	First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C. <b>2006</b> , 36, 94-9	8

- 867 Global transcriptional effects of PEG-IFN-alpha and ribavirin on peripheral blood cells obtained from patients with chronic hepatitis C. **2006**, 36, 277-87
- 866 N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. **2006**, 17, 179-88 119
- 865 Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site. **2006**, 49, 3052-5 59
- 864 Hepatitis C and steatosis: a reappraisal. **2006**, 13, 73-80 117
- 863 Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis. **2006**, 13, 457-65 25
- 862 A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. **2006**, 51, 808-12 41
- 861 From trials to a real hospital setting: effectiveness of pegylated interferon-alpha-2b/ribavirin combination therapy for naïve chronic hepatitis C patients. **2006**, 51, 1619-26 13
- 860 Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C. **2006**, 51, 960-7 8
- 859 Successful treatment with novel triple drug combination consisting of interferon-gamma, interferon alfacon-1, and ribavirin in a nonresponder HCV patient to pegylated interferon therapy. **2006**, 51, 956-9 3
- 858 Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia. **2006**, 118, 595-600 4
- 857 Antiviral therapy for chronic hepatitis C: past, present, and future. **2006**, 41, 17-27 128
- 856 Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. **2006**, 41, 862-72 22
- 855 Chronic Hepatitis B and C--current treatment and future therapeutic prospects. **2006**, 156, 391-6 3
- 854 Antiviral treatment of hepatitis C: present status and future prospects. **2006**, 12, 227-32 20
- 853 The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. **2006**, 63, 832-42 96
- 852 [Virus persistence in hepatitis C: lifelong infection despite therapy?]. **2006**, 101, 378-83 2
- 851 [Health economics of chronic infectious diseases: the example of hepatitis C]. **2006**, 49, 57-63 9
- 850 [Individualised treatment of chronic hepatitis C]. **2006**, 47 Suppl 1, S20, S22-5 1



849	Patients' experiences related to anti-viral treatment for hepatitis C. <b>2006</b> , 62, 148-55	31
848	Design and synthesis of 2,3,4,9-tetrahydro-1H-carbazole and 1,2,3,4-tetrahydro-cyclopenta[b]indole derivatives as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase. <b>2006</b> , 16, 2532-4	25
847	Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-alkyl-4-hydroxyquinolon-3-yl-benzothiadiazine sulfamides. <b>2006</b> , 16, 3367-70	33
846	Structure-based design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors. <b>2006</b> , 16, 5888-91	53
845	Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. <b>2006</b> , 53, 36-42	38
844	Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy. <b>2006</b> , 34, 23-7	33
843	Treatment of hepatitis C cryoglobulinemia: mission and challenges. <b>2006</b> , 9, 497-507	8
842	Psychiatric management of the hepatitis C patient. <b>2006</b> , 9, 508-19	22
841	Therapie der Hepatitis C. <b>2006</b> , 1, 126-132	1
840	Therapie der chronischen Hepatitis B und C: Problempatienten. <b>2006</b> , 1, 133-140	
839	Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders. <b>2006</b> , 8, 46-52	17
838	The impact of race and ethnicity on the treatment of hepatitis C disease. <b>2006</b> , 5, 79-85	1
837	Antifibrotic targets and therapy in HCV. <b>2006</b> , 5, 94-100	
836	Treatment of nonresponders to standard hepatitis C therapy. <b>2006</b> , 5, 108-113	
835	Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders. <b>2006</b> , 5, 114-120	
834	Future therapies for hepatitis C. <b>2006</b> , 5, 121-128	
833	Genotypic variations around the world: Is hepatitis C virus evolving?. <b>2006</b> , 5, 142-149	3
832	Coinfection with hepatitis C virus and HIV: The challenges of management. <b>2006</b> , 5, 154-161	

831	HIV coinfection with hepatitis C and hepatitis B. <b>2006</b> , 8, 409-18	
830	Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study. <b>2006</b> , 1, 113-8	1
829	Production of infectious hepatitis C virus particles in three-dimensional cultures of the cell line carrying the genome-length dicistronic viral RNA of genotype 1b. <b>2006</b> , 351, 381-92	37
828	In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance. <b>2006</b> , 351, 349-59	125
827	Hepatitis C virus genotype 1b chimeric replicon containing genotype 3 NS5A domain. <b>2006</b> , 355, 192-202	14
826	Antifibrotic agents for liver disease. <b>2006</b> , 6, 12-9	50
825	Management of hepatitis C in liver transplant recipients. <b>2006</b> , 6, 449-58	30
824	Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation. <b>2006</b> , 6, 825-33	28
823	Identification of hepatitis C virus (HCV) 2a-derived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-A24+ and HCV2a-infected patients. <b>2006</b> , 241, 38-46	4
822	Selective inhibitors of hepatitis C virus replication. <b>2006</b> , 71, 363-71	46
821	[Complementary treatments of chronic viral hepatitis C]. <b>2006</b> , 30, 197-214	6
820	High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial. <b>2006</b> , 30, 525-32	4
819	[Antiviral treatments during cirrhosis]. <b>2006</b> , 30, 899-902	
818	Les exacerbations au cours de l'hépatite C chronique seraient-elles plus fréquemment associées au génotype 2 ? <b>2006</b> , 30, 925-927	
817	[Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management]. <b>2006</b> , 30, 1281-95	3
816	[Budget impact analysis of the treatment of chronic hepatitis C in a hospital]. <b>2006</b> , 30, 291-9	4
815	Real-time multiplex PCR assay to quantify hepatitis C virus RNA in peripheral blood mononuclear cells. <b>2006</b> , 133, 195-204	12
814	Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. <b>2006</b> , 31, 335-44	66

813	Management of Hematologic and Neuropsychiatric Side Effects in Treatment of Chronic HCV Infection. <b>2006</b> , 2, 38-45	2
812	Primary Care of the Patient with Chronic Hepatitis C. <b>2006</b> , 2, 517-524	3
811	Variation in hepatitis C services may lead to inequity of health-care provision: a survey of the organisation and delivery of services in the United Kingdom. <b>2006</b> , 6, 3	30
810	Organizational change in management of hepatitis C: evaluation of a CME program. <b>2006</b> , 26, 145-60	7
809	Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. <b>2006</b> , 54, 3696-706	198
808	Diabetes in chronic liver disease: from old concepts to new evidence. <b>2006</b> , 22, 274-83	73
807	Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. <b>2006</b> , 43, 64-71	147
806	Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. <b>2006</b> , 43, 54-63	330
805	Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. <b>2006</b> , 43, 72-80	41
804	Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. <b>2006</b> , 43, 250-6	195
803	Therapy of hepatitis C: from empiricism to eradication. <b>2006</b> , 43, S207-20	142
802	Progression of liver fibrosis among injection drug users with chronic hepatitis C. <b>2006</b> , 43, 788-95	82
801	Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. <b>2006</b> , 43, 742-9	38
800	S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro. <b>2006</b> , 43, 796-806	61
799	Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfectd sustained virological responders from nonresponders. <b>2006</b> , 43, 943-53	75
798	The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. <b>2006</b> , 43, 661-72	137
797	Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. <b>2006</b> , 43, 954-60	412
796	Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. <b>2006</b> , 43, 961-72	96

795	Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. <b>2006</b> , 43, 1311-6	35
794	Tailoring antiviral therapy in hepatitis C. <b>2006</b> , 43, 909-11	11
793	Duration of peginterferon therapy in acute hepatitis C: a randomized trial. <b>2006</b> , 43, 923-31	116
792	Impact of obesity on treatment of chronic hepatitis C. <b>2006</b> , 43, 1177-86	106
791	Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. <b>2006</b> , 44, 335-40	99
790	Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. <b>2006</b> , 44, 352-9	74
789	CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. <b>2006</b> , 44, 736-45	64
788	Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. <b>2006</b> , 44, 728-35	174
787	Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: Summary of a single topic conference. <b>2006</b> , 44, 1344-54	44
786	HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia. <b>2006</b> , 44, 1146-57	31
785	Hepatitis C virus reinfection in injection drug users. <b>2006</b> , 44, 1139-45	128
784	IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. <b>2006</b> , 44, 1617-25	177
783	Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. <b>2006</b> , 44, 1598-606	42
782	Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. <b>2006</b> , 44, 1543-54	296
781	Growth factors during HCV therapy may be "cost-effective", but are they "effective"?. <b>2006</b> , 44, 1400-3	10
780	Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. <b>2006</b> , 44, 1675-84	131
779	Treatment of HCV recurrence: do the pretransplantation rules apply?. <b>2006</b> , 12, 1044-8	6
778	Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. <b>2006</b> , 12, 1805-12	84

777	Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. <b>2006</b> , 78, 83-90	90
776	Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon. <b>2006</b> , 78, 365-71	11
775	Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder. <b>2006</b> , 78, 446-51	21
774	HCV-related morbidity in a rural community of Egypt. <b>2006</b> , 78, 1185-9	37
773	Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment. <b>2006</b> , 78, 1304-11	8
772	Treatment of hepatitis C in hemophiliacs. <b>2006</b> , 81, 696-702	15
771	DNA-based immunization breaks tolerance in a hepatitis C virus transgenic mouse model. <b>2006</b> , 2, 78-83	7
770	High-Risk and Hepatitis C-Positive Organ Donors: Current Practice in Heart, Lung, and Liver Transplantation. <b>2020</b> , 34, 2492-2500	1
769	Measles Resurgence and Drug Development. <b>2020</b> , 41, 8-17	10
768	Frequent loss to follow-up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus. <b>2020</b> , 40, 1832-1840	8
767	Immunomodulation of the Natural Killer Cell Phenotype and Response during HCV Infection. <b>2020</b> , 9,	11
766	Factors affecting the recovery of hepatic reserve after sustained virologic response by direct-acting antiviral agents in chronic hepatitis C virus-infected patients. <b>2021</b> , 36, 367-375	3
765	Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model. <b>2021</b> , 11, 185-198	3
764	A real-world observational study of drug utilization and clinical outcomes of direct-acting antivirals and interferon therapy for hepatitis C treatment in Taiwan. <b>2021</b> , 37, 245-252	
763	Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands. <b>2021</b> , 22, 75-88	3
762	Effect of Hepatitis C Virus Infection on Heart Transplants in the Current Era. <b>2021</b> , 105, 2482-2489	
761	Therapeutic and Diagnostic Approaches for SARS-CoV-2. <b>2021</b> , 07, 63-79	0
760	Emerging Management of Hepatitis C in Transplant. <b>2021</b> , 951-969	

759	Treatment progress and expansion in Japan: From interferon to direct-acting antiviral. <b>2021</b> , 3, 321-334	0
758	Current Management of Patients with HCV Genotype 2. <b>2021</b> , 83-95	
757	Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals. <b>2021</b> , 77, 88-91	0
756	Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy. <b>2021</b> , 10, e2002214	5
755	Analysis of Different Types of Interferon-Associated Retinopathy in Patients with Chronic Hepatitis C Virus Infection Treated with Pegylated Interferon Plus Ribavirin. <b>2021</b> , 13,	0
754	Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. <b>2021</b> , 13,	3
753	Viral hepatitis: A brief introduction, review of management, advances and challenges. <b>2021</b> , 9, 139-151	
752	Feasible TLC-Spectro-Densitometry Technique for Simultaneous Determination of Two Hepatitis C Antiviral Drugs, Sofosbuvir and Simeprevir: Application to Combined Pharmaceutical Dosage Forms and Human Plasma. <b>2021</b> , 59, 576-583	1
751	Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C. <b>2021</b> , 15, 410-419	2
750	Blinding in Clinical Trials for Chronic Liver Diseases. <b>2021</b> , 41, 163-171	0
749	Challenges in hepatitis C elimination despite highly effective antiviral agents in patients with and without intravenous drug use. <b>2021</b> , 133, 641-646	1
748	A Review of Hepatitis B Virus and Hepatitis C Virus Immunopathogenesis. <b>2021</b> , 9, 409-418	0
747	Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. <b>2021</b> , 13,	0
746	Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease.. <b>2021</b> , 2, 1316-1325	
745	The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis. <b>2021</b> , 41, 2341-2357	0
744	Dietary daidzein inhibits hepatitis C virus replication by decreasing microRNA-122 levels. <b>2021</b> , 298, 198404	3
743	Update on the management and treatment of viral hepatitis. <b>2021</b> , 27, 3249-3261	6
742	Responsible Inclusion of Pregnant Individuals in Eradicating HCV. <b>2021</b> , 74, 1645-1651	3

741	Evaluation of HCV-related liver fibrosis post-successful DAA therapy. <b>2021</b> , 11,	0
740	aMAP score prediction of hepatocellular carcinoma occurrence and incidence-free rate after a sustained virologic response in chronic hepatitis C. <b>2021</b> , 51, 933-942	3
739	Viral hepatitis: Milestones, unresolved issues, and future goals. <b>2021</b> , 27, 4603-4638	3
738	Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. <b>2021</b> , 5, 929-940	4
737	Systematic Evolution of Ligands by Exponential Enrichment Technologies and Aptamer-Based Applications: Recent Progress and Challenges in Precision Medicine of Infectious Diseases. <b>2021</b> , 9, 704077	4
736	Haplotype Network Analysis and Phylogenetic Tree Construction of Hepatitis C Virus (HCV) Isolated from Tuban, Indonesia. <b>2021</b> , 4231-4235	1
735	Influence of IL28B gene polymorphisms on PegINF-RBV-mediated HCV clearance in HIV-HCV co-infected patients: A meta-analysis. <b>2021</b> , 29, 100909	
734	Assessing hepatitis C virus distribution among vulnerable populations in London using whole genome sequencing: results from the TB-REACH study. 6, 229	
733	Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects. <b>2021</b> , 65, e0060021	0
732	Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. <b>2021</b> , 13, 1069-1078	0
731	Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings. <b>2021</b> , 131, 108438	1
730	Hepatitis C. <b>2021</b> , 41-55	
729	SARS-CoV-2 therapeutics: how far do we stand from a remedy?. <b>2021</b> , 73, 750-768	6
728	Interferon signaling. 214-225	1
727	Pharmacology and Mechanisms of Action of Antiviral Drugs: Ribavirin Analogs. 36-42	1
726	New promises in the adjuvant, and palliative treatment of melanoma. <b>2007</b> , 135, 277-92	1
725	Interferon-Induced Effector Proteins and Hepatitis C Virus Replication. <b>2008</b> , 106-129	1
724	Interferon Treatment of Hepatitis C Virus Infection: From Basic Biology to Clinical Application. <b>2008</b> , 148-167	1

723	Hepatitis Virus Resistance. <b>2008</b> , 291-323	1
722	Hepatitis C Virus and Hepatocellular Carcinoma. <b>2012</b> , 571-583	2
721	Antiviral Targets in HCV. <b>2012</b> , 203-225	1
720	New treatment options for chronic hepatitis C. <b>2003</b> , 531, 219-26	1
719	Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. <b>2019</b> , 1911, 3-32	52
718	Mechanisms of Hepatitis C Virus Drug Resistance. <b>2009</b> , 531-545	1
717	Clinical Adverse Effects of Cytokines on the Immune System. <b>2007</b> , 319-348	4
716	Mathematical modeling of HCV infection and treatment. <b>2009</b> , 510, 439-53	14
715	Treatment of Viral Hepatitis in Children - 2008. <b>2009</b> , 405-429	1
714	Hepatitis C and Hepatocellular Carcinoma. <b>2009</b> , 259-281	4
713	Prevention of hepatitis C virus infection and liver cancer. <b>2014</b> , 193, 113-33	13
712	HCV NS3/4A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies. <b>2016</b> , 257-285	1
711	Discovery of Boceprevir and Narlaprevir: Ketoamide-Derived HCV NS3 Serine Protease Inhibitors for the Treatment of Chronic Hepatitis C. <b>2017</b> , 583-608	1
710	Drug-Induced Liver Injury. <b>2018</b> , 844-890.e17	1
709	Antiviral Drugs (Other than Antiretrovirals). <b>2010</b> , 565-610	3
708	Chronic Viral Hepatitis. <b>2010</b> , 1593-1617	1
707	Hepatitis C. <b>2010</b> , 2157-2185	4
706	Natural History of Hepatitis C. <b>2005</b> , 129-141	1



705	Neuropathies with Systemic Vasculitis. <b>2005</b> , 2335-2404	11
704	Drug-Induced Liver Injury. <b>2006</b> , 503-550	3
703	Hepatitis C. <b>2006</b> , 665-686	2
702	Viruses and Human Cancer. <b>2014</b> , 154-168.e7	1
701	HCV infection and hemodialysis. <b>2002</b> , 22, 331-339	28
700	Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment. <b>2002</b> , 16, 493-5	11
699	Hepatitis C infection: a clinical review. <b>2004</b> , 97, 364-73; quiz 374	25
698	Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. <b>2008</b> , 27, 142-8	89
697	Alpha interferon inhibits translation mediated by the internal ribosome entry site of six different hepatitis C virus genotypes. <b>2005</b> , 86, 3047-3053	17
696	Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles. <b>2006</b> , 87, 861-871	37
695	Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model.	1
694	Nucleoside Analog Inhibitors of Hepatitis C Viral Replication. 153-166	2
693	Antiherpesvirus, Anti-Hepatitis Virus, and Anti-Respiratory Virus Agents. <b>2009</b> , 217-264	4
692	Molecular Microbiology. 54-90	4
691	Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. <b>2006</b> , 116, 3006-14	119
690	Pegylated IFN- $\beta$ regulates hepatic gene expression through transient Jak/STAT activation. <b>2014</b> , 124, 1568-81	36
689	Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder. <b>2009</b> , 50, 500-5	16
688	A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. <b>2010</b> , 51, 137-48	27

687	Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritransplant Setting: A Case Report. <b>2016</b> , 17, 605-10	1
686	The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam. <b>2019</b> , 4, 129	3
685	Interleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virus. <b>2011</b> , 3, RRN1207	2
684	A novel unsupervised method to identify genes important in the anti-viral response: application to interferon/ribavirin in hepatitis C patients. <b>2007</b> , 2, e584	18
683	Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. <b>2008</b> , 3, e2123	40
682	Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. <b>2008</b> , 3, e2660	60
681	Genetic variability of hepatitis C virus before and after combined therapy of interferon plus ribavirin. <b>2008</b> , 3, e3058	14
680	Treatment of hepatitis C in children: a systematic review. <b>2010</b> , 5, e11542	26
679	Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. <b>2011</b> , 6, e17232	120
678	Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy. <b>2011</b> , 6, e24514	8
677	Interferon- $\gamma$ improves phosphoantigen-induced V $\beta$ V $\alpha$ T-cells interferon- $\gamma$ production during chronic HCV infection. <b>2012</b> , 7, e37014	15
676	Impact of obesity on the bioavailability of peginterferon- $\alpha$ and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. <b>2012</b> , 7, e37521	13
675	Selective hyper-responsiveness of the interferon system in major depressive disorders and depression induced by interferon therapy. <b>2012</b> , 7, e38668	20
674	The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function. <b>2012</b> , 7, e39163	37
673	HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. <b>2012</b> , 7, e39652	74
672	Kinetic and dynamic computational model-based characterization of new proteins in mice: application to interferon alpha linked to apolipoprotein A-I. <b>2012</b> , 7, e42100	2
671	Effect of different interferon- $\alpha$ preparations on IP10 and ET-1 release from human lung cells. <b>2012</b> , 7, e46779	12
670	Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses. <b>2012</b> , 7, e47492	38

669	Immunogenicity and acceptance of influenza A (H1N1) vaccine in a cohort of chronic hepatitis C patients receiving pegylated-interferon treatment. <b>2012</b> , 7, e48610	2
668	Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis. <b>2012</b> , 7, e52158	11
667	Infection frequency of hepatitis C virus and IL28B haplotypes in Papua New Guinea, Fiji, and Kiribati. <b>2013</b> , 8, e66749	7
666	Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis. <b>2013</b> , 8, e71262	11
665	Targeted deletion of FGL2 leads to increased early viral replication and enhanced adaptive immunity in a murine model of acute viral hepatitis caused by LCMV WE. <b>2013</b> , 8, e72309	16
664	Can antidepressants prevent pegylated interferon-ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials?. <b>2013</b> , 8, e76799	10
663	HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in S̃ Paulo, Brazil. <b>2014</b> , 9, e86413	24
662	In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening. <b>2014</b> , 9, e89109	19
661	Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis. <b>2014</b> , 9, e91822	28
660	Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis. <b>2014</b> , 9, e100128	12
659	HCV genome-wide genetic analyses in context of disease progression and hepatocellular carcinoma. <b>2014</b> , 9, e103748	3
658	Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis. <b>2014</b> , 9, e108616	24
657	Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. <b>2014</b> , 9, e110284	5
656	Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication. <b>2015</b> , 10, e0119172	10
655	Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. <b>2015</b> , 10, e0126984	33
654	Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study. <b>2015</b> , 10, e0134839	3
653	24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial. <b>2015</b> , 10, e0140853	2
652	Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study. <b>2015</b> , 10, e0145105	4

651	Drug Pricing Evolution in Hepatitis C. <b>2016</b> , 11, e0157098	14
650	Changing Epidemiology of Hepatitis C Virus Genotype among Patients with Human Immunodeficiency Virus/Hepatitis C Virus Co-Infection in China. <b>2016</b> , 11, e0161844	3
649	Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRASHEP-C Trials. <b>2016</b> , 11, e0166036	7
648	Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study. <b>2017</b> , 12, e0184404	7
647	Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection. <b>2018</b> , 13, e0191799	3
646	Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era. <b>2018</b> , 6, 431-437	10
645	Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C. <b>2019</b> , 7, 221-225	8
644	Herbal Medicines for Hepatitis C Virus Infection: The Exploratory Journey from Bench to Bedside Still Has a Long Way to Go. <b>2019</b> , 4, 9-18	1
643	Measuring Adherence to Hepatitis C Direct-Acting Antiviral Medications: Using the VAS in an HCV Treatment Clinic. <b>2018</b> , 111, 45-50	8
642	Assessment of Knowledge, Attitudes, and Practices Regarding Chronic Hepatitis C Treatment and Its Challenges: A Survey of Internal Medicine Residents in a Community Hospital. <b>2018</b> , 11, 31-35	2
641	Hepatitis C in Canada and the importance of risk-based screening. <b>2016</b> , 42, 57-62	9
640	[Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)]. <b>2007</b> , 148, 819-26	3
639	[Interferon in the treatment of viral hepatitis. The interferon was discovered 50 years ago]. <b>2007</b> , 148, 1539-43	1
638	[Successful elimination of hepatitis C virus after hepatic lobectomy in a patient with hepatocellular carcinoma]. <b>2008</b> , 149, 2143-8	0
637	[Influence of weight reduction on the effectiveness of combined peginterferon and ribavirin treatment in chronic HCV hepatitis]. <b>2008</b> , 149, 2189-92	2
636	[Silymarin in the treatment of chronic liver diseases: past and future]. <b>2008</b> , 149, 2413-8	16
635	[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection]. <b>2011</b> , 152, 1997-2009	6
634	EFFICACY OF TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN PATIENTS WITH CHRONIC HCV INFECTION UNDER REAL LIFE CONDITIONS. <b>2014</b> , 21, 23-32	1

633	[Alpha-interferon versus peg-interferon associated to ribavirin in the treatment of genotype 1 hepatitis C virus and human immunodeficiency virus coinfecting patients]. <b>2009</b> , 46, 132-7	1
632	Effect of HFE gene polymorphism on sustained virological response in patients with chronic hepatitis C and elevated serum ferritin. <b>2012</b> , 49, 9-13	2
631	Treatment of chronic hepatitis C in non-responsive patients with pegylated interferon associated with ribavirin and thalidomide: report of six cases of total remission. <b>2006</b> , 48, 109-12	6
630	[High prevalence of genotype 1 in individuals with hepatitis C in Belo Horizonte, MG]. <b>2008</b> , 41, 238-42	6
629	[Situation of lawsuits concerning the access to medical products by the Health Department of Santa Catarina State, Brazil, during the years 2003 and 2004]. <b>2010</b> , 15 Suppl 3, 3551-60	18
628	Expectoration of large bronchial casts secondary to the treatment of chronic hepatitis C with pegylated interferon and ribavirin. <b>2010</b> , 65, 745-8	3
627	Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling. <b>2010</b> , 30, 131-48	54
626	[The efficiency of antiviral therapy in patients with chronic -hepatitis C infected with hepatitis C virus recombinants]. <b>2016</b> , 88, 101-105	3
625	[Cytopenias and their correction during antiviral therapy of chronic hepatitis C in patients with genotype 1]. <b>2017</b> , 62, 174-178	2
624	Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. <b>2017</b> , 30, 327-343	5
623	Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C. <b>2012</b> , 20, 150-5	5
622	Risk prediction models for hepatocellular carcinoma in different populations. <b>2016</b> , 28, 150-60	5
621	Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV--focus on pegylated interferon-alpha. <b>2006</b> , 1, 399-409	2
620	Hepatitis C Virus: Efficacy of New DAAs Regimens. <b>2020</b> , 20, 143-149	12
619	A Primary Care-based Collaborative Hepatitis C Clinic: Clinical Structure and Virologic Outcomes with Direct Acting Antiviral Therapy. <b>2016</b> , 3, 70-78	1
618	Co-occurring Depression, Chronic Pain and Substance Use Disorders in People with Hepatitis C. <b>2016</b> , 3, 79-103	1
617	Hepatitis C crónica: aspectos clínicos, serológicos y de tratamiento en dos centros de atención en Bogotá-Colombia. <b>2014</b> , 29, 424-432	2
616	[Efficacy of combined antiviral therapy with pegylated interferon alpha-2a and ribavirin for chronic hepatitis C infection in intravenous drug users]. <b>2010</b> , 138, 43-9	1

615	[Late onset of severe thrombocytopenia during interferon treatment for chronic hepatitis C infection--case report]. <b>2010</b> , 138, 240-3	2
614	Advances in genomic research on hepatitis C virus with a useful tool, replicon system. <b>2008</b> , 57, 75-83	5
613	Meta-analysis of the Efficacy and Safety of Grazoprevir and Elbasvir for the Treatment of Hepatitis C Virus Infection. <b>2017</b> , 27, 150-160	1
612	Total clearance (CL/F) of ribavirin is the factor most influencing incidence of hemolytic anemia in interferon .ALPHA. plus ribavirin combination therapy. <b>2005</b> , 46, 107-118	4
611	A case of surgical treatment for hepatocellular carcinoma that developed in a chronic hepatitis C patient who had shown sustained virological response to interferon 11 years before. <b>2008</b> , 49, 248-254	6
610	Factors affecting efficacy of pegylated interferon alpha-2a in chronic hepatitis C patients with serotype 2. <b>2011</b> , 52, 236-243	3
609	Treatment Guidelines of Hepatitis C. <b>2012</b> , 53, 355-395	2
608	Hepatocellular carcinoma in a chronic hepatitis C patient 15 years after achieving a sustained virological response. <b>2012</b> , 53, 763-768	5
607	Protease inhibitors for the treatment of hepatitis C virus infection. <b>2017</b> , 5, Doc08	11
606	Current standards in the treatment of chronic hepatitis C. <b>2012</b> , 109, 352-8	16
605	Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. <b>2015</b> , 19, 1-409, v-vi	101
604	Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients. <b>2012</b> , 18, 268-71	1
603	Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C. <b>2012</b> , 18, 360-7	12
602	High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice. <b>2013</b> , 19, 60-9	5
601	No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients. <b>2014</b> , 20, 177-84	4
600	KASL clinical practice guidelines: management of hepatitis C. <b>2014</b> , 20, 89-136	30
599	Highly effective peginterferon 2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea. <b>2015</b> , 21, 125-30	3
598	KASL clinical practice guidelines: management of hepatitis C. <b>2016</b> , 22, 76-139	58

597	Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report. <b>2019</b> , 25, 326-330	3
596	[Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C]. <b>2008</b> , 14, 36-45	17
595	[Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C]. <b>2008</b> , 14, 46-57	14
594	[Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection]. <b>2008</b> , 14, 318-30	16
593	[Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: a comparative study]. <b>2008</b> , 14, 493-502	7
592	Impact of adherence to peginterferon-ribavirin combination therapy in chronic hepatitis C patients on achieving a sustained virologic response. <b>2009</b> , 15, 338-49	9
591	[A comparison of 24- vs. 48-week peginterferon plus ribavirin in patients with genotype 1 chronic hepatitis C]. <b>2009</b> , 15, 496-503	0
590	[Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection]. <b>2010</b> , 16, 38-48	8
589	[Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotype 1 and 4 patients with slow virologic response]. <b>2010</b> , 16, 201-5	2
588	Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin. <b>2011</b> , 17, 183-8	2
587	Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis. <b>2011</b> , 17, 220-5	13
586	Recent trends in the treatment of chronic hepatitis C. <b>2012</b> , 18, 22-8	12
585	New antiviral agents for hepatitis C. <b>2012</b> , 4, 5	26
584	Occult persistence and lymphotropism of hepatitis C virus infection. <b>2008</b> , 14, 2789-93	29
583	Treatment responses in Asians and Caucasians with chronic hepatitis C infection. <b>2008</b> , 14, 3416-20	40
582	Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it. <b>2008</b> , 14, 3621-7	10
581	Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. <b>2008</b> , 14, 6140-4	23
580	Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. <b>2008</b> , 14, 6467-72	21

579	Is pegylated interferon superior to interferon, with ribavirin, in chronic hepatitis C genotypes 2/3?. <b>2008</b> , 14, 6627-31	8
578	Pegylated interferon plus ribavirin for genotype 1b chronic hepatitis C in Japan. <b>2008</b> , 14, 7225-4230	18
577	Positional effect of mutations in 5'UTR of hepatitis C virus 4a on patients' response to therapy. <b>2009</b> , 15, 1480-6	19
576	Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. <b>2009</b> , 15, 328-33	17
575	Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population. <b>2009</b> , 15, 4429-33	13
574	Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells. <b>2009</b> , 15, 4499-510	31
573	APRI as a predictor of early viral response in chronic hepatitis C patients. <b>2009</b> , 15, 4923-7	6
572	Do statins reduce hepatitis C RNA titers during routine clinical use?. <b>2009</b> , 15, 5020-7	40
571	Costimulatory molecule programmed death-1 in the cytotoxic response during chronic hepatitis C. <b>2009</b> , 15, 5129-40	17
570	Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study. <b>2009</b> , 15, 5946-52	3
569	Safety of interferon beta treatment for chronic HCV hepatitis. <b>2004</b> , 10, 12-6	42
568	SEN virus does not affect treatment response in hepatitis C virus coinfecting patients but SEN virus response depends on SEN virus DNA concentration. <b>2004</b> , 10, 1893-7	6
567	Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. <b>2005</b> , 11, 1769-74	48
566	Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. <b>2005</b> , 11, 4484-9	13
565	Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy. <b>2005</b> , 11, 5521-4	4
564	Treatment of genotype 2 and 3 chronic hepatitis C virus-infected patients. <b>2005</b> , 11, 6188-92	2
563	New combination test for hepatitis C virus genotype and viral load determination using Amplicor GT HCV MONITOR test v2.0. <b>2005</b> , 11, 469-75	9
562	Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot study. <b>2005</b> , 11, 482-7	13



561	Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1). <b>2005</b> , 11, 580-3	4
560	Development of multiple myeloma in a patient with chronic hepatitis C: A case report and review of the literature. <b>2006</b> , 12, 2297-300	7
559	Is interferon-beta an alternative treatment for chronic hepatitis C?. <b>2006</b> , 12, 2730-6	6
558	Alterations of seminal and hormonal parameters: An extrahepatic manifestation of HCV infection?. <b>2006</b> , 12, 3073-6	55
557	Screening in liver disease. <b>2006</b> , 12, 5272-80	3
556	Triple antiviral therapy in HCV positive patients who failed prior combination therapy. <b>2006</b> , 12, 5293-300	5
555	Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C. <b>2006</b> , 12, 5554-6	11
554	Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. <b>2006</b> , 12, 7239-49	63
553	Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy. <b>2006</b> , 12, 7271-7	16
552	Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group. <b>2006</b> , 12, 784-90	17
551	Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial. <b>2006</b> , 12, 1265-9	13
550	CCL2-2518 A/G and CCR2 190 A/G do not influence the outcome of hepatitis C virus infection in the Spanish population. <b>2007</b> , 13, 2187-92	4
549	Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. <b>2007</b> , 13, 2416-26	72
548	Pegylated interferon-alpha plus taurine in treatment of rat liver fibrosis. <b>2007</b> , 13, 3237-44	26
547	Sequence diversity of hepatitis C virus: implications for immune control and therapy. <b>2007</b> , 13, 4808-17	72
546	Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?. <b>2007</b> , 13, 4903-8	3
545	Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study. <b>2007</b> , 13, 579-84	7
544	Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. <b>2007</b> , 13, 5343-50	35

543	Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment. <b>2007</b> , 13, 5411-2	16
542	Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. <b>2007</b> , 13, 5648-53	67
541	Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy. <b>2007</b> , 13, 1195-203	24
540	Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C. <b>2010</b> , 16, 1506-11	1
539	Pegylated interferon $\alpha$ 2b plus ribavirin for older patients with chronic hepatitis C. <b>2010</b> , 16, 4400-9	261
538	Peginterferon and ribavirin treatment for hepatitis C virus infection. <b>2011</b> , 17, 419-32	43
537	Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. <b>2011</b> , 17, 493-8	19
536	Mutations around interferon sensitivity-determining region: a pilot resistance report of hepatitis C virus 1b in a Hong Kong population. <b>2011</b> , 17, 5317-23	4
535	Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients. <b>2012</b> , 18, 55-63	21
534	Chronic hepatitis C: treat or wait? Medical decision making in clinical practice. <b>2012</b> , 18, 1339-47	22
533	New perspectives in occult hepatitis C virus infection. <b>2012</b> , 18, 2887-94	55
532	Can zinc enhance response interferon therapy for patients with HCV-related liver disease?. <b>2012</b> , 18, 3196-200	8
531	IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C. <b>2012</b> , 18, 4892-7	16
530	Vaccination with dendritic cells pulsed with hepatitis C pseudo particles induces specific immune responses in mice. <b>2012</b> , 18, 785-93	2
529	Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. <b>2012</b> , 18, 800-5	109
528	Factors associated with early virological response to peginterferon- $\alpha$ 2a/ribavirin in chronic hepatitis C. <b>2013</b> , 19, 1943-52	7
527	Sofosbuvir and ABT-450: terminator of hepatitis C virus?. <b>2013</b> , 19, 3199-206	19
526	Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?. <b>2013</b> , 19, 6947-56	11

525	Addicts with chronic hepatitis C: difficult to reach, manage or treat?. <b>2013</b> , 19, 8011-9	8
524	Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. <b>2013</b> , 19, 8940-8	29
523	Management of thrombocytopenia due to liver cirrhosis: a review. <b>2014</b> , 20, 2595-605	76
522	Individualization of chronic hepatitis C treatment according to the host characteristics. <b>2014</b> , 20, 2839-53	8
521	Chronic hepatitis C genotype 1 virus: who should wait for treatment?. <b>2014</b> , 20, 2867-75	6
520	Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases. <b>2014</b> , 20, 2913-26	23
519	Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview. <b>2014</b> , 20, 7555-69	34
518	Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection. <b>2014</b> , 20, 10984-93	18
517	Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. <b>2014</b> , 20, 12722-33	22
516	Study of pruritus in chronic hepatitis C patients. <b>2014</b> , 20, 17877-82	8
515	Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. <b>2015</b> , 21, 3480-91	17
514	Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. <b>2015</b> , 21, 4696-706	4
513	Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. <b>2015</b> , 21, 7412-26	35
512	Interferon- $\beta$ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. <b>2015</b> , 21, 8935-42	20
511	Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: first case report. <b>2015</b> , 21, 1009-13	7
510	Impact of new treatment options for hepatitis C virus infection in liver transplantation. <b>2015</b> , 21, 10760-75	23
509	S-adenosyl-L-methionine modifies antioxidant-enzymes, glutathione-biosynthesis and methionine adenosyltransferases-1/2 in hepatitis C virus-expressing cells. <b>2016</b> , 22, 3746-57	9
508	Pleiotropic effects of statins in the diseases of the liver. <b>2016</b> , 22, 6201-13	33

507	Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C. <b>2016</b> , 22, 8406-8413	4
506	Hepatitis C in injection drug users: It is time to treat. <b>2017</b> , 23, 3569-3571	21
505	Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment. <b>2017</b> , 23, 4538-4547	5
504	Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study. <b>2017</b> , 23, 7899-7905	6
503	Hepatitis C virus core protein-induced miR-93-5p up-regulation inhibits interferon signaling pathway by targeting IFNAR1. <b>2018</b> , 24, 226-236	6
502	Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir. <b>2018</b> , 24, 4554-4564	7
501	Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. <b>2019</b> , 25, 6094-6106	7
500	Liver-related effects of chronic hepatitis C antiviral treatment. <b>2020</b> , 26, 2931-2947	5
499	Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study. <b>2020</b> , 19, 2205-2212	20
498	Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C. <b>2009</b> , 24, 203-11	9
497	Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection. <b>2017</b> , 32, 1010-1017	2
496	Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world. <b>2019</b> , 34, 794-801	3
495	Prise en charge de l'hépatite chronique C: une urgence psychiatrique?. <b>2009</b> , 85, 629	0
494	Injection Drug Use and Hepatitis C: From Transmission to Treatment. <b>2003</b> , 33, 377-382	9
493	Comanagement of Depression and HCV Treatment. <b>2003</b> , 33, 385-391	15
492	Schizophrenia and Co-occurring General Medical Illness. <b>2005</b> , 35, 70-81	10
491	Analysis of the sensitivity of the impact resonance frequency test as a tool to determine the elastic properties of bituminous materials. <b>1957</b> , 7, 131	1
490	Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. <b>2005</b> , 66, 41-8	227

489	Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India. <b>2016</b> , 143, 331-40	7
488	Study of the effect of combined interferon and ribavirin therapy on the hearing profile of hepatitis C virus patients. <b>2015</b> , 31, 237-243	3
487	The new era of hepatitis C virus therapy. <b>2015</b> , 21, 345-54	2
486	SASLT guidelines: Update in treatment of Hepatitis C virus infection. <b>2016</b> , 22 Suppl, S25-57	15
485	Sustained virologic response to peginterferon alpha-2a and ribavirin in 335 patients with chronic hepatitis C: a tertiary care center experience. <b>2008</b> , 14, 58-65	12
484	Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients. <b>2008</b> , 14, 151-7	8
483	Oligonucleotide aptamers: potential novel molecules against viral hepatitis. <b>2017</b> , 12, 88-98	14
482	Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy. <b>2016</b> , 6, 245-248	3
481	Interferon-Inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response. <b>2017</b> , 145, 543-550	2
480	Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India. <b>2017</b> , 146, 23-33	11
479	Effect of CBT on Depressive Symptoms in Methadone Maintenance Patients Undergoing Treatment for Hepatitis C. <b>2011</b> , 2, 2-10	7
478	Seroprevalence of hepatitis B and C genotypes among young apparently healthy females of karachi-pakistan. <b>2008</b> , 3, 66-70	21
477	Predictors of Complete Early Virological Response to Pegylated Interferon and Ribavirin in Egyptian Patients with Chronic Hepatitis C Genotype 4. <b>2013</b> , 03, 78-83	1
476	Barriers and Strategies to Prevent HIV/AIDS among Pacific Countries: A Systematic Review Study. <b>2017</b> , 07, 20-33	1
475	Impact of past HBV exposure on virological response to combined interferon ribavirin therapy in patients with chronic HCV genotype 4. <b>2011</b> , 01, 38-43	2
474	Clinical characteristics of null responders to Peg-IFN $\alpha$ 2b/ribavirin therapy for chronic hepatitis C. <b>2010</b> , 2, 401-5	5
473	Safety of pegylated interferon and ribavirin therapy for chronic hepatitis C in patients with sickle cell anemia. <b>2010</b> , 2, 180-4	8
472	Twenty four-week peginterferon plus ribavirin after interferon-Induction for genotype 1b chronic hepatitis C. <b>2010</b> , 2, 226-32	9

471	Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review. <b>2013</b> , 5, 120-6	22
470	Strategies to reduce hepatitis C virus recurrence after liver transplantation. <b>2013</b> , 5, 237-50	12
469	Complementary and alternative medications in hepatitis C infection. <b>2014</b> , 6, 9-16	4
468	Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. <b>2014</b> , 6, 759-65	3
467	Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C. <b>2014</b> , 6, 520-6	5
466	Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients. <b>2014</b> , 6, 660-9	13
465	Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?. <b>2015</b> , 7, 1606-16	3
464	Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments. <b>2015</b> , 7, 2209-13	8
463	All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality. <b>2015</b> , 7, 2363-8	10
462	Era of direct acting antivirals in chronic hepatitis C: Who will benefit?. <b>2015</b> , 7, 2543-50	8
461	Hepatitis C virus: A global view. <b>2015</b> , 7, 2676-80	71
460	Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching. <b>2015</b> , 7, 2841-8	4
459	Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. <b>2015</b> , 7, 616-27	25
458	Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. <b>2015</b> , 7, 1133-41	18
457	Is the 25-year hepatitis C marathon coming to an end to declare victory?. <b>2017</b> , 9, 921-929	5
456	Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals. <b>2017</b> , 9, 1270-1277	3
455	Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1. <b>2017</b> , 9, 1340-1345	5
454	Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. <b>2017</b> , 9, 352-367	37

453	Treatment of psychological co-morbidities in common gastrointestinal and hepatologic disorders. <b>2010</b> , 1, 64-71	11
452	Association of ITPA polymorphism with outcomes of peginterferon- $\alpha$ plus ribavirin combination therapy. <b>2013</b> , 4, 54-60	5
451	Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study. <b>2012</b> , 6, 98-106	21
450	Predictive role of acute phase reactants in the response to therapy in patients with chronic hepatitis C virus infection. <b>2013</b> , 7, 82-8	6
449	Association between ITPA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy. <b>2015</b> , 9, 214-23	4
448	Low-Dose Pegylated Interferon $\alpha$ 2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus. <b>2016</b> , 10, 617-23	4
447	Hepatitis C Virus and Antiviral Drug Resistance. <b>2016</b> , 10, 890-895	12
446	The Synthesis of Diverse Adenosine 5'-phosphonate Analogues as Chain Terminators against Hepatitis C Virus (HCV). <b>2010</b> , 31, 1643-1648	3
445	The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C Virus Infection. <b>2010</b> , 1, e0004	13
444	Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey. <b>2015</b> , 32, 266-72	5
443	A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens. <b>2019</b> , 30, 708-713	4
442	Evaluation of an integrated care service facility for people living with hepatitis C in New Zealand. <b>2012</b> , 12, e229	11
441	Hepatitis C virus infection and dialysis: 2012 update. <b>2013</b> , 2013, 159760	20
440	Analysis of effect of antiviral therapy on regression of liver fibrosis in patient with HCV infection. <b>2014</b> , 26, 172-6	4
439	Identification of the most accessible sites to ribozymes on the hepatitis C virus internal ribosome entry site. <b>2003</b> , 36, 538-44	13
438	Does prophylactic antidepressant treatment boost interferon-alpha treatment completion in HCV?. <b>2013</b> , 2, 139-45	3
437	An Educational Initiative for Pharmacists to Inform Patients about Pegylated-Interferon and Ribavirin Combination Therapy in the Outpatient Clinic. <b>2012</b> , 38, 95-110	2
436	Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon- $\alpha$ 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial. <b>2014</b> , 14, e11608	19

435	A comprehensive long-term prognosis of chronic hepatitis C patients with antiviral therapy: a meta-analysis of studies from 2008 to 2014. <b>2015</b> , 15, e27181	7
434	The role of interleukin-28b gene polymorphisms in chinese patients with chronic hepatitis C treated with pegylated interferon and ribavirin. <b>2014</b> , 14, e18793	8
433	Efficacy of 24-week pegylated interferon alpha and ribavirin combination therapy in highly selected patients infected with hepatitis C virus genotype 1. <b>2015</b> , 15, e24955	6
432	The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C. <b>2016</b> , 16, e35278	4
431	Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. <b>2016</b> , 16, e37089	51
430	Molecular Tracing of Hepatitis C Virus Genotype 1 Isolates in Iran: A NS5B Phylogenetic Analysis with Systematic Review. <b>2016</b> , 16, e42938	7
429	Examination of the Activity of Camel Milk Casein against Hepatitis C Virus (Genotype-4a) and Its Apoptotic Potential in Hepatoma and HeLa Cell Lines. <b>2011</b> , 11, 724-730	35
428	The Correlation of IL28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C. <b>2011</b> , 11, 975-9	17
427	Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection. <b>2011</b> , 11, 968-974	5
426	Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study. <b>2017</b> , 72, 378-385	3
425	Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States. <b>2004</b> , 1, 92-100	8
424	A practical approach to managing patients with HCV infection. <b>2006</b> , 3, 63-8	6
423	Epidemiology of hepatitis C virus genotypes in northeastern Thai blood samples. <b>2014</b> , 15, 8837-42	3
422	Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhawa, Pakistan. <b>2015</b> , 16, 1037-40	6
421	A Recurrent Case of Cryoglobulin-related Leukocytoclastic Vasculitis with an Unexpected Etiology. <b>2019</b> , 11, e5783	1
420	Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection. <b>2021</b> , 27, 100566	0
419	Serum Fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment. <b>2021</b> ,	1
418	PEGYLATED INTERFERON ALPHA-2B IN COMPARISON TO INTERFERON ALPHA-2B AS A MONOTHERAPY FOR CHRONIS HEPATITIS C. <b>2001</b> , 2, 118-120	



417 Virale hepatitis. **2002**, 205-219

416 DOES EARLY TREATMENT OF ACUTE HEPATITIS C VIRUS INFECTION WITH INTERFERON ALFA-2B PREVENT THE DEVELOPMENT OF CHRONIC HEPATITIS?. **2002**, 3, 9-11

415 Pegylierte Alpha-Interferone. **2002**, 23,

414 Virusinfektionen. **2003**, 1506-1524

413 Novel combined approaches to hepatitis C therapies. **2003**, 399-411

412 Somatische Komorbidität. **2003**, 79-86

411 Infektiöse Lebererkrankungen. **2003**, 398-516

410 Antiviral Agents, RNA Viruses (Other than HIV), and Orthopoxviruses. **2003**, 359-455

409 Perspectives in HCV vaccine development. **2003**, 77-85

408 Hepatitiden. **2003**, 739-762

407 Verbesserung der virologischen Ansprechrate durch Therapie mit pegyliertem Interferon alpha-2-b plus Ribavirin nach Lebertransplantation bei Hepatitis-C-Zirrhose. **2003**, 345-347

406 Hepatitis C and Addiction. **2003**, 2, 7-17

405 Viral response to therapy: viral dynamics. **2004**, 157-173

404 Hepatitis. **2004**, 506-541

403 Virale Erkrankungen durch RNA-Viren. **2004**, 819-885

402 Verordnungsprofil der Internisten. **2004**, 1013-1041

401 Current and future therapy of chronic hepatitis. **2004**, 51-75

400 Neue Arzneimittel. **2004**, 24-87

399 Practical Experiences with Therapies for Chronic Hepatitis C in Hemophilia Patients. **2004**, 173-175

398 Pharmacokinetics of Biologicals. **2004**, 499-522

397 Favorable Outcome of Patients with C-Viral Liver Disease Treated with Interferon. **2004**, 167-175

396 Molecular Diagnoses of Human Immunodeficiency Virus and Hepatitis C Virus. **2004**, 309-325

395 Viral hepatitis in dialysis patients. **2004**, 1379-1407

394 Current standard of care in hepatitis C virus infection. **2004**, 141-156

393 Treatment with Interferon Alpha-2a in Patients with Hepatitis C and Hemophilia. **2004**, 167-172

392 Hepatitis C. **2004**, 117-143

391 Antiviral Treatment of Chronic Hepatitis B and C : Current Update. **2005**, 48, 440

390 The Usefulness of Combination Treatment with Interferon .BETA. Administered Twice-daily Followed by Interferon .ALPHA.-2b plus Ribavirin in Chronic Hepatitis C. **2005**, 46, 498-505

389 Treatment of anicteric acute hepatitis C with peginterferon alpha-2a plus ribavirin. **2005**, 62, 865-8

388 Ribavirin monotherapy increases sustained response rate in relapsers of end treatment virologic responders. **2005**, 11, 1663-7

387 Genotype of hepatitis virus. 3. Hepatitis C virus.. **2005**, 46, 480-485

386 Effective use of minute quantities of IFN for hard-to-cure cirrhosis of the liver with hepatitis C virus infection. **2005**, 46, 257-261

385 Interferon- therapy and Type 1 diabetes mellitus in patients with hepatitis C: pathophysiologic insights. **2005**, 2, 439-446

384 Interferon-therapy and Type 1 diabetes mellitus in patients with hepatitis C: pathophysiologic insights. **2005**, 2, 439-446

1

383 Challenges and Controversies in the Management of Hepatitis C Virus Infection (Part 1). **2005**, 2005,

382 Chorea induced by PEG-IFN and rivabirin therapy for type C chronic hepatitis. **2006**, 47, 129-133

1

381 Interferon alfa. **2006**, 1793-1831

380 An early prognosis for the treatment of Chronic Hepatitis C patients with Pegylated Interferon-ALPHA.2b plus Ribavirin-Monitoring analysis by the serum HCV core antigen values-. **2006**, 47, 355-356

379 Hepatitis C: a challenge to hepatologists and to the liver transplantation team. **2006**, 21 Suppl 1, 15-8

378 Current Treatment of Hepatitis C and Hepatocellular Carcinoma. **2006**, 2, 108-114

377 Long-term treatment effect of natural IFN-alpha for chronic hepatitis C: from the viewpoint of frontline practice. **2007**, 48, 272-277 1

376 [A case of vasculitis in chronic hepatitis C patient treated with pegylated interferon alpha-2a and ribavirin]. **2007**, 13, 419-22

375 [Short-term therapy with pegylated interferon plus ribavirin for the chronic hepatitis C genotype 2 patients]. **2007**, 13, 341-8 1

374 Treatment of Chronic Hepatitis C Virus Infection in Older Adults. **2007**, 13, 432

373 Chronic Hepatitis. **2007**, 237-256

372 [Treatment of hepatitis C in patients on renal replacement therapy]. **2007**, 148, 489-94

371 Treatment of Hepatitis C Virus Infection in Patients before and after Renal Transplantation. **2007**, 1, 225-234

370 Experiences on Antiviral Treatment for Chronic Viral B and C Hepatitis in Hungary (1998-2004). A Nation-Wide Study. **2007**, 1, 207-219

369 Interferon in the Treatment of Viral Hepatitis. On the 50th Anniversary of Interferon's Discovery. **2007**, 1, 271-279

368 The Role and the Possibilities of Natural Interferon Treatment for Chronic Hepatitis C: Our Experiences with Natural Interferon Treatment for Patients Debarred from Combined Antiviral Therapy due to the STOP Rule. **2007**, 1, 331-339 1

367 Thiobarbituric Acid Derivatives for Anti-HCV Agents Targeting NS5B RNA Polymerase. **2007**, 28, 1917-1918

366 Hepatitis C for addiction professionals. **2007**, 4, 34-41 1

365 Transplantation. **2008**, 631-704

364 Pegylated interferon  $\alpha$ 2b/ribavirin combination therapy for elderly patients with chronic hepatitis C with high viral load of HCV genotype 1b. **2008**, 49, 145-152

- 363 Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: a pilot, randomized study. **2008**, 14, 7220-4 3
- 362 The Effectiveness of Combination Therapy with Peginterferon  $\alpha$ 2a and Ribavirin in Chronic Hepatitis C. **2008**, 44, 72 1
- 361 C ??????. **2008**, 67, 49-51
- 360 Nadir platelet and neutrophil counts during the course of PEG-IFN  $\alpha$ 2b plus ribavirin combination therapy can be predicted by the values at week one: Towards achieving better efficacy. **2008**, 49, 239-247
- 359 A case of chronic hepatitis C in which a 72-week course of pegylated interferon and ribavirin combination therapy resulted in relapse but a subsequent interferon monotherapy could induce sustained virological response. **2008**, 49, 495-500
- 358 [Treatment of chronic hepatitis C: efficacy of initial treatment of peginterferon alpha-2a versus peginterferon alpha-2b plus ribavirin in naive chronic hepatitis C patients]. **2008**, 14, 443-5
- 357 Therapeutic Strategies Targeting the Innate Antiviral Immune Response. **2008**, 223-251
- 356 Prediction of efficacy and viral kinetics using COBAS TaqMan HCV "automated" during antiviral treatment of hepatitis C. **2008**, 49, 297-306 3
- 355 [Effectiveness of peg-interferon and ribavirin for hepatitis C in a patient with hypertension and diminished kidney function]. **2008**, 149, 889-92
- 354 Antiviral treatment for hepatitis C cirrhosis: is the effort justified?. **2008**, 149, 427-8
- 353 Clinical Features and a Clinician's Diagnostic Approach to Hepatocellular Carcinoma. **2009**, 309-326
- 352 Viral Phenotypic Resistance Assays. **2009**, 1187-1199
- 351 Les troubles psychiatriques liés au traitement de l'hépatite chronique C. **2009**, 80-92
- 350 Comorbidities in Black Patients with HIV/AIDS. **2009**, 159-177
- 349 État des lieux de la prise en charge psychiatrique et psychologique des patients VHC+ et VIH/VHC+ en France. **2009**, 8-15
- 348 INFECTIOUS HEPATITIS. **2009**, 527-547
- 347 Pegylated interferon alpha 2b for chronic hepatitis C.
- 346 Epidemiological Survey of Hepatitis C Virus Infection in Fife, Scotland. **2009**, 2, 282-288

345 State-of-the-Art Lecture: Treatment of hepatitis C. **2009**, 105-119

344 Pegylated interferon alpha 2a for chronic hepatitis C.

343 9 Virale hepatitis. **2009**, 83-99

342 Prevention and treatment of hepatitis virus infections in hematopoietic stem cell transplant recipients. **2009**, 1, e2009017

2

341 Response-guided therapy in Japanese chronic hepatitis C patients infected with genotype 1b and high viral load. **2009**, 50, 687-702

340 Rapid virological response obtained by natural IFN for a patient of chronic hepatitis C with a high viral load of HCV genotype 1b who is refractory to peg-interferon + ribavirin combination therapy. **2009**, 50, 590-592

339 Pegylated Interferons in the Adjuvant Treatment of Melanoma. **2009**, 555-564

338 Anti-HCV Agents in Development. **2009**, 159-183

337 Current and Future Therapy of Chronic Hepatitis C. **2009**, 71-96

336 Support of Patients During Antiviral Therapy for Hepatitis B and C. **2009**, 337-351

335 What to do if standard therapy for hepatitis C fails. **2009**, 1, 41

334 Supplementation With High Doses Of Vitamins E And C In Chronic Hepatitis C. **2009**, 259-269

333 Pegylated interferon alpha 2a for chronic hepatitis C.

332 Interferon Signaling. **2010**, 189-200

2

331 Pegylated interferon alpha 2b for chronic hepatitis C.

330 ANTIVIRAL DRUGS, INCLUDING IMMUNOGLOBULINS AND INTERFERONS. **2010**, 445-646

329 Viral Hepatitis. **2010**, 100-106

328 Les nouveaux traitements anti-VHC, comment les utiliser? De la virologie à la clinique. **2010**, 233-237

- 327 Chapter 19Chronic Liver Disease. **2010**, 0
- 326 Viral hepatitis. **2010**, 408-422
- 325 Hepatitis C. **2010**, 1313-1335.e6 1
- 324 Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis. **2010**, 2, e2010003 4
- 323 Drugs to treat viral hepatitis. **2010**, 1471-1476
- 322 CYTOKINES AND CYTOKINE MODULATORS. **2010**, 355-455
- 321 Screening compounds against HCV based on MAVS/IFN- $\lambda$  pathway in a replicon model. **2010**, 16, 5582-7 1
- 320 A case of hepatitis C related cirrhosis with sustained virological response by a long-term, intermittent use of low-dose natural interferon-alpha. **2010**, 51, 6-12 1
- 319 Hepatitis C Virus.
- 318 Antiviral Therapy. **2010**, 210-225
- 317 Protease and Polymerase Inhibitors for the Treatment of Hepatitis C Virus Infection. **2010**, 2976-2989
- 316 Interferon Alfa. **2010**, 2959-2975
- 315 Drug-Induced Endocrine Autoimmunity. **2011**, 157-179
- 314 Viral Dynamic Modeling and Simulations in HIV and Hepatitis C. **2011**, 227-250
- 313 Liver. **2011**, 773-803
- 312 Leber-, Gallenwegs- und Pankreaserkrankungen. **2011**, 445-528
- 311 Molecular Detection and Characterization of Hepatitis C Virus. **2011**, 557-577
- 310 Comment optimiser le traitement de l'hépatite chronique virale C?. **2011**, 155-156

- 309 A case of type 1 diabetes mellitus caused by low-dose, long-term natural interferon therapy for a patient with chronic hepatitis C. **2011**, 52, 335-343 0
- 308 Efficacy of combination therapy of pegylated interferon alfa-2b plus ribavirin for 48 weeks in chronic hepatitis C patients with serotype 1 high viral load: Results of multicenter trial in Tohoku area of Japan. **2011**, 52, 652-661
- 307 Viral Hepatitis C. **2011**, 427-432 2
- 306 Molecular Microbiology. **2011**, 27-59 7
- 305 Hepatitis C Virus. **2011**, 1437-1455 1
- 304 [Clubfoot in Uganda]. **2011**, 131, 8
- 303 The anti-viral effect and the influence on the values of ALT and AFP by low-dose PEG-IFN $\alpha$  treatment for prevention of cancer in patients with chronic hepatitis C. **2011**, 52, 94-101 1
- 302 Antiviral Agents. **2011**, 1687-1709
- 301 Double filtration plasmapheresis and peginterferon plus ribavirin combination therapy for chronic hepatitis C patients with genotype 1b and high viral load not cured by previous interferon therapy. **2011**, 52, 575-583
- 300 Antiviral therapy in patients after treatment for hepatitis C-related hepatocellular carcinoma. **2011**, 5, 77-81
- 299 Managing the Mature Person with Hemophilia. 44-48
- 298 Measuring HCV RNA and Assessing Virologic Response. **2012**, 149-157
- 297 Sex and Gender Differences in Gastroenterology and Hepatology. **2012**, 65-82
- 296 Long-Term Course of Patients with Mixed Cryoglobulinemia. **2012**, 219-226
- 295 Mutations and the Development of Anti-viral Resistance. **2012**, 227-249
- 294 The Genetics of Virologic Response. **2012**, 183-192
- 293 Response-Guided Therapy. **2012**, 159-169
- 292 Maintenance Therapy with Peginterferon. **2012**, 193-200

- 291 Treating Chronic HCV Without Interferon and/or Ribavirin. **2012**, 261-269
- 290 Chronic HCV and HIV Coinfection. **2012**, 75-91
- 289 Hepatitis C. 582-652
- 288 Treatment with Interferon and Ribavirin. **2012**, 115-130
- 287 Peginterferon, Ribavirin and Anti-viral Triple Therapy. **2012**, 251-260
- 286 Genotype 1: Standard Treatment. 65-73
- 285 Hepatitis C Genotype 4 Therapy: Progress and Challenges. 113-126
- 284 Individually Tailored Treatment Strategies in Treatment-naïve Chronic Hepatitis C Genotype 1 Patients. 74-83
- 283 Altered Dosage or Durations of Current Antiviral Therapy for HCV Genotypes 2 and 3. 97-103
- 282 Antivirals in Cirrhosis and Portal Hypertension. 132-139
- 281 Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients. **2011**, 11, 918-924 6
- 280 Cytopenias: How they Limit Therapy and Potential Correction. 160-168
- 279 Standard Therapy for Genotypes 2/3. 90-96
- 278 Genotype 1 Relapsers and Non-Responders. 84-89
- 277 A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C. **2012**, 18, 272-8 1
- 276 Response-guided therapy based on reaction to the initial dose using administration of peginterferon  $\alpha$ 2a alone or in combination with ribavirin in naïve patients with chronic hepatitis C of serotype 2 and high viral loads. **2012**, 53, 18-27
- 275 Telaprevir in combination with peginterferon alfa-2b and ribavirin therapy for genotype 1 Japanese chronic HCV patients: Impact on adherence and antiviral effects. **2012**, 53, 69-77
- 274 Study of peginterferon alfa-2b plus ribavirin combination therapy in type C compensated liver cirrhosis. **2012**, 53, 803-813



273 The importance of a prior psychiatric examination in pegylated interferon and ribavirin combination treatment for chronic hepatitis C. **2012**, 59, 39-44

272 Chronic Hepatitis. **2012**, 171-186.e4

271 Novel biosensor-based microarray assay for detecting rs8099917 and rs12979860 genotypes. **2012**, 18, 6481-8; discussion p. 6487

1

270 Chronic viral hepatitis C. 610-617

269 Mutation Analysis of Protein Kinase Binding Domain of HCV NS5A Gene Isolated from Patients with Chronic Hepatitis C. **2012**, 8, 519-526

2

268 Chronic Viral Hepatitis in Adults and Children: Hepatitis C. 208-225

267 Pegylated interferon and ribavirin combination therapy for chronic hepatitis C associated with thyroid dysfunction. **2013**, 54, 731-740

266 Liver. **2013**, 929-959

265 Leber, Gallenwege, Pankreas. **2013**, 144-169

264 Pharmacogenomics and Personalized Medicine for Infectious Diseases. **2013**, 603-635

0

263 Conjunctival Carcinoma. **2013**, 1-9

262 Efficacy and safety of pegylated interferon<sup>α</sup>-2a plus ribavirin treatment in refractory chronic hepatitis C patients -a multi-center study in Kyushu-. **2013**, 54, 266-276

261 Future directions in hepatitis C therapy. **2013**, 98-111

260 Pegylated interferon and ribavirin in the retreatment of chronic hepatitis C in Korea. **2013**, 7, 585-93

259 Treatment of Hepatitis C Before Liver Transplantation. **2014**, 1-14

258 Molecular-Genetic Testing in Hepatocellular Carcinoma and Its Premalignant Conditions. **2014**, 211-258

257 Conjunctival Carcinoma. **2014**, 339-347

256 Improved Sustained Virological Response Following Treatment with Pegylated-Interferon Alpha-2b Compared with Alpha-2a, Both with Ribavirin, for Chronic Hepatitis C Infection with Genotypes 2 and 3. **2014**, 05, 111-117

- 255 Establishment of a Practical Workflow Using a Next Generation Sequencer to Search for Novel SNPs Associated with the Anti-HCV Treatment Response. **2014**, 60, 568-575
- 254 Sequelae of Chronic Viral Hepatitis. 371-388
- 253 Plasticity of the Hepatitis C Virus Genome. 178-190
- 252 Hepatitis C Virus and Chronic Liver Disease. 1-11
- 251 Clinical Aspects of Hepatitis C Virus Infection. 241-264
- 250 Seminal parameters before and during combined antiviral (pegylated interferon  $\alpha$  and ribavirin) treatment in chronic hepatitis C virus patients in upper Egypt. **2014**, 26, 104-109
- 249 Management of Hepatitis C in the Pre- and Post-Transplant Setting: Then and Now. **2014**, 1,
- 248 STUDY OF SEROPOSITIVITY OF HBSAG AND ANTIHCV ANTIBODY IN HIV POSITIVE PATIENTS. **2014**, 3, 12881-12893
- 247 Nutritional Status and Body Composition Dynamics with Peginterferon Alpha and Ribavirin Combination Therapy in Chronic Hepatitis C Patients. **2014**, 11, 12-19
- 246 Two Types of Viral Hepatitis, Two Different Treats from Pharma -What's After the Liver Meeting? 2014?. **2015**, 2,
- 245 Treatment results and factors affecting sustained virological response in chronic hepatitis C patients in Northern India. **2015**, 5, 24-30
- 244 A Study on the Anxiety of the Chronic Viral Hepatitis Patients Receiving Pegylated Interferon Therapy. **2015**, 54, 506
- 243 Antiviral Drugs against Hepatitis Viruses. **2015**, 563-575.e3
- 242 Interferon- $\beta$  polymorphisms in pegylated-interferon- $\alpha$  plus ribavirin therapy for genotype-2 chronic hepatitis C. **2015**, 21, 3904-11
- 241 Chronische Hepatitis. **2015**, 1-10
- 240 Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C. **2015**, 7, 2688-95
- 239 Protease Inhibitor Resistance. **2015**, 1-17
- 238 Miscellaneous Antiviral Agents (Interferons, Imiquimod, Pleconaril). **2015**, 576-580.e2

237	Antiviral Agents. 1867-1893	
236	Hepatitis C.	
235	Can laboratory parameters be predictive factors for treatment effectiveness of patients suffering from viral hepatitis C?. <b>2015</b> , 69, 91-98	
234	Post HCV Infection Due to MX Gene Stimulation Produced Post Treatment with Imported and Locally Produced Egyptian Biosimilar IFN. <b>2015</b> , 16, 5635-41	
233	Hepatitis C Virus Infection. 1939-1957	
232	Acute Viral Hepatitis. 1886-1915	
231	Viral Variation and Response to Therapy. <b>2016</b> , 243-256	
230	Interferon alfa. <b>2016</b> , 158-208	
229	Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment Strategies. <b>2016</b> , 6, 35-42	
228	[Direct Acting Antivirals for Treatment of Hepatitis C Infection in Patients with Advanced Liver Disease]. <b>2016</b> , 67, 58-60	
227	21. Chronic Liver Disease. <b>2016</b> ,	
226	Evaluation of Interferon Resistance in Newly Established Genotype 1b Hepatitis C Virus Cell Culture System. <b>2016</b> , 4, 5-11	
225	Association of IL28B Genotypes and Baseline Serum Interferon-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China. <b>2016</b> , 10, 446-55	2
224	Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. <b>2016</b> , 4, 97-112	4
223	A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies. <b>2016</b> , 5, 2061	1
222	Genetic Variation in Interleukin-28B and Response to Peg-IFN $\alpha$ /RBV Combination Therapy in Patients with Hepatitis C Virus Infection. <b>2016</b> , 10,	
221	Viral Phenotypic Resistance Assays. <b>2017</b> , 1389-1407	1
220	Natural history of chronic hepatitis C development and progression as a consequence of iron and HFE or Tfr1 mutations. <b>2017</b> , 7, 33-40	

- 219 Sexually Transmitted Infections and Male Infertility: Old Enigma, New Insights. **2017**, 183-212 1
- 218 Is the 25-year hepatitis C marathon coming to an end to declare victory?.
- 217 The Impact of Interleukin-28B rs12979860 Polymorphism on Peginterferon-alpha and Ribavirin Combination Therapy in Iranian Patients with Hepatitis C Virus Genotype 1 Infection. **2017**, 1,
- 216 Molecular Characterization of HCV and Introduction of Biorisk Management CWA 15793-2008 at DHQ Divisional Headquarters Teaching Hospital & MBBS Medical College, Chattar Parri, Mirpur District AJK. **2017**, 4,
- 215 Treatment of Hepatitis C Virus Infection in the HIV- Infected Patients by Pegylated Interferon and Ribavirin in Tehran, Iran. **2017**, 4, 43623-43623
- 214 Treatment of Hepatitis C. 1-8
- 213 Analysis of competitive infectious diseases with multiple strains. **2017**, 104, 215-221 0
- 212 Treatment of Hepatitis C with Pegylated Interferon Alpha-2a and Ribavirin: Experience from Benin. **2018**, 08, 275-283 1
- 211 Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience. **2018**, 10, 88-94 0
- 210 Encyclopedia of AIDS. **2018**, 378-385
- 209 A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population. **2018**, 16, 61-67 2
- 208 Erythrocyte Membrane Protein Band 3 Predicts Interferon Ribavirin-Induced Anemia. **2019**, 08, 5-16
- 207 Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma.
- 206 Chronic hepatitis C: modern condition of the problem. **2019**, 23, 36-46 1
- 205 The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam. **2019**, 4, 129 3
- 204 Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea. **2019**, 13, 549-556 1
- 203 [Antiviral therapy of chronic hepatitis C: 30 years success story]. **2019**, 91, 110-115 1
- 202 Hepatitis C virus (HCV) : Development of anti-HCV agents and anti-HCV therapy. **2020**, 132, 131-143

- 201 Delays and Gaps in Progressing Through the Hepatitis C Virus Cascade of Care: An Underserved Safety-net Hospital Experience. **2020**, 8, 261-267 1
- 200 Antimicrobial Composition based on Highly Dispersed Zinc oxide and Ribavirin. **2020**, 36, 94-98
- 199 Emerging Management of Hepatitis C in Transplant. **2020**, 1-20
- 198 Twenty-year follow-up of an outbreak of hepatitis C in a small rural town of Argentina: The O'Brien Project. **2021**, 100577 0
- 197 Hepatitis in the clinics □Treatment options. **2008**, 1-20
- 196 Chronic hepatitis C: Portrait of a silent epidemic and the etiologic agent. **2008**, 95-120
- 195 Krankheiten der Leber und Gallenwege. **2008**, 409-419
- 194 Current therapy of hepatitis C. 109-114
- 193 Hepatitiden. **2005**, 779-804
- 192 Virusinfektionen. **2005**, 1581-1601
- 191 Akute und chronische infektiöse Hepatitiden. **2005**, 819-828
- 190 Treatment of Chronic Hepatitis C in Difficult-to-Treat□Patients in the Clinical Setting. **2008**, 192-214
- 189 Effects of Combined IFN-Alpha/Ribavirin Treatment in HCV Disease-Related Progression. **2008**, 215-236
- 188 Mechanisms of Interferon Action and Resistance in Chronic Hepatitis C Virus Infection: Lessons Learned from Cell Culture Studies. **2008**, 16-38
- 187 Immunological Parameters Influencing Adaptive Immune Responses to the Hepatitis C Virus. **2008**, 39-70
- 186 Treatment of Chronic Hepatitis C with Different Genotypes. **2008**, 130-147 2
- 185 Interferon-Based Therapy for Hepatitis C Virus Infections. **2008**, 168-191
- 184 New aspects of treatment of chronic hepatitis C. **2008**, 161-168

183	Clinical Strategies for Chemoprevention of Liver Cancer. <b>2005</b> , 503-516		
182	Prophylaxe und Therapie der Hepatitis A, B und C. <b>2007</b> , 107-116		
181	Akute und chronische infektiöse Hepatitiden. <b>2007</b> , 901-910		
180	Early treatment of acute hepatitis C infection may lead to cure. <b>2001</b> , 165, 1527		1
179	Hepatitis C and general practice: the crucial role of primary care in stemming the epidemic. <b>2005</b> , 55, 259-60		8
178	Paternal use of ribavirin-interferon alpha 2B combination therapy before conception. <b>2005</b> , 51, 1623-5		3
177	A case of cutaneous vasculitis with underlying hepatitis C and cryoglobulinaemia. <b>2008</b> , 77, 51-3		3
176	Early experience with chronic hepatitis C in Northern Ireland: epidemiology and response to monotherapy. <b>2004</b> , 73, 25-31		1
175	Treatment of intravenous drug users with chronic hepatitis C: treatment response, compliance and side effects. <b>2007</b> , 11, 196-8		7
174	Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic. <b>2005</b> , 97, 1703-7		12
173	Antiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment. <b>2003</b> , 1, Doc07		1
172	Management of chronic hepatitis C treatment failures: role of consensus interferon. <b>2009</b> , 3, 141-50		7
171	Measles control--can measles virus inhibitors make a difference?. <b>2009</b> , 10, 811-20		17
170	Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034. <b>2007</b> , 1, 1-9		3
169	Management of chronic hepatitis C: consensus guidelines. <b>2007</b> , 21 Suppl C, 25C-34C		49
168	Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 459-64	1.6	16
167	Treatment options for HCV nonresponders and relapse patients. <b>2010</b> , 6, 1-12		1
166	Skin rash during chronic hepatitis C therapy. <b>2010</b> , 6, 323-5		4

165	Hepatitis C Virus Therapy-related Skin Manifestations. <b>2010</b> , 6, 326-8	1
164	Health-related quality of life in Greek chronic hepatitis C patients during pegylated interferon and ribavirin treatment. <b>2010</b> , 14, 122-5	7
163	Hepatitis C (chronic). <b>2010</b> , 2010,	
162	Management of recurrent hepatitis C following liver transplantation. <b>2010</b> , 6, 637-45	7
161	The Need for New Anti-Hepatitis C Virus Therapeutic Strategies: Targeting the cellular micro-ribonucleic acids?. <b>2010</b> , 10, 312-7	
160	Treatment, care and support for people co-infected with HIV and hepatitis C: a scoping review. <b>2009</b> , 3, e184-95	1
159	The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients. <b>2007</b> , 3, 4-32	2
158	Mechanism of action of ribavirin in the treatment of chronic hepatitis C. <b>2007</b> , 3, 218-25	48
157	Epidemiology of hepatitis C virus infection & liver disease among injection drug users (IDUs) in Chennai, India. <b>2010</b> , 132, 706-14	17
156	Emerging therapies for chronic hepatitis C virus. <b>2008</b> , 4, 729-34	1
155	Hepatitis C Virus-related Mixed Cryoglobulinemia: Pathogenesis, Clinical Manifestations, and New Therapies. <b>2007</b> , 3, 695-703	12
154	IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. <b>2011</b> , 7, 366-73	5
153	Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B. <b>2011</b> , 11, 163-72	26
152	The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis C. <b>2011</b> , 11, 240-6	10
151	Rosuvastatin and chronic hepatitis C. <b>2011</b> , 11, 384-5	
150	Which is the IDEAL peginterferon for Hepatitis C: a meta-analysis of both pegylated interferons in the treatment of HCV-infected patients. <b>2010</b> , 10, 229-30	
149	Cognitive impairment in hepatitis C patients on antiviral therapy. <b>2008</b> , 4, 65-7	4
148	Viral hepatitis in Hawai'i--differing perspectives. <b>2010</b> , 69, 3-20	2

- 147 Evolution of viral RNA in a Chinese patient to interferon/ribavirin therapy for hepatitis C. **2012**, 24, 353-60
- 146 Lower-Dose and Long-Term Intermittent Interferon Therapy for Hepatitis C Genotype 2a may be a Possibility. **2008**, 4, 245-7
- 145 Management of hepatitis C virus infection: the basics. **2012**, 20, 154-61 14
- 144 Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. **2013**, 21, 27-35 23
- 143 Success of antiviral therapy in chronic hepatitis C infection relates to functional status of myeloid dendritic cells. **2013**, 138, 766-78 4
- 142 Hepatitis C treatment & management. **2014**, 7, 31-6 1
- 141 Frontiers in the treatment of hepatitis C virus infection. **2014**, 10, 90-100 7
- 140 Random effect model for identifying related factors to virological response in HCV patients. **2013**, 6, S65-9
- 139 Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. **2014**, 18, 57-64 5
- 138 Factors influencing therapeutic response to pegylated interferon plus ribavirin in the different genotypes of chronic hepatitis C. **2014**, 5, 219-22 5
- 137 Interleukin-28B (rs12979860) gene variation and treatment outcome after peginterferon plus ribavirin therapy in patients with genotype 1 of hepatitis C virus. **2014**, 19, 1062-7 4
- 136 Is response-guided therapy being applied in the clinical setting? The hepatitis C example. **2015**, 8, 22-8 2
- 135 Molecular and contextual markers of hepatitis C virus and drug abuse. **2009**, 13, 153-79 3
- 134 Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon and ribavirin. **2015**, 8, 10284-303 2
- 133 Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection. **2015**, 8, 142-7 60
- 132 Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Infection. **2015**, 8, 54-8 8
- 131 Hepatitis C Virus (HCV) Infection among Seronegative Patients undergoing Haemodialysis in a Remotely Located Tertiary Care Hospital of Northern India: Value of HCV-RNA and Genotypes. **2015**, 9, DC10-2 3
- 130 Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection. **2015**, 11, 294-346 4



- 129 The evolving role of interferons in viral eradication strategies. **2016**, 2, 121-3 1
- 128 HIV-HCV Coinfection. **2006**, 2, 357-365
- 127 Lack of Efficacy of Pegylated Interferon Monotherapy for Hepatitis C in Patients With End-Stage Renal Disease on Dialysis. **2006**, 2, 504-508
- 126 Update on the Use of Consensus Interferon in Difficult-to-Treat Hepatitis C Patients: A Review of Selected Posters From Digestive Disease Week May 20-25, 2006 Los Angeles, Calif. With commentary by: Fred Poordad, MDCedars-Sinai Medical Center Los Angeles, Calif. **2006**, 2, 1-12
- 125 Treatment Related Hematologic Changes in a Population of Iranian Patients with Chronic Hepatitis C Infection from 2009 to 2014. **2017**, 46, 1386-1394 1
- 124 Noninvasive Assessment of Fibrosis Regression in Hepatitis C Virus Sustained Virologic Responders. **2017**, 13, 587-595 7
- 123 Positive and Negative Predictive Factors for Treatment Response in Patients with Chronic Viral C Hepatitis. **2017**, 43, 318-324
- 122 Heart Transplantation Outcomes in Patients With Hepatitis C Virus Infection: Potential Impact of Newer Antiviral Treatments After Transplantation. **2017**, 34, S40-S48
- 121 The State of Hepatitis C Care in the VA. **2015**, 32, 20S-24S
- 120 Management of Hepatitis C in Patients With HIV. **2015**, 32, 15S-19S
- 119 Modelling the impact of different testing strategies for HCV infection in Switzerland. **2019**, 5, 191-203 1
- 118 Development and Validation of Head-space Gas Chromatographic Method in Tandem with Flame ionized detection for the determination of Residual solvents in Simeprevir API Synthesis. **2021**, 5175-5181
- 117 Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?. **2022**, 14, 1 1
- 116 Hepatitis C virus: A critical approach to who really needs treatment.. **2022**, 14, 1-44
- 115 Nurse practitioners as primary care site champions for the screening and treatment of hepatitis C virus.. **2022**,
- 114 Anemia in cirrhosis: An underestimated entity.. **2022**, 10, 777-789
- 113 Molecular dynamics simulations and MM-GBSA reveal novel guanosine derivatives against SARS-CoV-2 RNA dependent RNA polymerase.. **2022**, 12, 2741-2750 2
- 112 Targeting the Virus Capsid as a Tool to Fight RNA Viruses.. **2022**, 14,

- 111 The knowledge on HCV. **2022**, Publish Ahead of Print, 0
- 110 Hepatitis C Virus NS3/4A Inhibition and Host Immunomodulation by Tannins from : A Structural Perspective.. **2022**, 27, 1
- 109 Present and future management of viral hepatitis.. **2021**, 27, 8081-8102 0
- 108 Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia.. **2022**, 11, 1
- 107 Clinical and Molecular Basis of Hepatocellular Carcinoma after Hepatitis C Virus Eradication.. **2022**, 11, 1
- 106 Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease.. **2022**, 22, 98 1
- 105 Image\_1.TIF. **2020**,
- 104 Image\_2.TIF. **2020**,
- 103 Image\_3.TIF. **2020**,
- 102 Table\_1.DOCX. **2020**,
- 101 Table\_2.DOCX. **2020**,
- 100 Table\_3.DOCX. **2020**,
- 99 Table\_4.docx. **2020**,
- 98 Hepatitis C Virus Infection and the New Therapeutical Approach.. **2021**, 47, 353-360
- 97 Metabolic Impact of Diabetes Mellitus Type 2 in Hepatitis C Virus Infected Patients.. **2021**, 47, 405-411
- 96 The curing regimens of HCV: A SWOT analysis.. *Antiviral Therapy*, **2022**, 27, 13596535211072672 1.6 0
- 95 Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib.. **2022**, 0
- 94 Interferon-alfa: um interferente endógeno. **2021**, 95-122

93 Hepatite C e doenças autoimunes da tireoide. **2021**, 123-136

92 ISDR Pattern and Evolution in Patients with Chronic Hepatitis C Treated with Standard Or Peg-Ifn plus Ribavirin. *Antiviral Therapy*, **2003**, 8, 105-110 1.6 7

91 Normal Erythropoietin Response in Chronic Hepatitis C Patients with Ribavirin-Induced Anaemia. *Antiviral Therapy*, **2003**, 8, 57-63 1.6 8

90 Viral Dynamics and Pharmacokinetics of Peginterferon Alpha-2A and Peginterferon Alpha-2B in Naive Patients with Chronic Hepatitis C: A Randomized, Controlled Study. *Antiviral Therapy*, **2004**, 9, 491-497 1.6 68

89 Hepatitis C Virus-Rna Clearance in HIV-Coinfected Patients with Chronic Hepatitis C Treated with Pegylated Interferon plus Ribavirin. *Antiviral Therapy*, **2004**, 9, 505-509 1.6 21

88 Clinical Outcome to Interferon Therapy in Chronic Hepatitis C: Insights from Mechanistic Studies. *Antiviral Therapy*, **2004**, 9, 637-639 1.6

87 Pkr Gene Expression and Response to Pegylated Interferon plus Ribavirin Therapy in Chronic Hepatitis C. *Antiviral Therapy*, **2004**, 9, 763-770 1.6 8

86 Depressive Symptoms after Initiation of Interferon Therapy in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C. *Antiviral Therapy*, **2004**, 9, 905-909 1.6 21

85 Mitochondrial Effects of a 24-Week Course of Pegylated-Interferon plus Ribavirin in Asymptomatic HCV/HIV Co-Infected Patients on Long-Term Treatment with Didanosine, Stavudine or Both. *Antiviral Therapy*, **2004**, 9, 969-977 1.6 1

84 Area-Under-The-Curve for Peginterferon Alpha-2A and Peginterferon Alpha-2B is Not Related to Body Weight in Treatment-Naive Patients with Chronic Hepatitis C. *Antiviral Therapy*, **2005**, 10, 201-205 1.6 7

83 Open, Randomized, Multicentre Italian Trial on Peg-Ifn plus Ribavirin versus Peg-Ifn Monotherapy for Chronic Hepatitis C in HIV-Coinfected Patients on Haart. *Antiviral Therapy*, **2005**, 10, 309-317 1.6 28

82 Oligonucleotide-Based Therapeutic Options against Hepatitis C Virus Infection. *Antiviral Therapy*, **2006**, 11, 273-287 1.6 7

81 Incidence and Risk Factors for Mitochondrial Toxicity in Treated HIV/HCV-Coinfected Patients. *Antiviral Therapy*, **2005**, 10, 423-429 1.6 25

80 Future Therapies for Hepatitis C. *Antiviral Therapy*, **2006**, 11, 397-408 1.6 21

79 Impact of Steatosis on Long-Term Histological Outcome in Chronic Hepatitis C after Antiviral Therapy. *Antiviral Therapy*, **2006**, 11, 483-489 1.6 12

78 Evolution of Hepatitis C Virus Quasispecies during Therapy with Il2 Combined to Alpha Interferon and Ribavirin. *Antiviral Therapy*, **2005**, 10, 499-504 1.6 1

77 The Clinical Utility of Using Catrimox-14-Treated Whole Blood in Detecting Hepatitis C Virus RNA. *Antiviral Therapy*, **2005**, 10, 535-541 1.6 2

76 Amino Acid Variations in Hepatitis C Virus P7 and Sensitivity to Antiviral Combination Therapy with Amantadine in Chronic Hepatitis C. *Antiviral Therapy*, **2006**, 11, 507-519 1.6 31

75	Results of a Study of Prolonging Treatment with Pegylated Interferon- $\alpha$ plus Ribavirin in HIV/HCV-Coinfected Patients with No Early Virological Response. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 473-482	1.6	14
74	Impact of Ribavirin Exposure on Early Virological Response to Hepatitis C Therapy in HIV-Infected Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 657-662	1.6	18
73	A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Trial of Merimepodib (VX-497) and Interferon- $\alpha$ in Previously Untreated Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 635-643	1.6	22
72	Defective Synthesis of Granulocyte-Colony Stimulating Factor in Pegylated Interferon- $\alpha$ -Treated Chronic Hepatitis C Patients with Declining Leukocyte Counts. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 637-640	1.6	4
71	Treating Hepatitis C in HIV-Infected Patients: Where are We Now?. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 691-694	1.6	
70	The Prevalence, Clinical Features and Response to Antiviral Therapy of Patients with Chronic Hepatitis C who are Seropositive for Liver Kidney Microsome Type 1 Antibodies. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 715-720	1.6	5
69	The Impact of Haematopoietic Growth Factors on the Management and Efficacy of Antiviral Treatment in Patients with Hepatitis C Virus. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 769-776	1.6	26
68	Baseline Factors associated with Haematological Toxicity that Leads to a Dosage Reduction of Pegylated Interferon- $\alpha$ and Ribavirin in HIV- and HCV-Coinfected Patients on HCV Antiviral Therapy. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 841-847	1.6	12
67	Resistance of Hepatitis C Virus to Ns3 Protease Inhibitors: Mechanisms of Drug Resistance Induced by R155Q, A156T, D168A and D168V Mutations. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 847-856	1.6	30
66	Low-level HCV Viraemia after Initial Response during Antiviral Therapy: Transcription-Mediated Amplification Predicts Treatment Failure. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 423-428	1.6	4
65	The Magnitude of Week 4 HCV RNA Decay on Pegylated Interferon/Ribavirin Accurately Predicts Virological Failure in Patients with Genotype 1. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 401-406	1.6	5
64	Low Current and Nadir CD4+ T-Cell Counts are Associated with Higher Hepatitis C virus RNA Levels in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 455-460	1.6	9
63	Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 523-529	1.6	15
62	Premature Treatment Discontinuation in HIV/HCV-Coinfected Patients Receiving Pegylated Interferon plus Weight-Based Ribavirin. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 469-476	1.6	11
61	Dynamics of Apoptotic Activity during Antiviral Treatment of Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 779-787	1.6	6
60	Lack of Rapid Virological Response Predicts Interferon- $\alpha$ /Ribavirin Therapy failure in HCV Genotype 2 Patients: A Single-Centre Study. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 1033-1040	1.6	7
59	Modelling of Early Viral Kinetics and Pegylated Interferon- $\alpha$ Pharmacokinetics in Patients with HBeAg-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 1285-1294	1.6	8
58	Early Monitoring of Ribavirin Serum Concentration is not Useful to Optimize Hepatitis C Virus treatment in HIV-Coinfected Patients. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 1217-1224	1.6	12

57	Predictors of Severe Haematological Toxicity Secondary to Pegylated Interferon plus Ribavirin Treatment in HIV-HCV-Coinfected Patients. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 1225-1236	1.6	25
56	Ribavirin considerations in treatment optimization. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 23-30	1.6	13
55	Effect of Antiviral Treatment on Serum Markers of Liver Fibrosis in HIV-Hepatitis C virus-Coinfected Patients: The Fibrovic 2 Study [ANRS HC02]. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 211-219	1.6	19
54	Should Treatment of Hepatitis B Depend on Hepatitis B virus Genotypes? A Hypothesis Generated from an Explorative Analysis of Published Evidence. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 211-220	1.6	84
53	Virological relapse in chronic hepatitis C. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 303-313	1.6	13
52	Modelling Hepatitis C virus Kinetics: The Relationship between the Infected Cell Loss rate and the Final Slope of Viral Decay. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 459-464	1.6	25
51	Very Early Viral Kinetics on Interferon Treatment in Chronic Hepatitis C virus Genotype 4 Infection. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 581-589	1.6	3
50	Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 501-511	1.6	44
49	Antiviral Treatment for Chronic Hepatitis C in Illicit drug Users: A Systematic Review. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 467-479	1.6	8
48	Distinct Hepatitis C virus Kinetics in HIV-Infected Patients Treated with Ribavirin plus Either Pegylated Interferon $\alpha$ a or $\alpha$ b. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 511-517	1.6	5
47	Prediction of Sustained Virological Response by Ribavirin Plasma Concentration at Week 4 of Therapy in Hepatitis C virus Genotype 1 Patients. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 607-611	1.6	48
46	Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naive patients infected with genotypes 1B. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 723-730	1.6	11
45	Pegylated Interferon- $\alpha$ b plus Ribavirin: An Efficacious and well-Tolerated Treatment Regimen for Patients with Hepatitis C virus Related Histologically Proven Cirrhosis. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 663-673	1.6	30
44	Dynamic Evolution of Therapy for Chronic Hepatitis C: How will Novel Agents be Incorporated into the Standard of Care?. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 747-760	1.6	11
43	IP-10 Correlates with Hepatitis C Viral Load, Hepatic Inflammation and Fibrosis and Predicts Hepatitis C Virus Relapse or Non-Response in HIV-HCV Coinfection. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 969-976	1.6	65
42	Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 23-32	1.6	50
41	Management of Hepatitis C virus Genotype 2 or 3 Infection: Treatment Optimization on the Basis of Virological Response. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 143-154	1.6	14
40	The pattern of pegylated interferon- $\alpha$ b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 577-584	1.6	28

39	Virological Effects of Isis 14803, An Antisense Oligonucleotide Inhibitor of Hepatitis C Virus (HCV) Internal Ribosome Entry Site (IRES), on HCV Ires in Chronic Hepatitis C Patients and Examination of the Potential Role of Primary and Secondary HCV Resistance in the Outcome of Treatment. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 953-968	1.6	27
38	Viral Interaction and Responses in Chronic Hepatitis C and B Coinfected Patients with Interferon-Alpha plus Ribavirin Combination Therapy. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 125-133	1.6	58
37	Response to Interferon-Based Therapies in HIV-Infected Patients with Chronic Hepatitis C Due to Genotype 4. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 167-170	1.6	8
36	Chronic Hepatitis C and Genotyping: The Clinical Significance of Determining HCV Genotypes. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 1-11	1.6	102
35	News in Hepatitis C: Report from the 39th Annual Meeting of the European Association for the Study of the Liver. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 179-183	1.6	1
34	Impaired Response to Interferon- $\alpha$ B plus Ribavirin in Cirrhotic Patients with Genotype 3A Hepatitis C Virus Infection. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 797-802	1.6	14
33	A Sustained Virological Response to Interferon or Interferon/Ribavirin Reduces Hepatocellular Carcinoma and Improves Survival in Chronic Hepatitis C: A Nationwide, Multicentre Study in Taiwan. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 985-994	1.6	133
32	Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 9-16	1.6	22
31	A Phase I/II Study Evaluating Escalating Doses of Recombinant Human Albumin-Interferon- $\alpha$ Fusion Protein in Chronic Hepatitis C Patients who have Failed Previous Interferon- $\alpha$ Based Therapy. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 35-45	1.6	46
30	Outcome of Chronic Hepatitis C Patients who Required Early Termination of Pegylated Interferon- $\alpha$ plus Ribavirin Combination Therapy. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 1015-1020	1.6	23
29	Optimizing Treatment Outcomes in Chronic Hepatitis C: Management of Non-Response. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 955-970	1.6	1
28	Hepatitis C virus therapy to date. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 3-8	1.6	18
27	Chronic Liver Disease. <b>2022</b> , 209-227		
26	Breakthroughs in hepatitis C research: from discovery to cure. <i>Nature Reviews Gastroenterology and Hepatology</i> ,	24.2	5
25	Los beneficios de los nuevos antivirales pangenotípicos de acción directa en pacientes con enfermedad mental grave e infección por el virus de la hepatitis C: resultados de una revisión bibliográfica. <i>Gastroenterología Y Hepatología</i> , <b>2022</b> ,	0.9	0
24	Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , Volume 15, 1845-1864	3.4	2
23	Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment. <i>Journal of Liver Cancer</i> ,	0.7	0
22	Hepatitis C and Psychiatry. <b>2005</b> , 3, 194-202		

21	Partial nonstructural 3 region analysis of hepatitis C virus genotype 3a.	
20	Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group. <b>2022</b> , 5,	1
19	Hepatitis C. <b>2022</b> ,	0
18	Enhanced Complex Stability and Optimal JAK Geometry are Pivotal for a Potent Type III Interferon Response.	0
17	MicroRNA-122 Regulation of HCV Infections: Insights from Studies of miR-122-Independent Replication. <b>2022</b> , 11, 1005	0
16	Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects. <b>2022</b> , 23, 11936	0
15	The Role of the Microbiota Gut-Liver Axis during HCV Chronic Infection: A Schematic Overview. <b>2022</b> , 11, 5936	0
14	Engineering a High-Affinity Anti-Methoxy Poly(ethylene glycol) (mPEG) Antibody for Sensitive Immunosensing of mPEGylated Therapeutics and mPEG Molecules.	0
13	????? ?????????? C ??????. ?????????????? ?????? ?????? (?????????????). <b>2022</b> , 22-28	0
12	Mathematical Processing of Absorption as Green Smart Spectrophotometric Methods for Concurrent Assay of Hepatitis C Antiviral Drugs, Sofosbuvir and Simeprevir: Application to Combined Pharmaceutical Dosage Forms and evaluation of the method greenness.	0
11	Genotype 4 hepatitis C virus-a review of a diverse genotype. <b>2023</b> , 68, 54-59	0
10	Liver Function Tests in Hepatitis C Patients of Local Population of Lahore. 12-16	0
9	Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital. <b>2023</b> , 8, 92	0
8	Current Knowledge of Th22 Cell and IL-22 Functions in Infectious Diseases. <b>2023</b> , 12, 176	1
7	A Novel Approach to Develop New and Potent Inhibitors for the Simultaneous Inhibition of Protease and Helicase Activities of HCV NS3/4A Protease: A Computational Approach. <b>2023</b> , 28, 1300	0
6	Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C. 29, 949-966	0
5	Hepatitis C: treatment. <b>2023</b> , 251-279	0
4	Eliminaci3n del virus de la hepatitis C en un centro penitenciario: una experiencia de 18 a3s. <b>2023</b> ,	0

- 3 Reprogramming viral immune evasion for a rational design of next-generation vaccines for RNA viruses. 14,
- 2 Elimination of hepatitis C virus in a prison: An 18-year experience. **2023**,
- 1 A Literature Review on the Antiviral Mechanism of Luteolin. **2023**, 18, 1934578X2311715